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Outline of this thesis 
Radioimmunotherapy (RIT) can be defined as irradiation of cancer cells by 
radionuclides attached to monoclonal antibodies to guide the radionuclide 
to the tumor selectively. Theoretically, the doses absorbed by the tumor 
should be as high as possible, whereas the radiation doses absorbed by 
normal tissues should be low This approach differs from conventional 
chemotherapy, leading to toxicity m many tissues containing dividing cells, 
and from external beam radiation, in which the surrounding tissue of the 
tumor will absorb high doses, by the fact that the toxic agent is guided 
specifically to the tumor cells, as "magic bullets". 
B-cell non-Hodgkin's lymphoma in advanced stages can have an indo-
lent course, but has a bad prognosis quoad vitam One of the new treat-
ment modalities is the use of monoclonal antibodies like ntuximab, which 
can induce responses in about half of the treated patients. Studies with 
radiolabeled monoclonal antibodies in the same group of patients with 
relapsed or refractory indolent lymphoma, however, revealed higher re-
sponse rates when compared to unlabeled antibody treatment. Chapter 1 
of this thesis describes the current status of antibody treatment and ra-
dioimmunotherapy of patients with non-Hodgkin's lymphoma. 
In Chapter 2, the development of a mouse lymphoma model for preclin-
ical RIT studies is described. In this animal model, biodistnbution studies 
with radiolabeled anti-CD22 antibodies were performed in order to select 
the optimal radionuclide for RIT, as described in Chapter 3. 
Finally, a phase I cluneal study with the selected radiopharmaceutical 
186Re-epratuzumab was conducted The aims of the study were to de-
termine the safety and the maximum tolerated dose of this radiolabeled 
antibody preparation in patients with relapsed or refractory B-cell NHL, 
and to obtain preliminary data on efficacy of this treatment. The results 
of this study are described in Chapter 4, whereas the dosimetric analysis 
is described m Chapter 5. 
Squamous cell carcinoma of the head and neck (HNSCC) is a common 
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malignancy with a good prognosis for patients diagnosed in an early stage. 
However, two thirds of the patients present with advanced stages of the 
disease. In this group of patients, a significant proportion will have lo-
coregional recurrence or distant metastases after first-line treatment, con-
sisting of surgery and/or external beam radiation therapy. Since HNSCC 
is a relatively radiosensitive tumor, R1T could play a role in an adjuvant 
setting. Chapter 6 gives an overview of current treatment and the role of 
RIT in the treatment of HNSCC. 
In Chapter 7, the results of a phase I clinical study with 18('Re-
bivatuzumab are discussed. The primary aim of the study was to deter-
mine the maximum tolerated dose in patients with recurrent HNSCC or 
metastases, for whom no other curative treatment was available. Thera-
peutic effects of this therapy were monitored as well. The results of dosi-
metric analysis are described in Chapter 8, in relation with toxicity that 
was observed. 
In Chapter 9 a general discussion and future perspectives are provided. 
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Abstract 
In the past decade, several new antibody-based therapies — using either 
radiolabeled or unlabeled monoclonal antibodies — have become available 
for the treatment of patients with refractory or recurrent non-Hodgkin's 
lymphoma (NHL). Unlabeled monoclonal antibodies (mAbs) kill lymphoma 
cells by activating host immune effector mechamsms, or by inducing apop-
tosis. These mAbs can also be used to guide radionuclides to the lym-
phoma. This radioimmunotherapy (RIT) has been studied with various 
nuclides (131I, 90Y, 67Cu, and 186Re) and with various mAbs In this review 
the radionuclides, methods of dosing, and recent RIT studies m patients 
with B-cell NHL are reviewed. Most of these studies demonstrate that RIT 
is an effective new treatment modality for NHL. 
Introduction 
The diagnosis and treatment of patients with malignant lymphomas orig-
inated m 1832, the year that Thomas Hodgkin described a disease that 
is still known as Hodgkin's disease [1]. Hodgkin's disease is just one cir-
cumscribed entity of malignant lymphoma (characterized by the growth 
of Reed-Sternberg and Hodgkin cells), and all other types of malignant 
lymphoma are known as non-Hodgkin's lymphoma (NHL) Therefore, the 
recognition and description of NHL, being a very heterogeneous group of 
lymphoma types, took quite a long time. In the twentieth century, various 
schemes of classification were introduced. In 1942, a lymphoma classifica-
tion based on clinical and histological criteria was mtroduced by Gall and 
Mallory. In 1956, Rappaport presented a lymphoma classification which 
used two criteria to differentiate lymphoma subtypes: architecture and 
cell size (small, intermediate, and large). In 1978, Lermert was the first to 
recognize the follicle center cell, which became the basis of Lennert's Kiel 
classification. The "Revised European American Lymphoid neoplasms" 
(REAL) classification was mtroduced in 1994 (Table 1.1). Nowadays the 
REAL classification is widely used in Europe and North America and has 
recently been adopted in the new WHO classification [2]. For staging of the 
disease the Ann Arbor classification is still used, which is summarized in 
Table 1 2. 
I Precursor B-cell neoplasms Precursor B-lymphoblastic leukemia/lymphoma 
II Peripheral B-cell neoplasms 1 B-cell chrome lymphocytic leukemia/prolymphocytic leukemia/small 
lymphocytic lymphoma 
2 Lymphoplasmacytoid lymphoma/immunocytoma 
3 Mantle cell lymphoma 
4 Follicle center lymphoma, follicular 
Provisional cytological grades I (small cell), II (mixed small and large ce 
III (large cell) 
Provisional subtype diffuse, predominantly small cell type 
5 Marginal zone B-cell lymphoma 
Extranodal MALT type 
Provisional subtype nodal 
6 Provisional entity splemc marginal zone lymphoma 
7 Hairy cell leukemia 
8 Plasmacytoma/plasma cell myeloma 
9 Diffuse large Β cell lymphoma 
Subtype primary mediastinal (thymic) B-cell lymphoma 
10 Burkitt's lymphoma 
11 Provisional entity diffuse large B-cell lymphoma, Burkitt like 
Table 1 1 REAL classification of Β cell neoplasms 
Stage I Involvement of a single lymph node region, a single organ or a site other than the lymph nodes 
Stage II Involvement of two or more lymph node areas above or below the diaphragm; disease is found 
in only one organ or area outside the lymph nodes and in lymph nodes around it 
Stage III Involvement of lymph node areas on both sides of the diaphragm; disease may have spread to 
an area or organ near lymph nodes or to the spleen 
Stage IV Widespread involvement of one or more sites other than lymph nodes with or without lymph 
node involvement; disease has spread to only one organ outside the lymph node area, but the 
lymph node area is far away from the organ site 
Fable 1.2: Ann Arbor staging system 
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Standard treatment for NHL 
The incidence of NHL in the USA is 20.1 new cases per 100,000 inhabi­
tants per year. Treatment of NHL depends on tumor type, grade and stage 
of the disease. Patients with stage I NHL of an indolent type are treated 
with local external radiotherapy, with a cure rate of 80%-90%. Patients 
with stage II NHL of an indolent type are also treated with local radio­
therapy, but the chance for long-time disease-free survival is reduced to 
40%-50% at best. Patients with more advanced stages of indolent types of 
NHL are considered to be incurable. They can be treated with chloram­
bucil or COP (cyclophosphamide, vincristine, and predmsone), generally 
resulting in temporary remissions. After several relapses the lymphoma 
will become therapy resistant or it will histologically dedifferentiate to an 
NHL of higher malignancy grade. Patients with intermediate- or high-grade 
NHL are treated with anthracyclm-contaimng combination chemotherapy 
(three to four cycles for patients with stage I, eight cycles for patients with 
stage II, III, or FV), followed by radiotherapy if necessary in stage I disease, 
and on indication in the more advanced stages. 
Up to now only myeloablative therapy followed by allogeneic stem cell 
transplantation can potentially cure patients with relapsed low-grade NHL 
[3]. An initial "wait-and-see" policy in patients with advanced stages of low-
grade NHL without symptoms is accepted, as it does not influence overall 
survival. 
New treatment modalities for NHL are based on the use of monoclonal 
antibodies (mAbs). In this paper the developments in mAb-based therapies 
are reviewed. 
Immunotherapy with monoclonal antibodies 
In 1980, the first use of an idiotypic monoclonal antibody against malig­
nant lymphoma cells in a patient was described [4]. In this particular case 
antibody 89 ("Ab 89") was used to treat patient "N.B." without a clinical 
response. More immunotherapies were conducted, using mAbs against 
the immunoglobulin variable region (idiotype) of B-cell malignancies. With 
these anti-idiotype mAbs, responses were seen [5]. However, developing 
antibodies for each individual patient is very impracticable. These difficul­
ties can be avoided by using mAbs that recogmze antigens more univer­
sally expressed on the surface of the Β cells, such as HLA-DR, CD 19, CD20, 
CD21, CD22, CD37, and CD52. These antigens are expressed on Β cells in 
different stages of development. The earliest pre-B cells are defined by the 
expression of the cell surface antigens HLA-DR, CD34, and CD 19. Later in 
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their development stage, the pre-B cells express the pan-B-cell restricted 
antigen CD20, which functions as an ion channel. After maturation of the 
pre-B cells, the cells are exported to the peripheral blood and to lymphoid 
tissues. Mature Β cells express, amongst others, HLA-DR, CD19, CD20, 
CD21, CD24, and CD22. CD22 is a pan-B-cell adhesion molecule, and CD21 
is an Epstein-Barr virus receptor. During development, Β cells acquire sev­
eral other antigens (CD37, CD39, CDw75, CD76) which are present until 
the conversion to plasma cells. CD52 is not restricted to Β cells. It is also 
present on other leukocyte subspecies. 
Each of the Β cell-associated antigens has been used as a target anti­
gen to design an antibody-based immunotherapy. The success of such a 
therapy partly depends on many characteristics of the Β cell-associated 
antigen. The ideal target antigen has the following characteristics [6]: 
1. It should be expressed only on the malignant cell, and not on normal 
cells, to prevent elimination of the latter. 
2. The density of expression of the antigen on the B-cell surface should 
be high. 
3. The antigen should not be expressed in various variants. 
4. The antigen should not be secreted or shed by the malignant Β cell, 
as mAbs could interact with these circulating antigens. 
5. The antigen-antibody complex should not be internalized by the cell, 
to allow recognition of this cell by the immune system as a cell to 
be removed. (However, internalization of the antigen-antibody com­
plex is not always an unwanted characteristic. When using the mAb 
as a carrier of immunotoxins, internalization is needed to bring the 
toxin into the cell. Similarly, internalization could also be exploited 
to bring a radionuclide into a cell, as will be discussed later.) 
There are several mechanisms by which mAbs can kill lymphoma cells. 
Killer cells, being non-phagocytic mononuclear Τ cells, can recognize the 
Fc part of the bound mAb and subsequently kill the cell [7]. This is called 
antibody-dependent cellular cytotoxicity (ADCC). Furthermore, the mAb 
can activate the complement system. In complement-dependent cytotoxic­
ity (CDC), the conformational change in the Fc region of the IgG mAb with 
the antigen on the cell surface initiates the classical complement path­
way, resulting in lysis of the target cell [7]. Induction of apoptosis, or 
programmed cell death, is the goal of many anti-cancer therapies. Cross-
linked antibodies can induce apoptosis in lymphoma cells [8]. Finally, an-
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tibodies can interfere with a vital function of the target antigens on cells 
[9]. 
The first immunotherapy studies with mAbs against Β cell-associated 
antigens revealed that large quantities of murine antibody can repeatedly 
be infused into patients provided that the infusion rate is low. A rapid 
drop in circulating cells that bear the target antigen can be observed after 
a single mAb injection. Such a response usually lasts only a few hours. 
When antibody is infused every 3-4 days for several weeks, a sustained 
decrement may be achieved [9]. 
One of the problems to overcome when using murine mAbs is the de­
velopment of human anti-murine antibodies (HAMAs). HAMAs are endoge­
nous human antibodies directed against mouse antibodies. These antibod­
ies can be non-specific anti-isotypic, directed against constant regions in 
murine antibodies, or anti-idiotypic, directed against specific idiotypes of 
an injected mAb [10]. Both types of HAMA can limit effective mAb therapy 
by: 
1. Induction of immune complex formation, leading to serum sickness 
or renal toxicity 
2. Inhibition of binding of the mAb to tumor cells 
3. Increased removal of mAbs by the reticuloendothelial system [11] 
Usually, HAMA formation is clinically silent. However, anaphylaxis 
has been reported in a patient treated with murine mAbs in the pres­
ence of HAMAs, even after plasmapheresis [12]. Not all patients treated 
with murine mAbs develop HAMAs. It has been suggested that patients 
with lymphoid malignancies develop HAMA less frequently than patients 
treated with murine mAbs for other diseases, possibly because of the im­
munosuppressive nature of the disease and as a result of prior immuno­
suppressive therapy [13]. Especially the latter seems quite important, since 
HAMA formation occurred in 65% of previously untreated patients after 
treatment with a radiolabeled mAb [14], while none of 14 patients treated 
with the combination of fludarabine and the same radiolabeled mAb devel­
oped HAMAs [15]. HAMAs are not necessarily associated with decreased 
effectivlness of mAb therapy. It has been reported that the presence of 
HAMAs may even be associated with improved survival [16]. This associa­
tion may represent the effect of a functioning immune system. The pres­
ence of anti-idiotypic HAMAs might facilitate host recognition of tumor, 
as these antibodies mimic tumor cell antigen [16]. 
To overcome the development of HAMAs, human/murine chimeric con­
structs were developed. In a chimeric antibody, constant regions of the 
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heavy and light chains of the murine mAb are substituted by human re-
gions using molecular biological technology. Chimeric antibodies can gen-
erally be infused for a longer period of time without inducing HAMAs. 
Formation of human anti-chimeric antibodies is reported in a minority of 
patients with solid tumors treated with chimeric mAbs [17,18]. 
An even more sophisticated method to reduce the immunogenicity of 
murine antibodies is humanization of the antibodies. In a humanized an-
tibody, the murine hypervariable regions of the heavy and light chains 
(CDRs) are grafted into a human antibody framework. Theoretically, these 
mAbs should not be more immunogenic than regular human antibodies, 
although anti-idiotypic human anti-human antibodies (HAHAs) could still 
be induced against the hypervariable regions of these mAbs. 
By now a series of antibodies has become available for mAb treatment 
of NHL. Table 1.3 summarizes the mAbs that were clinically used. Only 























































Table 1.3: Monoclonal antibodies used for therapy of NHL 
Rituximab 
The most widely used antibody for unlabeled antibody therapy is C2B8, 
also known as rituximab (Rituxan, MabThera). This mAb, directed against 
CD20, can induce both CDC and ADCC [5], and — probably most impor-
tantly — apoptosis [8]. It is a chimeric human IgGl kappa antibody with 
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murine variable regions isolated from a murine anti-CD20 origin antibody 
(2B8) [19]. In a phase I single-dose escalation study, relevant anti-tumor re-
sponses were seen in 6 out of 15 patients [20]. In the subsequent multiple-
dose trial, 20 patients with relapsed NHL were treated with four weekly 
doses of rituximab [21]. Six out of 18 patients had a partial remission. The 
treatment was well tolerated. Based on the data from this trial, a weekly 
dose of 375mg/m2 was selected for a phase II trial, in which 34 évaluable 
patients were treated weekly for 4 weeks [22]. Complete remissions (CRs) 
were seen in three patients, and partial remissions (PRs) in 14. In the fol-
lowing phase III single-agent trial in 151 évaluable patients, CRs and PRs 
were recorded in 6% and 44% of patients, respectively [19]. To date, ritux-
imab is the only commercially available mAb for the treatment of NHL. 
Alemtuzumab 
Campath-IH (alemtuzumab, Campath, MabCampath) is a humanized IgGl 
mAb against the panlymphoid cell antigen CD52, registered for the treat-
ment of patients with chrome lymphocytic leukemia. It was also studied 
for the treatment of patients with NHL. Initially two patients with NHL 
were treated with alemtuzumab [23]. In both patients, lymphoma cells 
were cleared from the blood and bone marrow and splenomegaly resolved. 
One patient had lymphadenopathy which also resolved. Of the first seven 
patients treated in a phase II multicenter trial, three showed complete or 
partial responses [24]. In this study, patients with recurrent or progres-
sive low-grade NHL were treated with three weekly intravenous infusions 
of alemtuzumab. The study was prematurely stopped due to unaccept-
able toxicity. The most significant toxicity was profound lymphopenia and 
associated infection, usually of viral origin. Six of seven patients had cul-
ture or serologically documented infections and four patients had two or 
more of such episodes. All infections responded to temporary discontinu-
ation of antibody therapy and appropriate antiviral or antibiotic treatment. 
It was concluded that alemtuzumab has therapeutic activity against low-
grade NHL. However, application is limited by marked lymphopenia and 
an unacceptably high frequency of serious infections. 
In 1998, the European Study Group of Campath-1H Treatment in Low-
Grade NHL came to similar conclusions based on the results of a multicen-
ter phase II trial of alemtuzumab in 50 patients with advanced, low-grade 
NHL [25]. In this study six patients (14%) with B-cell lymphomas achieved 
a PR. Lymphopenia (< 0.5 xl09/l) occurred in all patients. Grade 4 neu-
tropenia was observed in 14 patients (28%). Opportumstic infections were 
diagnosed m seven patients and mne patients had bacterial septicemia. 
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Three patients died of infectious complications. Phase II studies with alem-
tuzumab are still being conducted in NHL patients. 
Epratuzumab 
hLL2 (epratuzumab, LymphoCide) is a humanized IgGl antibody against 
CD22. A phase I/II study, treating patients with indolent NHL with doses 
of epratuzumab ranging from 120-1000mg/m2 per week for 4 consecu­
tive weeks, revealed no dose-limiting toxicity [26]. However, 84% of these 
patients experienced one or more adverse events, the vast majority being 
grade 1 toxicity, like nausea, fatigue, chills, and fever. There was no evi­
dence of any HAHA response. Reduction of circulating Β cells occurred in 
several patients. 
No responses were seen at the lowest dose levels of 120mg/m2 per 
week and 240mg/m2 per week. Six of 14 patients treated at a dose level of 
360mg/m2 per week responded (2 CR, 4 PR), as well as 3 of 11 patients at 
the dose level of 480mg/m2 per week (1 CR, 2 PR). No objective responses 
were seen on the two highest dose levels of 600 and 1000mg/m2. There­
fore, future trials will use a dose of 360mg/m2 for 4 consecutive weeks. 
Epratuzumab is also studied for the treatment of diffuse large B-cell 
lymphoma. Preliminary data show that objective responses were seen in 5 
out of 22 patients (3 CR, 2 PR) [27]. Finally, epratuzumab is also studied in 
combination with rituximab in patients with follicular lymphoma (n = 16) 
and diffuse large B-cell lymphoma (n = 3), leading to a response rate of 
53% (10/19) [28]. 
Radioimmunotherapy 
Radionuclides 
Monoclonal antibodies can be used to guide radionuclides to malignant 
cells. Radiolabeled antibody treatment could in particular be effective for 
NHL, since it is a relatively radiosensitive and immunogenic malignancy. 
This treatment modality — radioimmunotherapy (RIT) — is fundamentally 
different from external beam radiation. The latter is based on relatively 
high dose rates for short periods of time. Between the treatment sessions 
there are periods of hours to days that no radiation is administered. Using 
RIT, the radiation is continuously delivered with a lower peak rate [29]. 
Radionuclides suited for RIT usually emit ^-radiation for irradiation 
of the tumor (cells). It is preferable for the radionuclide also to emit low-
energy y-radiation in a low abundancy in order to allow scintigraphic imag-
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mg while avoiding the need for extensive safety measures to prevent high 
doses for family members and medical staff. The radionuclide should have 
a half-life of several days to ensure the delivery of a sufficiently high dose 
to the tumor for a prolonged period of time. 
As long ago as in the late 1940s it was possible to label proteins with 
iodine-131 (131I) [30] For decades, 1 3 1 I was the main radionuclide used for 
RIT. However, the physical properties of 1 3 1 I are not ideal for RIT It has rel­
atively low-energy ^-emissions (mean 192 keV) and relatively high-energy 
y-rays (362 keV). The latter lead to high radiation doses for relatives and 
medical staff. Nevertheless, from the beginning the results of RIT in pa­
tients with NHL with 131I-labeled antibodies have been very promising. To 
avoid hypothyroidism caused by free radioiodme, adequate blockage of 
the thyroid gland with potassium chloride and potassium iodine is neces­
sary. 
More recent RIT studies used yttrium-90 (90Y) instead of 1 3 I I . 90Y de­
cays by pure ^-emission. The ^-particles of 90Y have a longer range 
than the 0-partides of Π 1 Ι because of the higher mean energy of the 
former. As 90Y does not emit y-rays, the m vivo distribution of the 
90Y-labeled antibodies can not be visualized. As discussed earlier, some 
target antigens are internalized by the cell after binding to an antibody 
(eg. CD22). 90Y is a radiometal that is retained intracellularly, whereas 
1 3 1 I is released from the cell after dehalogenation [31,32]. When tar­
geting internalizing antigens, the use of 90Y is preferred. To facili­
tate labeling of an antibody with 90Y, a chelating agent has to be con­
jugated to the mAb Once released from the chelate, 90Y is incorpo­
rated in the mineral bone, which could result in high radiation doses to 
the normal bone marrow. Chelators used to label antibodies with 90Y 
are mainly derivatives of diethylene tnamine penta-acetic acid (DTPA). 
Nowadays the most widely used chelators are macrocychc chelators 
like l,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetra-acetic acid (DOTA), 
1,4,7,1 l-tetraazacyclotetradecane-N,N',N",N"'-tetra-acetic acid (TETA), or 
6-[p-(bromoacetamido)benzyl]-TETA (BAT). These are chelating agents that 
form the most stable complexes with Y(III). 
Rhenium-186 (186Re) is another metallic radionuclide suitable for RIT. 
It emits both β- and y-radiation. The y-rays (emitted in only 9% of the 
disintegrations) are of low energy (137keV) whereas the ^-emissions are 
of medium energy (mean 362 keV). The low-energy and low-abundancy y 
is ideal for imaging and will not lead to high doses for medical staff and 
relatives of the patient. Although doses that are allowed for out-patient 
treatment may vary considerably depending on local legislation, in several 
countries there is no requirement to hospitalize patients after therapy with 
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186Re. The N2S2 chelate mercaptoacetyltriglycine (MAG3) can be used to 
attach 186Re to the mAb [33]. These radioimmunoconjugates are stable in 
vifro and in vivo, and radioimmunoconjugates with relatively high specific 
activities can be prepared. Another method of labeling antibodies with 
Re exploits sulphhydryl groups of the antibody to complex the rhenium 
species [34]. Although it was thought that rhenium would be retained in 
cells like other metalic radiolabels, some studies suggested the opposite 
[35]. 
Copper-67 (67Cu) can also be chosen for RIT. It has low-energy ß-
emissions (average 141 keV) and medium-energy y-rays (185 keV) suitable 
for imaging. It has been used for RIT since the early 1980s. 67Cu can be 
linked to a mAb using the macrocyclic chelator TETA. Unlike some other 
radiometals, 67Cu is not deposited in the skeleton or bone marrow [36]. 
However, it is not widely used owing to its limited availability. 
The most relevant properties of these ^-emitting radionuclides are 
summarized in Table 1.4. 
Radionuclide Half-life 0d\trdf;e Y M a x · range Advantages 





8.0 days 192 362 
64.0 h 935 
90.7 h 362 137 
61.9 h 141 185 
2.9 Easy labelling 
Inexpensive 





Ideal y for imaging 
1.8 Out-patient 
treatment possible 
Ideal y for imaging 
High radiation burden to medical 
staff and relatives 
In-patient treatment 
Thyroid blockage required 
Higher bone marrow dose in case 
of unbound yttrium 
No imaging possible 
Laborious labeling 
Laborious labeling 
Limited availability of nuclide 
Low ß-energy 
Table 1.4: Radionuclides used for RIT 
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Another approach is the use of radionuclides emitting «-radiation. Al-
pha particles have a very limited range in tissue (micrometers instead of 
millimeters) and a high linear energy transfer. At present, bismuth-213 
(213Bi) is used for RIT in patients with acute myelogenous leukemia by the 
group of Scheinberg at Memorial Sloan-Kettermg Cancer Center, New York 
[37] The half-life of this «-emitting nuclide is short (45.6 mm); this has the 
consequence that it is not feasible to use 213Bi in combination with mAbs 
that need hours or even days to target tumor sites which are not immedi-
ately accesible, as is the case in NHL. Because of the very short range of 
the «-particles, using «-emitters is not very suitable for treatment of bulky 
disease (as in NHL), but they could be attractive for use in micrometastatic 
diseases or minimal residual disease [38]. 
Dosimetry 
Radiation dose calculations, dosing schedules, and doses delivered to tu-
mors and normal organs are subject to intensive discussion There are 
various ways to determine the radioactivity dose to be administered: 
• Fixed doses 
• Body weight-based doses 
• Body surface area-based doses 
• Doses based on the estimated whole body dose 
• Doses based on the estimated red marrow dose 
For all radiolabeled mAbs, phase I studies have been conducted to deter-
mine the maximum tolerated dose (MTD). Without exception, dose-hrmting 
toxicity consists of leuko- and thrombocytopenia. In general, dosimetric 
calculations cannot forecast the outcome of therapy, nor can they predict 
the grade of toxicity following RIT. The need for patient-specific dosime-
try is a matter of debate. Some research groups advocate individual dosing 
based on a diagnostic study for dosimetric purposes. Others have shown 
that RIT can safely be based on the body weight of the patient only, with-
out the need for dosimetric calculations before treatment, provided that 
platelet counts are normal and bone marrow involvement is less than 25% 
[39]. 
Radiolabeled antibodies 
An overview of clinical studies with various mAbs and various radionu-
clides is presented in Table 1 5 
Study 
DeNardoeffl/. 1990 [40] 
Goldenberg et al. 1991 [41] 
Czuczman et al. 1993 [42] 
Pressera / . 1993 [43] 
Juweid et al. 1995 [44] 
White et al. 1996 [45] 
DeNardo et al. 1998 [46] 
Behref al. 1999 [47] 
Juweid et al. 1999 [31] 
Lindén et al. 1999 [48] 
O'Donnell et al. 1999 [36] 
Witzig et al. 1999 [49] 
Vose et al. 2000 [50] 
Davis et al. 2001 [51] 
Witzig et al. 2002 [52] 
Behref a/. 2002 [53] 
Postema et al. 2003 [54] 
Turner et al. 2003 [55] 
Scheidhauer et al. 2003 [56] 
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2 CR, 8 PR, 3 SD, 1 PD, 4 NE 
2 PR, 3 SD, 2 NE 
1 PR, 12 SD 
6 CR 
1 PR 
10 CR, 1 PD, 1 SD 
1 CR, 1 PR, 5 unk 
1 CR, 1 PR, 11 unk 
1 unk 
2 PR, 1 NE 
2 CR, 1 PR, 3 SD, 3 PD 
7 CR, 4 PR, 9 SD, 1 PD 
2 CR, 1 PR, 1 PD, 1 unk 
3 CR, 1 PR, 1 unk 
1 CR, 1 PR, 5 SD, 6 PD 
2 PR, 5 PD 
3 PR, 1 SD, 4 PD 
1 CR, 6 PR 
13 CR, 21 PR 
15 CR, 12 PR 
14 CR, 9 PR 
22 CR, 36 PR 
6 CR, 1 PR 
1 CR, 4 PR, 4 SD, 6 PD 
19 CR, 6 PR 
9 CR, 5 PR 
12 CR, 7 PR 
RID, Radioimmunodetection 
PD, progressive disease; NE, 
, tracer dose; CR, complete response; PR, partial response; SD, stable disease; 
not évaluable; unk, unknown 
Table 1.5: RIT of patients with NHL 
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Lym-1 
In 1987, DeNardo ef al. at UC Davis Medical Center, Sacramento, CA, 
treated a patient with Richter's syndrome — a malignant lymphomatous 
histological transformation of chronic lymphocytic leukemia — with a se­
ries of injections of 131I-Lym-l, currently also known as Oncolym, with a 
good clinical response and reduction of tumor volume [57], After this suc­
cess, 18 patients with B-cell NHL were treated with 131I-Lym-l at doses of 
l.ll-2.22GBq at 2-6 week intervals until a cumulative dose of 11.1 GBq 
had been administered or until HAMA responses were observed [40]. The 
rationale for fractionated doses of RIT was based on evidence that the ra­
diation dose to the tumor can be increased and that the dose tolerated by 
normal tissues is higher when the dose is fractionated [46]. Two patients 
had a CR following treatment, eight had a PR, three had SD, and one had 
disease progression. Four patients received only one treatment dose of 
^'I-Lym-l, without any response: these patients died or developed HAMA, 
so further treatment could not be given [40]. 
More recently, the same group determined the non-myeloablative MTD 
of the first two doses of 131I-Lym-l in 21 patients [46]. A maximum of four 
doses of 131I-Lym-l was allowed. The MTD of the first two doses of 1 3 1 I-
Lym-1 appeared to be 3.7GBq/m2. In this study, only three patients were 
repeatedly treated at this highest dose level. All three had CRs following 
treatment. Among all 21 patients, seven CRs and four PRs were reported. 
The DeNardo group also used Lym-1 labeled with 67Cu. Twelve patients 
were included in a phase I/II study using 67Cu-2IT-BAT-Lym-l for RIT of pa­
tients with progressive NHL after anthracycline-based chemotherapy [36]. 
A total of four courses of R1T was planned. Only one of 12 patients ac­
tually received all four doses. Three different dose levels were chosen. 
If grade 4 hematological toxicity occurred, the next dose was reduced by 
50%. One CR and six PRs were seen. The authors concluded that doses of 
6 'Cu greater than 1.85 GBq/m2 resulted in serious hematological toxicity. 
anti-Bl 
The group of Kaminski and Wahl at the University of Michigan Medical 
Center in Ann Arbor, MI, focussed on the treatment of NHL with 1 3 1 I-
labeled antibodies against CD20. They used the murine IgG2a anti-Bl an­
tibody, known as tositumomab. Nine patients were treated in a phase I 
dose-escalating study with one {n = 5) or two {n = 4) doses of 131I-anti-
Bl (Bexxar), preceded by a tracer dose and by variable amounts of unla­
beled antibody to determine whether presaturation of non-specific bind­
ing sites or reservoirs of non-malignant Β cells would allow better access 
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to tumor sites [58]. Optimal tumor targeting was obtained when adminis-
tering 685 mg unlabeled anti-Bl prior to administration of the radioiodi-
nated antibody. In some cases, pretreatment with unlabeled mAbs helped 
radiolabeled mAbs bypass an antigenic sink. Doses were calculated us-
ing increasing whole-body radiation doses as derived from a tracer dose 
study. Myelotoxicity occurred when whole-body radiation doses exceeded 
0.75 Gy, which was thus defined as the MTD [59]. In this non-myeloablative 
dose-escalating study in 28 patients, 14 patients had a CR and eight had a 
PR. 
In the following multicenter phase II trial, all patients received a dosi-
metric dose of 185 MBq 131I labeled to 35mg anti-Bl, preceded by an in-
fusion of 450mg unlabeled antibody [50]. After 1-2 weeks, 450mg unla-
beled antibody was again adminstered, followed by a therapeutic dose of 
131I-anti-Bl that led to an estimated whole-body dose of 0.75 Gy, if platelet 
counts were above 150xl09/l . If platelet counts were between 100 and 
150 xl09 / l , the whole-body dose was lowered to 0.65 Gy. Of 47 patients, 
six experienced a CR and 16 a PR. 
Finally, a randomized open-label multicenter study was conducted, 
comparing the efficacy and safety of 13 ̂ -labeled tositumomab to unla-
beled tositumomab in patients with relapsed or refractory CD20-positive 
NHL [51]. Seventy-eight patients were enrolled. The original NHL type was 
follicular lymphoma in 97% of patients, with 17% having experienced trans-
formation to an aggressive histology. Patients receiving 131I-tositumomab 
therapy were dosed as aforementioned. The patients randomized to un-
labeled tositumomab treatment received two doses of 485 mg, i.e. the 
same total antibody dose that is administered to patients treated with 131I-
tositumomab. Confirmed responses were documented in 23 of 42 (55%) 
patients who received tositumomab RIT (33% CR, 21% PR), and 6 of 36 (17%) 
patients who received tositumomab (8% CR, 8% PR), respectively. The me-
dian duration of confirmed responses for Bexxar-treated patients has not 
been reached yet, and for unlabeled tositumomab treated patients it was 
18 months. This study documents that the radioiodine component of RIT 
using 131I-tositumomab provides significant therapeutic effect over and 
above that provided by unlabeled tositumomab with an acceptable toxic-
ity profile [51]. In June 2003, the FDA approved Bexxar for the treatment of 
patients with CD20-positive follicular NHL, with and without transforma-
tion, whose disease is refractory to rituximab and has relapsed following 
chemotherapy. 
At present, the group in Ann Arbor is also using RIT as first-line treat-
ment, employing the same dosimetric and therapeutic procedures and 
doses as described above. In a phase II trial with 131I-anti-Bl in 76 pre-
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viously untreated patients with advanced stage follicular NHL, 48 patients 
achieved a CR and 26 a PR [14]. The 3-year progression-free survival was 
68.2% in this study. 
At the University of Washington in Seattle, WA, the group of Press et 
al. used the same 131I-labeled anti-Bl mAb for the treatment of refractory 
NHL. Their approach is different from that at Ann Arbor, as they re-infuse 
stem cells to enable administration of high, myeloablative doses of radiola-
beled anti-Bl. In aiming at myeloablation, toxicity to organs other than the 
bone marrow will limit the radiation dose that can be tolerated. Therefore 
a dose escalation study was designed in which the dose to tumor and crit-
ical normal organs was calculated using dosimetry and biopsy specimens 
after a diagnostic procedure with 131I-labeled mAbs. Doses were escalated 
based on the radiation dose absorbed by normal organs, ranging from 10 
to 30.75 Gy. This study showed that doses less than 27.25 Gy to normal 
organs did not cause serious, irreversible non-hematological toxicity [43]. 
In a subsequent trial, doses of 131I-anti-Bl estimated to deliver 27Gy to the 
dose-limiting organ, generally the lungs, were administered [60]. Recently, 
Johnson and Press updated the results of this myeloablative RIT with 131I-
labeled mAbs [61]. Complete responses were reported in 30 of 36 patients. 
A long-term follow-up study of the 29 patients treated with myeloabla-
tive doses of 131I-anti-Bl antibody has documented estimated overall and 
progression-free survival rates of 68% and 42%, respectively, with a median 
follow-up time of 42 months. To optimize the durability of responses, 
this group is currently conductmg a phase I/II trial studying the toxicity 
and efficacy of 131I-anti-Bl antibody given in combination with high-dose 
etoposide and cyclophosphamide, followed by autologous hematopoietic 
stem cell rescue. The role of RIT as reported here differs from other forms 
of R1T. In these cases RIT replaces total body irradiation. The duration 
of response achieved by this highly effective approach should especially 
be compared with the duration of response after chemotherapy followed 
by total body irradiation and stem cell support. In the aforementioned 
trial, the overall survival and the progression-free survival of the group 
treated with myeloablative RIT appear to be better than in the convention-
ally treated group [62]. 
2B8 
The anti-CD20 antibody 2B8 was the basis of the chimeric antibody nt-
uximab. This murine IgGl mAb labeled with 90Y is also applied in RIT. 
In an initial study both anti-Bl (n = 4) and 2B8 (n = 14) were labeled 
with t)0Y [63]. RIT was preceded by various amounts of unlabeled 2B8, 
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resulting in improved biodistribution of the radiolabeled antibody and 
decreased doses to the spleen and spine. In a subsequent multicenter 
trial, patients were pretreated with unlabeled ntuximab (C2B8), followed 
by 90Y-labeled ibritumomab (Y2B8, Zevalm). Fifty patients were treated 
in the phase I/II study [49]. Fifteen patients were treated with either 
7.4 or 11.1 or 14.8MBq/kg 90Y-2B8. In the next 35 patients a dose of 
14.8MBq/kg was chosen if platelet counts were above 150xl09/l, and a 
dose of ll.lMBq/kgif platelet counts ranged between 100 and 150xl09/l . 
RIT in this group of 35 patients was preceded by infusion of 250mg/m-
ntuximab. The overall response rate in both groups was 68% (13 CRs and 
21 PRs). As hematological toxicity correlated best with the amount of 90Y 
per kg body weight [64], doses of 14.8MBq/kg and 11.1 MBq/kg, respec-
tively, are used as described above. 
In a subsequent phase III trial, R1T with 90Y-ibritumomab was com-
pared with control immunotherapy with ntuximab in 143 patients with 
relapsed or refractory low-grade follicular or transformed CD20-positive 
NHL [52]. Patients received either a single intravenous dose of 14.8 MBq/kg 
of qoY-ibritumomab (n = 73) or four weekly doses of 375 mg/m2 of ntux-
imab (n = 70). The RIT group was pretreated with two ntuximab doses 
(2 50 mg/m2) to improve biodistribution and one dose of indium-111 (1HIn) 
ibritumomab for imaging and dosimetry. The overall response rate was 
80% for the 90Y-ibritumomab group versus 56% for the ntuximab group. 
CR rates were 30% and 16% in the RIT and ntuximab groups, respectively. 
Median duration of response did not differ between the two groups. Nei-
ther did the time to progression. Reversible myelosuppression was the 
primary toxicity noted with 90Y-ibritumomab. Zevalm was approved by 
the FDA in February 2002 [65]. 
C2B8 
In an increasing number of studies, the chimeric version of the 2B8 mAb 
is used for radiolabelmg and RIT. Behr et al. reported on the myeloab-
lative use of 131I-labeled ntuximab mstead of ibritumomab. In a study 
of five patients — two with high-grade and three with low-grade NHL — 
who received myeloablative RIT followed by autologous stem cell support, 
a CR was achieved m three [47]. When this approach was used in seven 
patients with mantle cell lymphoma, an aggressive and prognostically un-
favorable type of NHL, it even achieved a CR in six cases and a PR in one 
[53]. Another German group presented data on both myeloablative and 
non-myeloablative RIT using '3 ' I-ntuximab [56]. With the latter procedure 
in 26 patients, an overall response rate of 54% was achieved. Myeloablative 
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RIT of 25 patients led to a CR in 48%, and a PR in 28% of treated patients. 
In Australia, a phase II trial in 42 patients with relapsed or refractory 
NHL was conducted, using their own dosing regimen [55]. First, an infu-
sion of 375mg/m2 unlabeled rituximab was administered, followed by a 
tracer dose of 200 MBq 131I-rituximab. Dosimetric analysis was used to de-
termine the amount of radioiodine needed to deliver a whole body dose of 
0.75 Gy, comparable to the dosing scheme of 131I-tositumomab. This cal-
culated amount of 131I-rituximab was administered a week after the tracer 
dose, again preceded by an infusion of 375mg/m2 unlabeled rituximab. 
This approach led to grade 4 hematological toxicity in 2 of 42 patients. 
Nineteen patients of 35 évaluable patients (54%) showed CRs, 6 patients 
(17%) showed a PR to RTT. Nowadays, iodinated rituximab is used in Ger-
man, Australian and UK RIT trials. 
LL2 
At the Garden State Cancer Center, Belleville, NJ, a mAb against CD22 was 
developed. The murine IgG2a mAb or the F(ab')2 fragment was labeled with 
1311 and administered to 16 patients with NHL for radioimmunodetection. 
Seven patients were treated with 131I-LL2, consisting of a first injection of 
1.11 GBq, followed 1 week later by an injection of 0.74GBq [41]. In this 
study two PRs were seen. An update of this study, using variable doses 
of 131I-labeled murine IgG, F(ab')2, and in one case chimeric IgG, showed 1 
CR and 2 PRs in 17 patients treated with non-myeloablative doses of LL2 
[44]. Three other patients were treated with myeloablative doses of 131I-
LL2 followed by re-infusion of previously harvested bone marrow, two of 
whom achieved a PR. 
As described earlier, a humanized version of LL2 (hLL2, epratuzumab) 
was produced in order to reduce the immunogenicity. This antibody was 
used for RIT with both 131I and 90Y. The pharmacokinetics, dosimetry, and 
initial therapeutic results with 131I- and 111In-/90Y-labeled hLL2 were com-
pared [31]. Doses were calculated applying an estimated red marrow dose 
of 1 Gy, or 0.5 Gy in case of prior high-dose chemotherapy, as determined 
after administration of a tracer dose of 2 2 2 MBq ' 3 1 1- or n ' In-hLL2. Pro tein 
dose in all infusions was 0.75 mg hLL2 per kg body weight. In the 131I-hLL2 
treatment group (n = 13), one CR and one PR were observed. In the 90Y-
hLL2 group (n = 7), two PRs were seen. Treatment with both radiolabels 
was equally safe, and pharmacokinetics and dosimetry were similar, but 
the tumor dosimetry of 90Y-hLL2 appeared to be more favorable than that 
of 131I-hLL2. As CD22 is an antigen that is internalized by the Β cell, the 
use of 1 3 11 is thought to result in release of the radioiodine after process-
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ing of the labeled mAb in the cell. In contrast, radiometals are retained 
by the cell after internalization of the radioimmunoconjugate, which may 
contribute to the more successful use of 90Y attached to hLL2. Even at 
low doses of 90Y-hLL2, objective responses were seen. A group at the Uni-
versity Hospital in Lund, Sweden, gave patients two or three injections of 
only 185 MBq 90Y-hLL2/m2. Patients with prior high-dose chemotherapy 
and stem cell rescue received only 92.5 MBq 90Y-liLL2/m2. In five of eight 
patients, partial or complete responses were observed [66]. 
Currently the MTDs of non-myeloablative RTF with 90Y-hLL2 and 
myeloablative RIT with 90Y-hLL2 followed by stem cell re-infusion are be-
ing determined in two multicenter trials. 
At the University Medical Center Nijmegen, The Netherlands, we have 
been studying the use of 186Re-labeled hLL2 in a dose escalation study. 
The results of this study are discussed in Chapter 4 of this thesis [54]. 
Other mAbs used for RIT 
The antibodies and radionuclides described above are those that are cur-
rently of major interest. Other combinations have been used for RIT. MB-1 
is a mAb that targets CD37. The use of 131I-MB-1 in six patients, three of 
whom received a myeloablative dose level, led to CR in all six patients [43]. 
In later studies this group switched to anti-Bl. 
OKB7 is a mAb directed against CD21. Czuczman et al. described the 
use of 131I-OKB7 in 18 patients [42], in a phase I dose escalation trial. The 
MTD appeared to be 7.4 GBq 131I-OKB7 in four doses of 1.85 GBq. In one 
patient a PR and in 12 patients a mixed response were reported. No further 
studies of OKB7 in NHL patients have been published. 
White et al. described good clinical results using RIT with 90Y-labeled 
anti-idiotype antibodies: two CRs and one PR in nine patients [45]. Never-
theless, development of anti-idiotype mAbs is very laborious. 
Future role of RIT 
The promising results of RIT for the treatment of NHL justify further trials 
with radiolabeled mAbs. The response rates in future trials may increase if 
patient selection is not limited to those who have been heavily pretreated 
and have recurrent or refractory NHL. If patients are treated earlier af-
ter diagnosis and RIT is given before or in combination with conventional 
therapy, higher doses and more cycles of RIT could probably be given, as 
these patients have a better bone marrow reserve than those who have 
had multiple cycles of chemotherapy. Both approaches are currently being 
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persued. As mentioned above, first-line treatment of 76 patients with fol-
licular lymphomas using 131I-tositumomab showed a response rate of 97% 
[14]. At present more trials are being conducted with the same radiophar-
maceutical, e.g. in previously untreated patients with low-grade NHL after 
treatment with COP, and in patients with follicular NHL after treatment 
with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone). 
RTT could also be used in patients who are free of disease after conven-
tional therapy in order to establish a longer lasting disease-free interval. 
90Y-ibritumomab has been used in this group of patients in a pan-European 
trial 
Conclusion 
RIT is a new and apparently successful treatment modality for refractory 
or relapsed NHL. Various combinations of mAbs and radionuclides have 
been studied. Future randomized, prospective trials must determine the 
role of RIT in NHL management, as well as the most suitable mAbs and 
radionuclides. 
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Abstract 
The ability of a human B-cell lymphoma cell line to grow subcutaneously as 
tumors in nude mice was investigated. The effect of pretreating mice with 
cyclophosphamide or whole-body irradiation (WBI) was compared with no 
pretreatment of the mice. Both methods of pretreatment resulted in a 
higher tumor implantation rate, compared with that for non-pretreated 
controls. In mice that underwent WBI-pretreatment, a tumor implanta-
tion rate of 100% was observed, whereas mice pretreated with cyclophos-
phamide had a tumor implantation rate of 80%. In nonpretreated control 
mice, an implantation rate of only 50% was observed. Three weeks af-
ter injection, tumor size was significantly larger in mice of the pretreated 
groups, compared with that in mice of the group that did not receive pre-
treatment. Furthermore, particularly m the group pretreated with WBI, the 
tumors grew more synchronously, compared with tumors in the control 
group. Results of this study indicate that pretreatment with cyclophos-
phamide or WBI improves the tumor implantation rate of Ramos cells in 
nude mice, providing a workable animal model for studying human B-cell 
lymphoma. 
Introduction 
Immunotherapy with monoclonal antibodies (mAbs) and radioim-
munotherapy with radiolabeled mAbs are new treatment modalities for pa-
tients with recurrent or widespread malignancies. Patients with malignant 
B-cell lymphomas may respond especially well to this kind of treatment 
[1]. Mice with human tumors are used as models to optimize this kind 
of treatment (e.g., to determine which monoclonal antibody and which 
radionuclide would be the best choice for this kind of treatment). Ma-
lignant lymphomas are usually disseminated m vivo, as represented by 
mouse models using severe combined immune deficient (SCID) mice [2-5]. 
For evaluation of radioimmunotherapy, only one circumscribed, subcuta-
neous tumor lesion that allows evaluation of tumor growth, is preferable. 
For this purpose, athymic BALB/c mice bearing a subcutaneous lymphoma 
xenograft are used in most animal studies [6-12]. Transplantation of hu-
man lymphoma cells in nude mice is difficult [6]. Vuist et al. reported 
failure of several Burkitt's lymphoma cell lines (BJAB, EB3, Ramos, Jiyoye, 
and Namalwa) to grow subcutaneously. Only the Daudi cells eventually 
grew in BALB/c nude mice younger than eight weeks [6]. Leonard et al. 
observed that, after subcutaneous injection of Namalwa cells, none of the 
inoculated BALB/c nude mice developed a tumor [7]. In nude mice, num-
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bers of Β cells, natural killer (NK) cells, and macrophages are at least sim­
ilar to those in immunocompetent mice [13]. This residual immunologic 
defense is considered to prevent growth of some human tumors in nude 
mice [13-15]. 
To enhance induction and growth rates of tumor xenografts in nude 
mice, the following immunosuppressive strategies can be used: pretreat­
ment with cyclophosphamide [13,14], and pretreatment with whole-body 
irradiation (WBI) [7,13,15]. In the study reported here, the effect of both 
methods on tumor implantation and growth rate of Ramos cells in nude 
mice was investigated. 
Materials and methods 
Animals and husbandry 
Female, home-bred mice of the seventh generation BALB/c-nu inbred strain 
were studied. The mice were serologically screened for known rodent 
viruses according to recommendations of the Federation of European Lab­
oratory Animal Science Associations (FELASA) and were found negative 
for these viruses. The mice were housed behind strict barriers to main­
tain the specific-pathogen-free status. At the start of the experiment, the 
mice were six to eight weeks old and weighed 20.6 ± 1.0 g. The mice were 
housed in wire- and filter-topped Macrolon type-II cages (375 cm2, Techni-
plast, Utrecht, The Netherlands), five mice per cage, with autoclaved saw­
dust bedding (Woodyclean 3/4, BMI, Helmond, The Netherlands). Cages 
were cleaned once a week. Food pellets (RMH-GS, Hope Farms, Woerden, 
The Netherlands) and acidified tap water (HCl, pH 2.5 to 3) were provided 
ad libitum. The animal room had a controlled photoperiod (7 a.m. to 
7 p.m., lights on; 7 p.m. to 7 a.m., lights out), temperature (210C), rela­
tive humidity (±55%), and ventilation (15 air changes/h). 
Animals were treated and used humanely, according to the require­
ments of Dutch legislation. This experiment was approved by the internal 
review board for the use of laboratory animals. 
Cell culture 
Ramos cells (CRL-1596, American Type Culture Collection, Manassas, VA) 
were cultured in RPMI 1640 medium supplemented with 10% fetal bovine 
serum, penicillin (100U/ml), streptomycin (100μg/ml), and 100 mM L-
glutamine. Cell cultures were kept in logarithmic growth phase and were 
maintained in a humidified 5% CO2 atmosphere at 370C. On the day of 
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tumor cell inoculation, cell suspensions were centrifuged m 50-ml tubes 
at 500xg during 5 mm, washed once in RPMI 1640 medium, and resus-
pended in RPMI 1640 medium (108 cells/ml), then were injected into mice 
within 1 h. 
Experimental procedure 
Mice were randomly divided into three groups of 10 mice/group. One 
group served as a control group and did not receive any pretreat­
ment. The second group received cyclophosphamide (100mg/kg of body 
weight) mtrapentoneally [14]. Cyclophosphamide (Endoxan-Asta, Dagra 
Pharma B.V., Diemen, The Netherlands) was obtamed from the Department 
of Clinical Pharmacy. The third group received WBI by use of external beam 
radiation with 15 MeV electrons at a dose of 6 Gy, usmg a hnear accelerator 
(Saturne 42F, GE Medical Systems, Bue, France) [2,15]. During the WBI pro­
cedure, mice were kept m plexiglass boxes. Twenty-four hours after pre-
treatment, IO7 Ramos tumor cells m 0.1 ml were injected subcutaneously 
mto the right flank of the mice. 
Tumor growth was momtored by use of caliper measurements in three 
dimensions, and was performed by the same mvestigator (JM). Tumor 
growth was classified as negative, positive (but not yet measurable), or 
measurable. As soon as tumors were measurable, measurements were car­
ried out three times a week. Tumor volume of measurable tumors was 
calculated by assuming that tumors were ellipsoids [16], and the mathe­
matical formula for calculating the volume of an ellipsoid (Verr χ length χ 
width χ height) was used. Minimal detectable tumor volume was 50 mm3. 
Mice were considered suitable for further experiments when tumor volume 
was between 50 and 1,000 mm3. 
Analysis of data 
Tumor volumes measured three weeks after inoculation were compared 
statistically using Wilcoxon tests 
Results 
Figure 2.1 depicts mean tumor size m each group durmg three weeks af­
ter inoculation with tumor cells. Three weeks after injection, tumor sizes 
were significantly larger m both groups, compared with that for the control 
group (P = 0.01 for pretreatment with cyclophosphamide, Ρ < 0.01 for 
pretreatment with WBI). There were no significant differences between the 
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group pretreated with cyclophosphamide and the WBI pretreated group. 
Tumor behavior and tumor implantation rate markedly varied among the 
three groups. Therefore, the three groups are discussed separately. 
Control group 
In the control group, tumor growth was observed macroscopically 19 days 
after tumor induction in three mice (mean ± SD, 50 ± 10mm3). Tumor 
growth in these mice was relatively slow. On day 31 after tumor cell inoc-
ulation, all mice had a tumor with mean volume of 310 ± 322 mm3. Mean 
time from inoculation to first appearance of a tumor was 22 days. In five 
of these mice, tumors regressed. Thus, the tumor implantation rate in this 
group was 50%. 
Pretreatment with cyclophosphamide 
Macroscopic tumor growth in the mice that received pretreatment with 
cyclophosphamide, started 14 days after tumor cell inoculation, when four 
tumors appeared. On day 19 after tumor cell inoculation, all mice had a 
tumor, with mean volume of 213 ± 230 mm3. Two tumors regressed; thus, 
the tumor implantation rate in this group was 80%. 
Pretreatment with WBI 
In the group of mice that were irradiated prior to tumor inoculation, tumor 
growth became apparent 14 days after inoculation in nine mice, with mean 
volume of 100 ± 111 mm3. On day 19, all mice had a tumor, with mean 
volume of 257 ± 132 mm3. Regression of tumors was not observed; thus, 
the tumor implantation rate in this group was 100%. 
Discussion 
Tumor growth profiles of the groups indicate that both pretreatment meth-
ods enhanced tumor survival and growth rate. Tumor survival rate in-
creased from 50% to 80% in association with cyclophosphamide, and to 
100% in association with WBI. To allow evaluation of various therapeu-
tic strategies, it is essential that tumors do not spontaneously regress. 
In addition, in both pretreated groups, therapeutic experiments could be 
started within three weeks after tumor induction. Considering that tumors 
measuring between 50 and 1,000 mm3 could be used for further experi-
ments, 50% of the mice pretreated with cyclophosphamide were suitable 
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for actual experiments between days 18 and 21 after tumor cell inocula­
tion. For mice of the WBI-pretreated group, 100% were suitable for further 
experiments between days 14 and 21. In a subsequent experiment in 20 
mice, each pretreated with cyclophosphamide, 80% of the mice (16/20) had 
developed tumors with suitable size 14 days after inoculation. 
In the study reported here, we used athyrmc BALB/c mice. In most pre-
climcal studies with (radiolabeled) mAbs, athyrmc BALB/c mice were used 
[6-12]. Athymic BALB/c mice lack functional Τ cells. The SCID mice have 
even less residual immunity than do athymic mice; the former lack func­
tional Τ and Β cells. However, both mouse strains still have some NK-cell 
activity. Since SCID mice are even more immunodeficient than are BALB/c 
mice, these mice are also used m models of disseminated hematologic ma­
lignancies [2-5]. In those experiments, the lymphoma cells are injected 
intravenously, not leading to umformly comparable tumors. Induction of 
subcutaneous, human Hodgkin lymphoma xenografts in SCID and athymic 
mice were described by Kapp et al. [17]. After subcutaneous mjection of 
three Hodgkin lymphoma cell lines in three groups of five athymic mice, 
tumor growth was not seen in athymic mice. In three groups of five SCID 
mice, tumors were seen m three of five, three of five, and one of five of 
these mice. A fourth Hodgkin cell Ime induced subcutaneous tumors in 
three of five nude mice and five of five SCID mice. Finally, a fifth cell line 
did not grow at all in nude and SCID mice [17]. 
Results of this study indicated that both methods of pretreatment can 
improve the implantation rate of Ramos tumors in athymic BALB/c mice. 
Use of WBI-pretreatment was associated with tumor implantation rate up 
to 100%, rapid mduction of tumor growth, and synchronous growth of 
the tumors. Pretreatment with cyclophosphamide yielded less favorable 
results, but is easy to carry out, with good tumor implantation rate, 80%, 
in this experiment. 
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Abstract 
Radioimmuno therapy (RIT) is a new and effective treatment modality in 
patients with non-Hodgkm's lymphoma. The monoclonal antibody (mAb) 
hLL2 (epratuzumab), a humanized mAb directed against the CD22 antigen, 
and which internalizes, can be labeled with various radionuclides. The 
biodistribution of hLL2 labeled with 1311,186Re, 177Lu, and 88Y was studied 
in nude mice with subcutaneous human lymphoma xenografts in order to 
determine the most suitable of these four radionuclides for RTT with hLL2. 
Methods: Human Ramos lymphoma xenografts were transplanted m 
cyclophosphamide-pretreated athymic BALB/c mice. Four groups of mice 
were injected intravenously with 131I-, 186Re-, 88Y-, or 177Lu-labeled hLL2, 
respectively. To determine the non-specific tumor uptake, two groups of 
mice received 88Y-labeled or 131I-labeled control antibody, cG250. The 
biodistribution of the radiolabel was determined 1, 3, and 7 days postin-
jection (p.i.). 
Results: Radiolabeled hLL2 had a higher tumor uptake than the non-
specific mAb at all time-points, irrespective of the radiolabel used. Tumor 
accretion of 88Y- and 177Lu-hLL2 was higher than tumor uptake of 131I- and 
186Re-hLL2. Activity in the bone, represented by the femur without bone 
marrow, was higher for 177Lu- and 88Y-hLL2 than for 131I- and 186Re-hLL2 
on day 7 p.i. 
Conclusion: The use of the residuahzmg radiolabels 88Y and 177Lu in 
combination with a mAb directed against an internalizing antigen resulted 
in higher uptake and better retention of the radiolabel in the tumor. 
Introduction 
Radioimmunotherapy is an effective treatment modality for patients with 
non-Hodgkm's lymphoma (NHL) Various monoclonal antibodies (mAbs) 
and radionuclides are being used for this purpose [1,2]. At present, only 
the murine 90Y-labeled ibntumomab is approved for commercialization by 
the United States Food and Drug Administration [3]. Another radiolabeled 
murine antibody, 131I-tositumomab, is currently being studied in phase III 
clinical trials [4]. Both mAbs are of murine origin and both are directed 
against CD20 In contrast, hLL2 (epratuzumab) is a humanized mAb tar-
geting CD22 CD22 is a B-cell restricted marker, expressed on the B-cell 
surface during differentiation from the pre-B-cell stage [5]. Expression is 
lost during terminal differentiation to the plasma cell stage [5]. CD22 is 
rapidly internalized after binding the mAb LL2 [6]. Flow cytometric anal-
ysis of various Burkitt's lymphoma cell lines incubated with LL2 revealed 
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that 70% of Daudi cells, 42% of Raji cells, and 28% of Ramos cells were 
labeled with LL2 [7]. 
Currently, hLL2 is being investigated in clinical studies, labeled with 90Y 
[8] and 1 8 6Re [2,9] Previous studies, both in mice and humans, suggested 
a more favorable uptake in the tumor of 90Y-labeled hLL2, represented by 
the y-emitter ' " i n labeled to hLL2, than of radioiodinated hLL2 [10,11]. 
At present, two other radionuclides, 1 8 6Re and 177Lu, could be of interest 
for RIT. 177Lu is a radiometal with similar chemical properties as 90Υ . In 
contrast to 90Y, it emits y-radiation that could be used for imaging and 
dosimetric analysis. 1 8 6Re is a group-VII element, like 9 9 mTc, with ideal 
y-emissions of 137keV in 10% of disintegrations. The role of these ra­
dionuclides in combination with this internalizing mAb has not yet been 
determined in vivo. In the present study, the biodistribution of hLL2 la­
beled with four radionuclides, 1 3 1 I , 186Re, 88Y (as a representative of the 
pure ^-emitter C)0Y ), and 177Lu, was compared in a nude mice model with 
human lymphoma xenografts. 
Materials and methods 
Cells 
For the grafting of lymphoma xenografts, Ramos cells (CRL-1596, Amer­
ican Type Culture Collection, Manassas, VA) were cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum, 100U/ml of peni­
cillin, 100^g/ml streptomycin, and 100 mM L-glutamine. Cell cultures 
were kept in log phase and maintained in a humidified 5% CO2 atmosphere 
at 37 0C. On the day of tumor cell inoculation, cell suspensions were cen-
trifuged in 50-ml tubes at 1000 g for 5 minutes, resuspended in RPMI 1640 
medium (108 cells/ml), and injected within 1 hour. 
Animals and husbandry 
Female, locally-bred BALB/c nude inbred strain mice were used. The mice 
were serologically screened for known rodent viruses according to rec­
ommendations of the Federation of European Laboratory Animal Science 
Associations (FELASA) and found to be negative for these viruses. The 
mice were housed behind strict barriers to maintain a specific pathogen-
free status. At the start of the experiments, the mice were 6-8 weeks old. 
The mice were housed in wire- and filter-topped Macrolon type II cages 
(375 cm2, Techniplast, Utrecht, The Netherlands), five mice per cage, with 
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autoclaved sawdust bedding (Woodyclean 3/4, BMI, Helmond, The Nether-
lands). Food pellets (Ssniff R/M-H, 10 mm, Ssniff Spezialdiaten GmbH, 
Soest, Germany) and acidified tap water (HCl, pH 2.5-3) were provided ad 
libitum. The animal room had a controlled photoperiod (07:00-19:00 hours 
light, 19:00-07:00 hours no light), temperature (210C), relative humidity 
(approximately 55%), and ventilation (15 air changes/hour). Animals were 
treated and used according to the ethical requirements of Dutch legisla-
tion. This investigation was approved by the internal review board for the 
use of laboratory animals. 
Tumor grafts 
Lymphoma xenografts were grafted as previously described [12]. The 
mice were injected with 0.1mg/g cyclophosphamide (Endoxan-Asta, Da-
gra Pharma B.V., Diemen, The Netherlands) intraperitoneally. Twenty-four 
hours after pretreatment, 5x10' Ramos tumor cells in 0.2 ml were injected 
subcutaneously in the right flank of the mice. As soon as tumors were mea-
surable, 2-3 weeks after implantation, mice were considered to be eligible 
for injection with radiolabeled hLL2 for the biodistribution study. 
Antibodies, radionuclides, and labeling procedures 
hLL2 (epratuzumab, vials of 52 mg/10 ml) was obtained from Im-
munomedics, Inc. (Morris Plains, NJ), and stored at 4-80C. The chimeric 
mAb, cG250, an antibody directed against carbonic anhydrase isoform IX, 
which is not expressed on lymphoma cells, was used as a negative control. 
It was stored, treated and labeled similarly to hLL2. 
The radionuclide '311 was obtained from MDS Nordion S.A. (Fleurus, Bel-
gium), 186Re from Mallinckrodt Medical BV (Petten, The Netherlands), 88Y 
from Los Alamos National Laboratory (Los Alamos, NM), and 177Lu from 
the University of Missouri Research Reactor (Columbia, MO). The physi-
cal properties of these radionuclides are listed in Table 3.1. Labeling of 
hLL2 with 131I was performed using the iodogen method [13]. For labeling 
of 88Yand 177Lu, isothiocyanatobenzyl-diethylenetriaminepentaacetic acid 
(ITC-DTPA) was used as a chelator [14]. Mercaptoacetyltriglycine (MAG3) 
was used as a chelator for the labeling of the mAbs with 18(lRe [15]. 
After labeling, the radiolabeled mAbs were separated from unbound 
radioactivity by PD10 column gel filtration. Radiochemical purity of all 
preparations exceeded 95%, as determined by ITLC on silicagel strips using 
0.15 M citrate buffer, pH 5.0, as the mobile phase. The specific activity of 
each radiolabeled antibody preparation is listed in Table 3.2. Unlabeled 
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Half-life y Energy (abundance) Mean β energy 
~~ΓΓΓ\ 8.0 days 364keV(81%) 192keV 
'8, ,Re 3.8 days 137keV(10%) 362keV 
ΚΚΥ 107 days l,836keV (99%) -
',(IY 2.7 days - 935 keV 
'
77
Lu 6.7 days 208 keV 149 keV 
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Table 3.2: Groups of mice with lymphoma 
hLL2 was added to the radiolabeled antibody preparations until a total 
protein dose of hLL2 of 50 pg per animal was attained. 
Biodistribution and tumor dosimetry 
All mice were injected intravenously with 50 pg radiolabeled hLL2 per an­
imal via the tail vein on day 0. Six groups of at least 10 mice each were 
treated according to the radiolabel that was used (Table 3.2). 
The animals in each group were sacrificed on day 1, 3, or 7 postinjec-
tion (p.i.), respectively, by CO2 suffocation. Directly after death, blood was 
obtained by cardiac puncture. Tumor, thigh muscle, lung, liver, spleen, 
kidney, duodenum, and femur, without bone marrow, were dissected. The 
femur was flushed with 10 ml saline four times to remove the bone mar­
row. Periosteum was removed, and the femur dried for at least 1 hour. 
After weighing, the tissue samples and the calibration standards were 
counted in a well-type gamma counter (1480 Wizard 3", Wallac, Turku, 
Finland). The amount of radioactivity in the samples was expressed as 
percentage of the injected dose per gram sample weight {% ID/g). 
The absorbed tumor doses per administered unit of activity were esti-
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mated using the biodistribution data [16]. The trapezoidal method was 
used, given the mean uptake in the tumor at the three different time-
points, assuming that the activity at the time of injection was zero, and 
postulating that only physical decay was responsible for decime of activity 
in the tumor after 7 days p.i. [16]. After multiplication by the S values for 
each isotope, assuming umformly distributed activity in small unit-density 
spheres, the absorbed tumor dose resulted, expressed as Gy/MBq. 
Statistical analysis 
For comparison of the four radiolabels, one-way analysis of variance 
(ANOVA) was performed, using Bonferrom post-test correction. For com­
parison of 131I-hLL2 with 131I-cG250, and 88Y-hLL2 with 88Y-cG250, respec­
tively, unpaired i-test with Welch correction was used. Differences were 
considered statistically significant if Ρ < 0.05. 
Results 
The human lymphoma xenograft was transplanted in a total of 125 mice. 
At the time of dissection the mean tumor weight was 0.49 g. The biodistn-
bution of the radiolabeled antibody preparations on 1, 3, and 7 days p.i. is 
summarized in Table 3.3. 
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Day 1 p.i. Day 3 p.i. Day 7 p.i. 
(%ID/g±SD) (%ID/g±SD) (%ID/g±SD) 
Blood 
131I-hLL2 13.32±1.64 9.73±3.45 5.25±1.96 
18CRe-hLL2 16.26±1.40a 11.19±1.70 7.09±1.79 
177Lu-hLL2 15.29±2.97 11.52±1.72 8.74±1.47 a 
88Y-hLL2 13.83±1.29 11.84±2.07 5.68±2.33 
M 1I-cG250 17.35±2.39b 13.64±1.54 b 9.25±1.85 b 
88Y-cG250 16.92±1.65 c 15.11+0.88° 11.51±0.6Γ 
Muscle 
l ,1I-hLL2 1.45±0.25 1.00±0.23 0.52±0.23 
18,1Re-hLL2 1.43±0.34 1.09+0.20 0.67±0.16 
,77Lu-hLL2 1.26±0.26 1.00±0.18 0.90±0.19 a 
88Y-hLL2 1.32±0.22 1.07±0.20 0.78±0.46 
1 t lI-cG250 1.15±0.18b 0.88±0.08 0.67±0.12 
88Y-cG250 1.52±0.18 1.33+0.23 1.14±0.10 
Tumor 
131I-hLL2 4.75±1.03 4.40±0.99 2.27±1.08 
l8fiRe-hLL2 4.52±1.16 6.05 + 1.57 3.92±1.40 
l77Lu-hLL2 8.17±1.23'1 12.01±3.69α 12.03±2.71 a 
88Y-hLL2 6.64±1.61' , 14.14±3.19' , 8.34±3.18d 
, 3 1I-cG250 2.82±0.92b 2.05±0.10 b 1.59±0.21 
88Y-cG250 3.35±0.45 t 3.32±0.3Γ 2.84±0.14 l 
Lung 
n iI-hLL2 8.49±1.49 6.14±2.16 3.34±1.37 
18f>Re-hLL2 10.04±1.82 7.45 + 1.20 4.95±1.82 
177Lu-hLL2 8.79±1.56 7.67±0.96 6.67±1.13'' 
88Y-hLL2 7.59±0.91 7.42±1.22 4.27±1.37 
n i I-cG250 9.74±1.23 7.88±0.86b 4.91±0.76 b 
88Y-cG250 8.52±0.62 8.80±0.91 6.99±0.95 c 
Spleen 
131I-hLL2 3.55±0.78 2.60±0.93 1.38±0.65 
18CRe-hLL2 4.91+0.63d 3.51±0.58 2.06±0.54 
177Lu-hLL2 5.39±1.59a 6.16±1.14 a 7.81±1.44 a 
88Y-hLL2 3.84±0.46 4.26±0.48· , 3.98±1.06· , 
m I - c G 2 5 0 2.99±0.70 2.02±0.33 1.50±0.37 
88Y-cG250 4.53+0.39 4.51±0.41 6.34±0.62 c 
Kidney 
131I-hLL2 4.27±0.51 2.99±0.88 1.61±0.56 
'8r'Re-hLL2 5.04±0.61 3.54±0.47 2.21±0.61 
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Day 1 p.i. Day 3 p.i. Day 7 p.i. 
(% ID/g±SD) (% ID/g±SD) (% ID/g±SD) 
'"Lu-hLLZ 
8KY-hLL2 

























































































''Uptake of hLL2 with this radiolabel significantly higher 
when compared with hLL2 with other radiolabel(s) at this 
time-point (P < 0.05) 
bUptake of 131I-cG250 significantly different when com­
pared to n iI-hLL2(P <0.05) 
cUptake of 88Y-cG250 significantly different when com­
pared to 88Y-hLL2 (P < 0.05) 
Table 3.3: Biodistribution of radiolabeled antibodies in a human lym­
phoma model 
The control antibodies 1 3 1 I - and 88Y-cG250 had longer circulation times 
than n i I - and 88Y-hLL2, probably due to the fact that chimeric antibodies 
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Figure 3.1: Uptake in lymphoma xenografts. 
were used as control antibodies. There was no significant difference in 
amount of circulating radiolabeled hLL2 on the three time-points when 
comparing the four different radiolabels. Tumor uptake of 177Lu- and 88Y-
hLL2 was significantly higher when compared with tumor accretion of 131I-
and 186Re-hLL2 on days 1, 3, and 7 p.i. 1311- and 88Y-hLL2 tumor uptake was 
significantly higher when compared with 131I- and 88Y-cG250, respectively, 
at all time-points, as shown in Figure 3.1. Using the tumor uptake data and 
the mean tumor weight of 0.49 g, the aborbed tumor doses per adminis-
tered unit of activity were estimated: 0.8 Gy/MBq for 131I-hLL2, 1.0 Gy/MBq 
for 186Re-hLL2, 2.1 Gy/MBq for 177Lu-hLL2, and 3.2 Gy/MBq for 90Y-hLL2. 
The uptake in the liver and the spleen of 177Lu and 88Y was significantly 
higher when compared to the uptake of 186Re and 131I, both for radiola-
beled hLL2 and for radiolabeled cG250. Uptake of 177Lu in the kidney was 
significantly higher when compared with the other three radiolabels. 
Since unbound 88Y and 177Lu tend to be incorporated in mineral bone, 
the activity in the bone was determined, as shown in Figure 3.2. The data 
show significantly higher accumulation in the bone of 88Y and 177Lu than 
of 131I and 186Re (P < 0.05 on day 7 p.i.). 
Discussion 
In the present study we have determined the biodistribution of the hu-
manized anti-CD22 antibody LL2 labeled with different radionuclides in 
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Figure 3.2: Uptake in femur. 
nude mice with human lymphoma xenografts. The data show that uptake 
in the tumor varies from 2-14% ID/g, depending on the radionuclide and 
the time after injection. If the animals would have been treated at MTD, 
these uptake values would have led to an absorbed tumor dose of approx-
imately 15 to 60 Gy. The fact that tumor uptake is not high may partly 
be due to the cell line used. As stated earlier, about 28% of Ramos cells 
are reactive with liLL2 [7]. However, with this cell line a workable animal 
model for these studies was obtained, as described earlier [12]. This study 
also indicated that tumor uptake of yttrium- and lutetium-labeled hLL2 
is higher when compared to 131I- and 186Re-labeled hLL2. In a previous 
study, tumor uptake of the radioiodinated hLL2 did not exceed that of the 
non-specific control antibody in a mouse lymphoma model [17], but the 
present study shows a significant difference in tumor uptake of radioiodi-
nated hLL2 over radioiodinated cG250. In vivo, 131I-labeled hLL2 is rapidly 
catabolized within the lysosomes after internalization by the tumor cell. 
The radiolabel catabolites are rapidly released from the lysosomes and the 
cell [6,18]. To improve retention of the radioiodine in the cell, a residual-
izing iodine radiolabel, dilactilol-iodo-tyramine, was developed, leading to 
higher retention of 131I in tumors in nude mice [18]. 
Other studies suggested to use radiometals, like 111In, 90Y, '"Lu, 
or 67Cu for radioimmunodetection and radioimmunotherapy, since these 
have a higher intracellular retention following internalization than iodine 
[10,11,17,19-21]. Not only absorbed doses in tumors appeared to be 
higher when using 90Y-hLL2 instead of 131I-hLL2, tumor-to-marrow, tumor-
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to-lung and tumor-to-kidney ratios also increased in a clinical study [11]. 
Some studies suggest the use of '"Lu instead of qoY [16,22]. 177Lu has 
as an advantage over 90Y in that it emits y-radiation, which is useful for 
dosimetry and/or imaging. Since only 11% of disintegrations of 177Lu are 
accompanied by medium-energy y-rays, treatment could also be given on 
an outpatient basis in most countries. The present results show compa-
rable uptake of 177Lu and 90Y in both tumor and other organs. Therefore, 
177Lu could be an interesting alternative for 90Y. De Jong et al. recently 
suggested that the optimal tumor diameter for R1T with 90Y-labeled pep-
tides is 34 mm [22]. For RIT of smaller tumors, 90Y is less suitable. At 
present, RIT is mostly studied in patients with recurrent or refractory lym-
phoma. 90Y is a good choice, given the tumor size in this patient popula-
tion. However, in patients with minimal residual disease receiving consoli-
dation therapy, 17'Lu could be a better choice than 90Y. In this experiment, 
uptake of 177Lu in normal organs, such as spleen, liver, and kidneys, was 
highest compared with the other radionuclides, although this observation 
was not reported by others. This observation does not prove that absorbed 
doses in the organs mentioned will be higher, but attention should be paid 
to absorbed doses in normal organs in future RIT trials in patients. Look-
ing at the favorable physical properties of ^'Lu, 6 'Cu would be a suitable 
alternative radiometal that could be used for RIT of lymphoma. Studies 
in mice and patients with lymphoma showed that the use of 67Cu-labeled 
anti-lymphoma mAb Lym-1 is more preferable than the use of 131I-labeled 
Lym-1 [20,21]. Because of the high costs and sporadic production, b7Cu 
was not included in our study, although a direct comparison of this ra-
dionuclide with 177Lu and 90Y would be very interesting. 
Uptake in the bone of 177Lu was as high as the bone accretion of 88Y, 
suggesting that both radiometals are incorporated into the mineral bone to 
the same extent. This property could be disadvantageous for RIT. The bone 
marrow is the dose-limiting organ when giving non-myeloablative RIT. In-
corporation of unbound radiometals in the bones could result in higher 
absorbed doses in the bone marrow, limiting the maximum activity dose 
of the radiolabeled antibody preparations that can be administered safely. 
A factor that might have influenced the uptake in the bone is the chela-
tor used. The effect of the chelator was investigated by Govindan et al. in 
athymic mice with Ramos lymphoma xenografts; liLL2 was labeled with 88Y 
using either benzyl-DTPA or l,4,7,10-tetraazacyclododecane-N,N',N",N"'-
tetraacetic acid (DOTA) [23]. Biodistributions of 88Y-benzyl-DTPA-hLL2 
and 88Y-DOTA-hLL2 were comparable, except for the uptake in the bone, 
which was higher when benzyl-DTPA was used as a chelator [23]. This 
observation was even more pronounced in the recently published study, 
54 3. Biodistribution of radiolabeled hLL2 in nude mice 
comparing 88Y-2-(4-isothiocyanatobenzyl)-6-methyl-DTPA-hLL2 with 88Y-
D0TA-hLL2 in the same animal model [24]. Up to 4-fold more yttrium 
was present in the bones after 7 and 10 days p.i. when using the former 
radiopharmaceutical, compared to the latter [24]. DeNardo et al. presented 
data concordant with these findings. Both 67Cu and 90Y did not show in-
creased bone uptake when a macrocyclic chelator was used to label Lym-1, 
which was the case when DTPA was used as a chelator [19]. Therefore, the 
use of DOTA-hLL2 seems preferable in the clinical situation. 
186Re is not incorporated in mineral bone, and thus in vivo release of 
l86Re does not cause enhanced radiation doses to the bone marrow. Al-
though the physical characteristics of 186Re seem to be ideal for RIT of 
lymphoma and despite the fact that unbound 186Re is rapidly excreted 
mainly via urine, the uptake in tumors appears to be lower when com-
pared to 90Y- and 177Lu-hLL2. This observation is in line with the results 
of Steffens et al. comparing 186Re with " ^ n and 125I in combination with 
G250 in a renal cell carcinoma mouse model [25]. Shih et al. also concluded 
that upon internalization, 186Re has relatively poor intracellular retention 
[26]. Although the clinical results with 186Re-hLL2 are promising [9], it is 
suggested by the present study that 90Y-hLL2 might be a better choice. 
The clinical relevance of biodistribution studies and dosimetric analysis 
in animal models should not be overestimated. Although this study sug-
gests that the combination of 90Y or 177Lu and hLL2 might be preferable, 
it remains to be demonstrated that clinical responses will be better when 
using these radionuclides, since there is no obvious difference in the thera-
peutic efficacy of 131I-tositumomab as compared to 90Y-ibritumomab, both 
targeting the same CD20 antigen. Response rates ranging from 60 to 80% 
have been obtained in comparable patient populations with both prepara-
tions [4, 27]. Other factors, such as (i) the way the radiolabeled antibody is 
handled in VJ'VO, (ii) the chelator that is used, and (iii) the extent of myelo-
toxicity in a group of patients who have received prior myelosuppressive 
chemotherapy, are probably as important in determining the antitumor 
efficacy of radiolabeled antibody preparations. 
In conclusion, although 186Re has advantages over the radiometals 
177Lu and 90Y when labeled to hLL2, the latter two display the most fa-
vorable tumor uptake. Like other studies, this investigation confirms that 
the biodistribution and tumor uptake of 131I-hLL2 are the least suitable for 
this purpose. 
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Abstract 
Purpose: Radioimmunotherapy (RTT) is an effective, new treatment modal-
ity for non-Hodgkm's lymphoma (NHL). The aim of this study was to deter-
mine the maximum tolerated dose and a first impression of the therapeutic 
potential of 186Re-epratuzumab in patients with NHL. 
Experimental Design: Patients with relapsed or refractory CD22-
positive NHL of diverse histopathology and prior treatments received 
99mTc-labeled epratuzumab (anti-CD22 IgGl), followed by RIT with 186Re-
epratuzumab 1 week later. Dose escalation of RIT was started at 
0.5 GBq/m2. Three patients were entered per dose level. If no dose-limiting 
toxicity occurred, the dose was increased by 0.5 GBq/m2; otherwise three 
additional patients were included on that dose level. 
Results: A total of 18 patients received a diagnostic dose of 
99mTc-epratuzumab. Fifteen patients were actually treated with 186Re-
epratuzumab at four different dose levels, 0.5, 1.0, 1.5, and 2.0GBq/m2. 
During or after infusion of 186Re-epratuzumab, no adverse reactions were 
seen. In all patients, a transient decrease of leukocyte and platelet levels 
was observed 1 month after treatment. At the 1.5 -GBq/m2 dose level, one 
grade 4 hematological toxicity was observed. At the highest dose level 
of 2 GBq/m2, no grade 4 hematological toxicity was seen, but WBC and 
platelet counts of two of the three patients did not recover completely. 
One patient had a complete remission lasting 4 months. Four patients 
had a partial response, lasting 3, 3, 6, and 14 months, respectively. Four 
patients had stable disease for 3, 3, 7, and 9 months, respectively. 
Conclusions: 186Re-epratuzumab at a dose of 2.0 GBq/m2 is well toler-
ated without major toxicity. A single dose of 186Re-epratuzumab led to 
objective responses m 5 of 15 treated patients. 
Introduction 
In the last decade, radioimmunotherapy (RIT) has become a rather suc-
cessful treatment modality for patients with refractory or relapsed non-
Hodgkin's lymphoma (NHL) [1,2]. Several phase I/II studies with 13lI- or 
90Y-labeled monoclonal antibodies (mAbs) have shown promising thera-
peutic results. One radiolabeled antibody, 90Y-labeled ibritumomab, has 
been approved recently for commercialization by the United States Food 
and Drug Administration after a successful randomized phase III trial [3-
5]. In this study, radiolabeled antibody treatment was shown to be sig-
nificantly more effective than treatment with unlabeled antibodies alone 
[5]. The two currently most widely studied and used mAbs are the murine 
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anti-CD20 antibodies, ibritumomab and tositumomab. Although study re-
sults confirm the enormous potential of these new drugs against NHL, 
they both have the disadvantage of being murine antibodies. The use of 
murine mAbs could induce the formation of human anti-mouse antibodies 
(HAMAs), eventually preventing repeated treatment with this radiophar-
maceutical Therefore, the use of chimeric or, preferably, humanized anti-
bodies is desirable. 
Another important issue in RIT is the choice of the radionuclide to 
be used. Both 90Y and 131I are widely used in RIT. 131I could be dis-
advantageous, however, because it emits high-energy, high-abundance y-
rays, requiring hospitalization of treated patients for radiation safety rea-
sons. It also emits low-energy ß-radiation with a limited penetration 
range m tissue, which could also be disadvantageous when treating pa-
tients with bulky disease 90Y emits high-energy ß-radiation but lacks y-
emissions, prohibiting scintigraphic evaluation after treatment. Rhemum-
186 (186Re) has ideal physical characteristics for RIT. It has medium-energy 
^-emissions and low-abundance y-photons with ideal energy (137keV) for 
scintigraphic imaging. 
In this study, the humamzed anti-CD22 mAb epratuzumab was used, 
which is also being investigated as an unlabeled mAb as well as a mAb 
labeled with the radionuclides 131I and 90Y. The aim of the study was to 
determine the safety and the maximum tolerated dose (MTD) of RIT using 
epratuzumab labeled with 186Re. 
Materials and methods 
Patient population 
This dose-escalation study was performed in patients with B-cell NHL who 
had relapsed after or did not respond to at least one line of treatment and 
who were not eligible for potentially curative high-dose chemotherapy fol-
lowed by stem cell support. All patients had histologically proven, CD22-
positive NHL. Patients had to have a life expectancy of at least 2 months 
and had to be at least 18 years of age. Patients had to have a WHO per-
formance status of 0, 1, or 2 No other antitumor therapy should be given 
within at least 3 weeks before study entry. WBC count had to be at least 
2.5 xl09 / l , and platelet count had to be at least 75 xl09 / l Patients were 
excluded in case of life-threatening infection, allergic diathesis with cur-
rent complaints, organ failure, pregnancy, known seropositivity for HIV, 
> 25% bone marrow involvement by lymphoma as determined by bone 
marrow histology and histochemistry, concomitant treatment with other 
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investigational drugs, or spread of the malignancy to the central nervous 
system. The study was approved by the institutional review board of the 
University Medical Center Nijmegen. Written informed consent was ob­
tained from all patients. 
Antibody 
Epratuzumab (hLL2) is a humanized monoclonal IgGl antibody directed 
against CD22 on Β cells [6]. CD22 is expressed in the cytoplasm of early 
pre-B and progenitor cells and appears on the surface of mature Β cells. 
The CD22 antigen is broadly expressed on both normal and malignant 
Β cells, with a distribution comparable to that of CD20, although anti­
gen density may be more variable [7]. Unlabeled epratuzumab is used in 
clinical trials in chemotherapy-refractory NHL patients [8] and in combina­
tion with rituximab [9]. Initial data of the phase I/II dose-escalation study 
show that the lowest dose level at which objective responses were seen was 
the dose level with four weekly infusions of 240mg/m2 epratuzumab [8]. 
Epratuzumab was kindly provided by Immunomedics, Inc. (Morris Plains, 
NJ) as a sterile pyrogen-free solution. 
Labeling 
Epratuzumab was labeled with 9 9 m Tc using mercaptoacetyltriglycine 
(MAG3) as a chelator according to the method described by Visser et al 
[10]. A preparation with a specific activity of 100MBq/mg was prepared. 
Patients received 750 MBq of 99mTc-MAG3-epratuzumab. The protein dose 
of the preparation was adjusted to 0.5 mg/kg body weight with unlabeled 
epratuzumab. 
186Re-epratuzumab was prepared according to the same method [10]. 
Again, the protein dose of the preparation was adjusted to 0.5 mg/kg body 
weight by adding unlabeled epratuzumab to the radiolabeled preparation. 
Protocol 
Pretherapy evaluation consisted of history, physical examination, blood 
sampling for hematological and biochemical analysis, bone marrow histol­
ogy and cytology, and computed tomography of the chest and abdomen. 
After inclusion, a diagnostic dose of 750 MBq of 99mTc-epratuzumab was 
administered i.v. over 45 min. One week after this diagnostic procedure, 
the patient was hospitalized overnight for RIT with 186Re-epratuzumab. 
The infusion time of 186Re-labeled epratuzumab was also 45 min. The 
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starting dose level was 0.5 GBq/m2 body surface area. If no dose-limiting 
toxicity occurred (i.e., no grade 3 or 4 non-hematological toxicity and no 
grade 4 hematological toxicity according to the National Cancer Institute 
Common Toxicity Criteria 2.0) in consecutive patients, the dose level was 
escalated by 0.5 GBq/m2. Three patients were included at each dose level. 
If dose-limiting toxicity was observed in one patient at a specific dose level, 
three additional patients were treated at that same dose level. In case of 
dose-limiting toxicity in two or more patients at a particular dose level, 
the dose level below that level would be considered the MTD. Patients 
were monitored weekly for adverse reactions and toxicity. Patients were 
evaluated for responses 4-6 weeks after RIT, using physical examination, 
biochemical analysis, computed tomography scanning, and bone marrow 
examination, as far as involved at the start. In case of stable disease (SD) 
or responses, this procedure was repeated every 3 months thereafter. 
Pharmacokinetics 
Blood samples for pharmacokinetics were taken 10 min, 30 min, and 1, 2, 
3, 4, and 24 h after injection of the diagnostic dose of 99mTc-epratuzumab. 
After RIT, blood samples were taken at the same time points and addition­
ally after 2, 5, 7, and 14 days. mAb blood clearance rates were determined 
by counting the samples in a shielded well-type counter. The plasma clear­
ance of 99mTc-epratuzumab was fit to a monoexponential function, and the 
blood clearance of 186Re-epratuzumab was fit to a biexponential function. 
On the basis of these curves, Ύιη (the time point when 50% of the activ­
ity was cleared from the circulation), Ti/..,« (representing the distribution 
phase), and Ύι/>,β (representing the elimination phase) were calculated. 
HAHA analysis 
Serum samples for human anti-human antibody (HAHA) analysis were ob­
tained before the infusion with 99mTc-epratuzumab, before the infusion 
with 186Re-epratuzumab, and 7, 14, 28, and 56 days after treatment. An 
ELISA performed by Immunomedics, Inc. was used to assess human anti-
hLL2 antibodies. Results were reported as a number (in ng/ml) or as un­
detected (< 1 ng/ml). Levels above 50ng/ml are considered to be elevated 
(results from Immunomedics, Inc.). 
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Scintigraphy 
One hour and 1 day after injection of the diagnostic dose, a whole body 
scan was made with a double-head gamma camera (Siemens Multispect 2; 
Siemens Medical Solutions USA, Inc., Hoffmann Estates, IL) equipped with 
low-energy, high-resolution collimators. Scintigraphy after RJT was per­
formed 1 h, 1 day, 2 days, and 5 days postinjection at a speed of 5 cm/min. 
Dosimetry 
Scans made after RIT were used for dosimetric analysis. Regions of in­
terest (ROIs) were drawn around the whole body, heart, right lung, liver, 
spleen, left kidney, and testes. Background regions were drawn adjacent 
to these ROIs. Using the counts in the ROIs, corrected for background, res­
idence times in the organs as listed above were estimated. These residence 
times were entered in MIRDOSE3, version 3.1 (Oak Ridge Associated Uni­
versities, Oak Ridge, TN) to calculate absorbed doses. For males, the adult 
phantom was used; for females, the adult female phantom was used. The 
absorbed dose in the bone marrow was calculated using the blood-derived 
method as described by Shen et al. [11]. 
Results 
Patient characteristics 
Eighteen patients (12 men and 6 women) were included, 15 of whom 
were actually treated. The mean age was 57 years (range, 41-75 years). 
Patient characteristics are listed in Table 4.1. The number of courses 
of chemotherapy and/or external beam radiation before inclusion in our 
study ranged from 1-7, with a median number of 4. Of these patients, 
three had had high-dose chemotherapy followed by autologous periph­
eral stem cell transplantation. Three patients were not treated with 186Re-
epratuzumab because of unfavorable biodistribution (η = 2), as described 
in "Scintigraphy" and because of an acute allergic reaction to the first, 
diagnostic infusion (?i = 1), as described in "Toxicity" section. Patients 
were treated at four different dose levels, 0.5 GBq/m2 (n = 3), 1.0GBq/m2 
(n = 3), 1.5 GBq/m2 (n = 6), and 2.0GBq/nr (n = 3). 
Toxicity 
During or directly after infusion of the diagnostic dose of 750 MBq of 
qqmTc-epratuzumab, fever and chills were observed in 9 of 18 patients 
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within 1 h after infusion. This reaction was self-limiting and required no 
specific medical intervention. Chills lasted 30-45 min, whereas the fever 
lasted several hours. One patient experienced an acute allergic reaction 
with airway obstruction within half an hour after infusion, for which ad-
ministration of clemastine and prednisolone and inhalation of albuterol 
and ipratropium were required. One patient had slight dyspnea during 
infusion, which diminished after stopping the infusion. After restart of 
the infusion at half speed, the dyspnea did not recur. Two patients had 
a vasovagal episode after infusion. Finally, one patient had herpetiform 
lesions on the left lower arm 1 week after the diagnostic infusion. During 
infusion of the therapeutic dose of 186Re-epratuzumab, no clinical adverse 
reactions were seen in any of the patients. Within 1 h after infusion, fever 
was observed in only two patients. In all patients, platelet and leukocyte 
levels decreased 4-6 weeks after the therapeutic injection. The nadirs are 
listed in Table 4.1. 
















































































Dose level Nadir platelets Nadir WBC Duration 
Histology (MBq/nr) (xlO'Vliter) (xlO'Vliter) Response·1 (days) 
3 Mantle cell lymphoma 
7 Follicle center cell lymphoma 
4 Follicle center cell lymphoma 
4 Diffuse large B-cell lymphoma 
5 Small lymphocytic lymphoma 
4 Follicle center cell lymphoma 
3 Diffuse large B-cell lymphoma 
4 Small lymphocytic lymphoma 
1 Mantle cell lymphoma 
4 Marginal zone B-cell lymphoma 
4 Follicle center cell lymphoma 
5 C Follicle center cell lymphoma 
2 Mantle cell lymphoma 
5 C Diffuse large B-cell l y m p h o m a 
4C Follicle center cell l y m p h o m a 
1 Mantle cell l y m p h o m a 
6 Marginal zone lymphoma 






















































































a PD, progressive disease; CR, complete response; NA, not applicable. 
b No real nadir was observed: blood counts increased following therapy. 
c One of the pretreatments consisted of autologous peripheral stem cell 
Table 4.1: Patient characteristics and therapeutic effects 
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Figures 4.1 and 4.2 depict the platelet and WBC count, respectively, 
over time. In only one patient was a grade 4 hematological toxicity ob­
served (WBC of 0.5 xl09/l) 6 weeks postinfusion of 1.5GBq/m2. In pa­
tient 2 (0.5 GBq/m2 dose level), an isolated WBC count drop was observed 
as early as 2 weeks after therapy and was probably caused by a viral infec­
tion. Other toxicity consisted of a facial zoster reactivation (n = 1), oral 
candidiasis (n = 1), and loss of taste (n = 1). 
Pharmacokinetics 
Elimination from the circulation of both 9 9 mTc- and 186Re-labeled 
epratuzumab varied widely between patients. Table 4.2 shows Τι/2, Ύι/,,α, 
and Τι/̂ ,β in all patients. The Τι/.,,β varied from 30.3 to 176.1 h, indicating 
that the antibody is circulating for a long time, as expected when using a 
humanized mAb. The percentage of the injected dose that was excreted 
via the urine is also listed in Table 4.2. Up to 45.9% of injected dose could 
be detected in the urine, indicating that after catabolization of the mAb, 
186Re-MAG3 is cleared renally. 
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Figure 4.1: Platelet counts after RIT. 
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Table 4.2: Pharmacokinetic data of ( ) ,)mTc- and l8('Re-labeled epratuzumab 
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HAHAs 
A total of 90 samples of 18 patients were analyzed quantitatively for HA-
HAs. In seven patients, HAHA levels could be detected, ranging from 0.5 
to 50ng/ml. Six of these seven patients with detectable HAHAs had de-
tectable HAHA levels before RTL No positive HAHA results were obtained. 
Special attention was paid to serum samples of the patient experiencing 
an adverse reaction shortly after infusion of 99mTc-epratuzumab. Neither 
HAHA nor HAMA levels could be detected in serum samples obtained be-
fore infusion; 1,3, and 4 h after infusion; and 1 and 9 days after infusion. 
There was no relation between the presence of low levels of HAHAs be-
fore treatment and the occurrence of chills and fever after the infusion of 
radiolabeled epratuzumab. 
Scintigraphy 
On scintigrams made 1 h and 1 day after injection of 99mTc-epratuzumab, 
mainly activity in the blood pool was observed. In some patients, lym-
phoma targeting was observed, as illustrated in Figure 4.3. Two patients 
appeared to have major bone marrow uptake after the diagnostic injec-
tion, as shown in Figure 4.4. Both patients were known to have bone mar-
row involvement (but < 25% involvement). Both patients were excluded 
from further RIT because treatment with 186Re-epratuzumab could have 
resulted in serious and potentially irreversible myelotoxicity. 
During the first days after RTT, visualization of lymphoma improved. 
Figure 4.5 shows scintigrams of a patient who had lymphoma localization 
in the inguinal regions. 
Dosimetry 
Doses absorbed in normal organs are listed in Table 4.3. The organ with 
the highest absorbed dose is the spleen because the spleen is a lym-
phoid organ housing CD22-positive cells and involved in NHL. All absorbed 
doses were far below critical values. Therefore, RTF with 186Re-labeled 
epratuzumab is thought to be safe. Tumor dosimetry is not available yet. 
The dosimetric analysis will be discussed in more detail in Chapter 5. 
Therapeutic effects 
A summary of the therapeutic effects is listed in Table 4.1. One patient 
responded completely; for 4 months no lymphoma could be demonstrated. 
Four patients showed a partial response (PR) lasting 14, 6, 3, and 3 months, 
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I hour pi. 1 day p.i. 
Figure 4.3: Scintigraphy after infusion of 99rnTc-epratuzumab, showing a normal 
biodistribution and targeting of an abdominal lymphoma. 
respectively. Four patients had SD for 9, 7, 3, and 3 months, respectively, 
after RIT. Six patients progressed after RIT. 
Discussion 
The present study shows that RIT with 186Re-labeled epratuzumab is safe, 
despite the fact that most patients were heavily pretreated before RIT. 
As expected, a transient decrease in blood counts was dose-limiting. Al-
though grade 4 hematological toxicity was observed in only one patient 
treated at the third dose level of 1.5 GBq/m2, the slow recovery of platelet 
counts in two of the three patients at the highest dose level suggests that 
further dose escalation was clinically unacceptable and would probably re-
sult in prolonged low blood cell counts, increasing the risk of side effects. 
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hour p.i. 1 day p.i. 
Figure 4.4: Scintigraphy after infusion of 99mTc-epratuzumab, showing unfavor-
able biodistribution with targeting of bone marrow and an enlarged spleen. 
Platelet counts of one of the two patients recovered slowly, returning to 
normal within 5 months. The time to full recovery of the platelet counts 
of the other patient is unknown because he was treated in another hospital 
12 weeks after RIT with other myelotoxic therapy. The Common Toxicity 
Criteria used to define toxicity did not classify prolonged cytopenia as a 
separate entity, although this aspect should be taken into consideration. 
Strictly speaking, no grade 4 toxicity was observed in the group treated at 
the dose level of 2.0GBq/m2. Therefore, a dose of 2.0GBq/m2 is consid-
ered to be the MTD. 
The use of 186Re has several advantages. First of all, being a group-VII 
element, 99mTc and 186Re have similar chemical properties. 99mTc-labeled 
mAbs can therefore be used for an imaging procedure before RIT, rep-
resenting 186Re-labeled mAbs. The need for a diagnostic procedure was 
demonstrated in this study: two patients were considered to have < 25% 
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1 day p.i. 2 days p.i. 5 days p.i. 
Figure 4.5: Scintigraphy after Infusion of 186Re-epratuzumab, showing targeting 
of inguinal lymphoma. 
bone marrow involvement based on classical histological examination, but 
scintigraphy showed that uptake in the bone marrow was so extensive that 
RIT was contraindicated in these patients. Although taking bone marrow 
samples at more than one site can be advised to prevent sampling errors, 
a diagnostic procedure before RIT should be advocated. 
A second advantage of the use of 186Re is the fact that it emits low-
energy, low-abundance y-radiation. The y-emissions are ideal for imaging, 
making it unnecessary to label mAbs with a second radiolabel to perform 
dosimetry. The quality of the images is high, comparable with the qual-
ity of images made using 99mTc. Because only 10% of disintegrations are 
accompanied by y-emissions, the exposure rate after treatment is low, at 
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0.68 ± 0.24 
1.36 ±0 .09 
1.13 ±0.31 
2.33 ±0 .40 
Table 4 3 Pharmacokinetic data of l)',mTc and l8t'Re-labeled epratuzumab 
least lower than 5^Sv-m2/h. In most countries, it is therefore possible to 
treat patients on an outpatient basis. Initial dosimetric analysis, as men-
tioned earlier, reveals that absorbed doses in normal organs are far below 
critical values. Further dosimetric analysis of the data of this stud> is 
currently in progress. 
A disadvantage of the use of 186Re-labeled mAbs is the laborious label-
ing procedure, especially when compared with the labeling of mAbs with 
radiometals such as 90Y, 111In, and 177Lu . Another labeling procedure, us-
ing antibody sulfhydryl groups as effective carriers of reduced rhenium, as 
described by Griffiths et al. [12], is less laborious, but the low specific ac-
tivity of this radioimmunoconjugate requires large amounts of antibodies. 
Moreover, the method requires extensive reduction of disulfide bridges in 
the antibody molecule, leading to a loss of immunoreactivity. This labeling 
procedure is not thought useful for preparing doses needed for RIT [12]. 
Another disadvantage may be the lower retention of the radiolabel 
186Re in the tumor when compared with 90Y . Radiolabeled epratuzumab 
is rapidly internalized upon binding to a CD22-expressing target cell. Us-
ing radiometals such as 90Y would result in retention of the radiolabel 
[13] Preclinical data suggest that although 186Re is retained better than 
13'I m a mouse lymphoma model, tumor uptake of 90Y-labeled is signifi-
cantly higher [14]. After processing of the radiolabeled mAb, 186Re-MAG3 
is excreted from the target cell and excreted renally, as shown in Table 4.2. 
The ultimate goal of this study was to define a MTD for further analysis 
in a phase II study. In such a study, patients would receive repeated RIT 
cycles For this approach, a non-immunogemc mAb is required, such as 
the humamzed epratuzumab. The formation of HAMAs is observed in a 
minority of heavily pretreated patients with NHL treated with murine anti-
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CD20 mAbs [2,15]. Nevertheless, HAMA formation can be observed in over 
60% of patients when treating patients more upfront with murine mAbs 
[16], prohibiting further treatment. When using epratuzumab, HAMA for­
mation is not to be expected. The presence of HAHAs was determined 
before and after RIT with 186Re-epratuzumab, showing that in six of seven 
patients HAHAs were already present before RIT. The levels were low, with 
a maximum of 50ng/ml, in concordance with earlier observations [17], 
and below the threshold value for HAHA elevation in the test used. Other 
studies also reported that HAHA induction was hardly ever observed in pa­
tients who received epratuzumab [18,19]. Therefore, it should be feasible 
to repeatedly treat patients using radiolabeled epratuzumab. 
In conclusion, RIT with 186Re-epratuzumab is feasible and safe, with 
an MTD of 2.0GBq/m2. Even in this phase I study of refractive/relapsed 
patients who were heavily pretreated, objective responses were observed. 
A phase II study treating patients with repeated doses of radiolabeled 
epratuzumab is planned. Additional studies should reveal whether this 
approach leads to improved overall response rates, duration of responses, 
and survival of patients with NHL. 
Acknowledgments 
We thank Emile Β. Koenders for assistance in administering the radiola­
beled preparations and preparation of the calibration standards and phar­
macokinetics samples. We also thank the referring physicians, Drs. Sin­
nige, Schuitemaker, Wittebol, De Vries, and Pruijt, for their close coopera­
tion with our center in the treatment and follow-up of patients. 
This study was conducted with the support of The Netherlands Orga­
nization for Health Research and Development (ZonMw), project # 920-03-
073. 
References 
1. Postema EJ, Boerman OC, Oyen WJG, Raemaekers JMM, Corstens EHM. 
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl 
Med 2001; 28: 1725-1735. 
2. Goldenberg DM. The role of radiolabeled antibodies in the treatment 
of non-Hodgkin's lymphoma: the coming of age of radioimmunother­
apy. Cht Rev Oncol Hematol 2001; 39: 195-201. 
4. Radioimmunotherapy using 186Re-epratuzumab 77 
3. Wagner HN, Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-
Bennett DM, Lamonica DM, Conti PS. Administration guidelines for 
radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled 
anti-CD20 monoclonal antibody. JNucl Med 2002; 43: 267-272. 
4. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lam-
onica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, 
Witzig TE, Leigh BR. Biodistribution and dosimetry results from a 
phase III prospectively randomized controlled trial of Zevalin ra-
dioimmunotherapy for low-grade, follicular, or transformed B-cell 
non-Hodgkin's lymphoma. Crif Rev Oncol Hematol 2001; 39: 181-
194. 
5. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, 
Joyce R, Bartlett NL, Wiseman GA, Grillo-López AJ, Multani P, White 
CA. Randomized controlled trial of yttrium-90-labeled ibritumomab 
tiuxetan radioimmunotherapy versus rituximab immunotherapy for 
patients with relapsed or refractory low-grade, follicular, or trans-
formed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-
2463. 
6. Leung SO, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB, 
Hansen HJ. Construction and characterization of a humanized, inter-
nalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. 
Mol Immunol 1995; 32: 1413-1427. 
7. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunother-
apy of non-Hodgkin's lymphomas. Hematology (Am Soc Hematol 
Educ Program) 2001; 221-240. 
8. Leonard JP, Coleman M, Schuster MW, Chadburn A, Ely S, Yagan 
N, Sharkey RM, Hansen HJ, Goldenberg DM. Epratuzumab, a new 
anti-CD22, humanized, monoclonal antibody for the therapy of non-
Hodgkin's lymphoma (NHL): phase I/II trial results. Blood 1999; 94: 
92a-93a. 
9. Leonard JP, Coleman M, Matthews JC, Fiore JM, Dosik A, Shore 
T, Kapushoc H, Macri M, Wegener WA, Cesano A, Goldenberg DM. 
Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination im-
munotherapy for non-Hodgkin's lymphoma: preliminary response 
data. ProcAm Soc Clin Oncol 2002; 21: 266a. 
10. Visser GWM, Gerretsen M, Herscheid JDM, Snow GB, van Dongen 
GAMS. Labeling of monoclonal antibodies with rhenium-186 using 
78 4. Radioimmunotherapy using 18ClRe-epratuzumab 
the MAG3 chelate for radioimmunotherapy of cancer: a technical pro-
tocol. JNuclMed 1993; 34: 1953-1963. 
11. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practi-
cal determination of patient-specific marrow dose using radioactivity 
concentration in blood and body. JNuclMed 1999; 40: 2102-2106. 
12. Griffiths GL, Goldenberg DM, Diril H, Hansen HJ. Technetium-99m, 
rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer 
1994; 73: 761-768. 
13. Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen 
HJ, Blumenthal RD , Dunn RM, Juweid ME, Goldenberg DM. Advantage 
of residualizing radiolabels for an internalizing antibody against the 
B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997; 
44: 179-188. 
14. Postema EJ, Frielink C, Oyen WJG, Raemaekers JMM, Goldenberg DM, 
Corstens FHM, Boerman OC. Biodistribution of 131I-, 186Re-, 177Lu-, 
and 88Y-labeled hLL2 (epratuzumab) in nude mice with CD22-positive 
lymphoma. Cancer Mother Radiopharm 2003; 18: 525-533. 
15. Witzig TE. Radioimmunotherapy for patients with relapsed B-cell 
non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2001; 48 
Suppl 1: S91-S95. 
16. Kaminski MS, Estes J, Tuck M, Mann J, Fisher S, Kison P, Regan D, 
Stagg R, Kroll SM, Magnuson DE, Wahl RL. Iodine 1131 tositumomab 
therapy for previously untreated follicular lymphoma. Proc Am Soc 
Clin Oncol 2000; 19: abstract 11. 
17. Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger 
S, Swayne LC, Alavi A, Goldenberg DM. Pharmacokinetics, dosime-
try, and initial therapeutic results with 131I- and "^n-Z^Y-labeled 
humanized LL2 anti-CD22 monoclonal antibody in patients with re-
lapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999; 
5: 3292s-3303s. 
18. Behr TM, Wormann B, Gramatzki M, Riggert J, Gratz S, Béhé M, 
Griesinger F, Sharkey RM, Kolb Η-J, Hiddemann W, Goldenberg DM, 
Becker W. Low- versus high-dose radioimmunotherapy with human­
ized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum 
of Β cell-associated malignancies. Clin Cancer Res 1999; 5: 3304s-
3314s. 
4. Radioimmunotherapy using 186Re-epratuzumab 79 
19. Linden O, Cavallin-Stàhl E, Strand SE, Hindorf C, Tennvall J, Stenberg 
L, Ohlsson T, Darte L. 90-Yttrium-epratuzumab in patients with B-cell 
lymphoma failing chemotherapy, using a dose fractionated schedule. 
Cancer Biother Radiopharm 2002; 17: 490. 

Chapter 5 
Dosimetric analysis of 
radioimmunotherapy with 
186Re-epratuzumab 
Ernst J. Postema 
Wilhelmma C.A.M. Buijs 
Michel de Groot 
John M.M. Raemaekers 
Otto C. Boerman 
David M. Goldenberg 
Frans H.M. Carstens 
Wim J.G. Oyen 
Presented at the 50th Annual Meeting of the Society of Nuclear Medicine, 
June 21-25, 2003, New Orleans, LA 
Journal of Nuclear Medicine 2003; 44: 32P-33P 
81 
82 5. Dosimetric analysis of RIT with 186Re-epratuzumab 
Abstract 
Objective: Radioimmunotherapy (RIT) is an effective treatment modality 
for non-Hodgkin's lymphoma (NHL). In our center, 186Re-epratuzumab has 
been used for this purpose in a phase I dose-escalation study. The primary 
aim of this study was to assess the maximum tolerated dose (MTD) and 
safety of 186Re-epratuzumab in patients with NHL. This article describes 
the dosimetric analysis of RIT using 186Re-labeled epratuzumab in a phase 
I study in patients with refractory or relapsed NHL, in relation to safety 
and toxicity of this treatment modality. 
Methods: Patients with relapsed or refractory CD22-positive NHL re-
ceived 99mTc-labeled epratuzumab (anti-CD22 IgG; Immunomedics, Inc., 
Morns Plains, NJ), followed by RIT with 186Re-epratuzumab 1 week later. 
A total of 15 patients were treated with i.v. doses of 0.5, 1 0, 1.5, or 
2.0 GBq/m2. Whole body scintigraphy was acquired directly after, and at 1, 
2, and 5 days following RIT. Regions of interest were drawn around normal 
organs to estimate residence times. 
Results: During or after infusion of 186Re-epratuzumab, no adverse re-
actions were seen. Dose limiting toxicity consisted of transient leuko- and 
thrombocytopenia. MTD was established at 2.0GBq/m2. One patient had 
a complete remission lasting 4 months, and 4 patients had a partial re-
sponse, lasting 3, 3, 6, and 14 months, respectively. Thirteen (9 males, 4 
females) of 15 patient studies could be used for dosimetric analysis. The 
absorbed dose in the spleen, an organ often mvolved in NHL, was highest, 
with a mean of 1.89 ± 0.93mGy/MBq for males and 2.33 ± 0.40mGy/MBq 
for females All absorbed doses were within safe ranges. No correlation 
could be found between toxicity observed and the absorbed doses. 
Conclusion: RIT with 186Re-epratuzumab seems to be safe, and even at 
lower activity dosages, therapeutic responses were observed. Dosimetric 
analysis did not reveal high absorbed doses to normal organs. 
Introduction 
Radioimmunotherapy (RIT) of non-Hodgkin's lymphoma (NHL) is a suc-
cessful new treatment option [1,2]. Toxicity due to this therapeutic 
approach consists mainly of transient hematological toxicity when low 
dosages of radioactivity are used, whereas cardiopulmonary toxicity is 
dose-hmitmg in myeloablative RIT [3]. Dosimetry is the tool used to es-
timate absorbed doses to normal organs, in order to explain or to predict 
toxicity. In some cases, when using 131I-labeled monoclonal antibodies 
(mAbs), dosimetry is even used to determine the amounts of activity to be 
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administered [4]. Other studies, describing the use of 90Y-labeled mAbs, 
showed that dosimetry neither correlated with the toxicity observed, nor 
is needed to safely dose and administer radioactive mAbs [5,6]. 
In the present study, 186Re-labeled mAbs were used to treat patients 
with NHL. 1 8 6Re decays by both β- and y-emission. The mean energy of 
both ^-emissions is 362 keV (71% of disintegrations) and 309keV (22%), 
respectively. The low-energy (137keV), low-abundance (10%) y-radiation is 
ideal for scmtigraphy to be used for dosimetric analysis It also permits 
treatment on an outpatient basis, even at high doses, according to Dutch 
regulations. 
This paper describes the dosimetric analysis of RIT using 186Re-labeled 
epratuzumab in a phase I study in patients with refractory or relapsed 
NHL, m relation to safety and toxicity of this treatment modality. 
Materials and methods 
Patient eligibility 
This dose-escalation study was conducted in patients with B-cell NHL who 
had relapsed after or did not respond to at least one Ime of treatment and 
who were not eligible for potentially curative high-dose chemotherapy fol­
lowed by stem cell support. All patients had histologically-proven, CD22-
positive, NHL. Patients had to have a life expectancy of at least 2 months 
and had to be at least 18 years of age. Patients had to have a WHO perfor­
mance status of 0, 1, or 2. No other antitumor therapy was given within 
at least three weeks prior to study entry. White blood cell (WBC) count 
had to be at least 2.5 xl0 9/l and platelet count at least 75 xl09/l. Patients 
were excluded m case of hfe-threatemng infection, allergic diathesis with 
current complaints, organ failure, pregnancy, known seropositivity for hu­
man immunodeficiency virus (HIV), over 25% bone marrow mvolvement 
by lymphoma determined by bone marrow histology and histochemistry, 
concomitant treatment with other investigational drugs, or spread of the 
malignancy to the central nervous system. The study was approved by the 
institutional review board of the UMC Nijmegen. Written informed consent 
was obtained from all patients. 
Epratuzumab 
Epratuzumab (hLL2) is a humamzed monoclonal IgGl antibody directed 
against CD22 on Β cells [7]. Unlabeled epratuzumab is used m clinical tri­
als in chemotherapy-refractory NHL patients [8], and in combination with 
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rituximab [9]. Initial data of the phase I/II dose escalation study show 
that the lowest dose level at which objective responses were seen was 
the dose level with four weekly infusions of 360mg/m2 of epratuzumab 
[8]. Epratuzumab was kindly provided by Immunomedics, Inc., Morris 
Plains, NJ, as a sterile pyrogen-free solution. Epratuzumab was labeled 
with 186Re using 5-benzoyl-mercaptoacetyltriglycine (MAG3) as a chelator 
by the method as described by Visser et al. at the Radionuclide Center of 
the VU University Medical Center, Amsterdam, The Netherlands [10]. 
Study design 
The present cluneal trial was an uncontrolled dose-escalation study. After 
inclusion, a diagnostic dose of 750 MBq 99mTc-epratuzumab was adminis-
tered intravenously. One week after this diagnostic procedure the patient 
was hospitalized overmght for RIT with 186Re-epratuzumab. Patients were 
treated at four different dose levels, 0.5, 1.0, 1.5, and 2.0 GBq 186Re per m2 
body surface area (BSA). Three patients were included at each dose level, 
except for the dose level of 1.5 GBq/m2, at which 6 patients were treated. 
Patients were momtored weekly for adverse reactions and toxicity. Pa-
tients were evaluated for responses 4-6 weeks after RTT, usmg physical 
examination, biochemical analysis, CT scanning, and bone marrow exami-
nation, if involved at the start. In case of stable disease or responses, this 
procedure was repeated every 3 months. 
Scintigraphy 
Whole body scintigrams for visual assessment of biodistribution and for 
dosimetric analysis were acquired within one hour after injection, and 1, 
2, and 5 days p.i. In an Adams' phantom, a known aliquot of the injected 
dose (gamma camera standard) was scanned at the same time for refer-
ence purposes. Images were acquired using a Siemens double-head gamma 
camera. The images were processed at ICON workstations using a locally 
developed dosimetry tool. This tool allows copying and transferring re-
gions of interest (ROIs) between various whole body studies. ROIs were 
drawn around the gamma camera standard, the whole body, the heart and 
its background, the right lung and its background, the liver, the spleen 
and its background, the left kidney and its background, the skull, and the 
testes, if applicable, and their background. All images were reviewed by 
one physician. 
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Dosimetry 
Background correction 
The activity in the body and the activity in the standard were determined 
as the geometric mean of the counts in the anterior image and the counts 
in the posterior image, without background correction. The activity in the 
heart was determined as the geometric mean of the counts in the ante-
rior and in the posterior ROI minus background. The background in the 
anterior image was calculated by multiplying the counts per pixel in the 
ROI for the background of the heart by the number of pixels in the ROI 
of the heart. Similarly, the background in the posterior image was calcu-
lated. The partial background subtraction was used: only a fraction of the 
counts in the background ROIs was subtracted [11]. This fraction (F) was 
calculated by dividing abdomen thickness minus organ thickness by the 
abdomen thickness. For the heart, F equals 0.5 [11]. 
The activity in the lungs, spleen, and kidneys were determined as the 
geometric mean of the counts in the anterior and in the posterior ROI, 
minus F = 0.66 times the background in the anterior and the posterior 
image, respectively [12]. The background for each organ was calculated 
similarly as the background of the heart (see above). The activity in the 
lungs was assumed to be two times the amount of activity in the right 
lung. The activity in the kidneys was assumed to be two times the amount 
of activity in the left kidney. The activity in the liver was determined as 
the geometric mean of the counts in the anterior and in the posterior ROI. 
No background correction was made, since the liver occupies almost the 
entire thickness of the patient's abdomen [11]. The bone marrow in the 
skull is thought to represent 8.4% of the total bone marrow mass in the 
body. Therefore, counts in the skull were divided by 0.084 to obtain the 
total activity in the bone marrow. The activity in the testes was determined 
using the anterior image only. 
Attenuation correction 
The attenuation of the activity in the whole body and the abdominal organs 
was considered to be caused by 11.25 cm of tissue between the center of 
the patient and the skin. The attenuation of activity in the intrathoracic 
organs is less, because the lungs contain air, leading to less attenuation. 
Therefore the residence times of these organs are multiplied by 0.85 to 
correct for the differences in attenuation in the abdomen and thorax. 
The residence times of the activity in the testes were multiplied by 
0.25. The attenuation of the testes by an overlying layer of 1.5 cm soft 
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tissue can be defined using equation 5.1, in which μ equals 0.144 cm" 1 for 
137keV photons in tissue, and χ = 1.5 cm of tissue. The attenuation of 
the abdomen can be defined using the same equation and χ = 11.25 cm. 
By dividing An 25 by Αι 5, a correction factor of 0.25 is obtained. 
Αχ=Αο-β-
μχ. (5.1) 
Similarly, the activity m the skull was corrected, assuming a mean path 
of χ = 9 cm, leading to a correction factor of 0.72. 
Residence times 
Background and attenuation correction were applied as described above 
to each imaging time-point to yield time-activity curves for each organ. 
The activity in the whole body at each time-point was decay-corrected. 
Time-activity curves for the whole body were obtamed by assuming no bi­
ological clearance of injected activity at the first imaging time-point. The 
decay-corrected counts were fit to a smgle component exponential clear­
ance expression, yielding the biological half-life. Assuming that 100% of 
the injected dose was present at the first imaging time-point, the percent­
age of the injected dose for each following scan was calculated by dividing 
counts of each following scan by the counts of the first scan These data 
were fit m a smgle component exponential clearance expression, yielding 
the residence time value of the whole body. Residence times in all organs 
were calculated usmg the trapezoidal method. First, a linear extrapola­
tion between the assumed uptake fraction of 0 at time of injection and the 
measured fractional uptake at the time of the first image was made, not 
corrected for physical decay. From each time-point to each next time-point 
a Ime was drawn between the fractions of uptake. The sum of the areas 
under all these lines was calculated. The remaining area under the curve 
from the end of data collection until infinity was determined by consider­
ing only physical decay of the radionuclide. 
Absorbed doses 
The absorbed dose to the organs was calculated using the MIRD schema. 
Tumor, heart (contents), lungs, liver, spleen, kidneys, red marrow, testes, 
urmary bladder, and the rest of the body (remainder) were considered as 
source organs. For the bladder, the dynamic bladder model was used. A 
voiding interval of 4 h was assumed. Using the counts for the whole body, 
the biological half-life was determined, as described previously. Biolog­
ical half-life and voiding interval were entered into the dynamic bladder 
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model, yielding the residence time in the urinary bladder. The calculated 
residence times, as described in the previous section, were entered into 
the MIRDOSE3 computer program, version 3.1 (Oak Ridge Associated Uni-
versities, Oak Ridge, TN) [13], to compute the absorbed doses, using the 
reference adult software phantom for the male patients. For the female 
patients, the adult female phantom was used. 
Statistical analysis 
Associations between myelotoxicity and doses were calculated with 
Microsoft® Excel 2002 software using Pearson correlation test 
Results 
Patient characteristics 
Eighteen patients ( 12 men and 6 women) were included, of whom 15 were 
actually treated. The mean age was 57 years (range 41-75). Patient charac-
teristics are listed in Table 4 1, and are described in more detail in Chapter 
4 of this thesis. The number of courses of chemotherapy and/or external 
beam radiation prior to inclusion in our study ranged from 1-7, with a 
median number of 4 
During or directly after infusion of the diagnostic dose of 750 MBq 
99mTc-epratuzumab, fever and chills were observed in 9 out of 18 patients 
within 1 hour after infusion. This reaction was self-limiting and required 
no specific medical intervention. One patient experienced an acute allergic 
reaction with airway obstruction within half an hour after infusion. Other 
infusion-related side effects were mild and did not require medical inter-
vention. During infusion of the therapeutic dose of 186Re-epratuzumab, 
no clinical adverse reactions were seen m any of the patients. Within one 
hour after infusion, fever was observed in only two patients. In all patients, 
platelet and leukocyte levels decreased 4-6 weeks after the therapeutic in-
jection A grade 4 hematological toxicity was observed (WBC of 0.5 xl09/l) 
6 weeks post infusion of 1.5GBq/m2 in only one patient. In patient # 2 
(0.5 GBq/m2 dose level), an isolated WBC count drop was observed as early 
as two weeks after therapy, probably caused by a viral infection. 
A summary of the therapeutic effects is listed in Table 4.1. One patient 
responded completely; for 4 months no lymphoma could be demonstrated. 
Four patients showed a partial response lastmg 14, 6, 3, and 3 months, 
respectively. Four patients had stable disease for 9, 7, 3, and 3 months, 

































































































































































































































































Table 5.1: Absorbed doses (mGy/MBq) to normal organs in male patients 
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Absorbed doses 
The absorbed doses for male and female patients are listed in Tables 5.1 
and 5.2, respectively. The organ with the highest absorbed dose appeared 
to be the spleen, with a mean of 1.89 ± 0.93mGy/MBq for males and 
2.33 ± 0.40mGy/MBq for females. Other organs absorbing doses exceed-
ing 0.5mGy/MBq were the kidneys, liver, lungs, heart, urinary bladder 
wall, and the testes. The mean absorbed doses to the red marrow were 
0.60 ± 0.19mGy/MBq and 0.61 ± 0.14mGy/MBq for male and female pa-
tients, respectively. 
Correlation between toxicity and absorbed doses 
Since hematologic toxicity appeared to be dose-limiting, and since no other 
serious toxicity was observed, platelet and WBC nadir levels were com-
pared with a) whole body absorbed dose, b) red marrow absorbed dose, c) 
total injected activity, d) injected dosage per m2 BSA, e) injected dosage 
per kg body weight, and f) the number of prior chemotherapies. The re-
sults of this analysis are summarized in Table 5.3. Correlations between 
nadir of platelets and WBCs, and the 6 parameters mentioned above, could 
not be found. 
Discussion 
Dosimetric analysis of RIT using 186Re-epratuzumab showed absorbed 
doses that are comparable to absorbed doses when using other ^ R e -
labeled mAbs, like humanized bivatuzumab [14], chimeric cU36 [15], and 
intraperitoneally administered murine NR-LU-10 [16], although the kidney 
doses induced by the latter were remarkably lower. The lack of corre-
lation between hematological toxicity and dosages was also described in 
other lymphoma RIT studies [5,17]. Nevertheless, some other RIT tri-
als were able to determine factors associated with hematological toxicity 
[14,15,18]. The method to estimate the absorbed dose to the red marrow 
probably plays a major role. If there is no targeting of the bone marrow, 
a blood-derived method can be safely used [19]. Unfortunately, in lym-
phoma patients, the red marrow quite often contains lymphoma. There-
fore, the red marrow is a potential target. A camera-derived method to 
estimate the absorbed marrow dose is preferable. If the marrow doses of 
the patients described in this study would have been calculated using a 
blood-derived method, as described in the previous chapter of this thesis, 
the mean marrow dose would have been underestimated: 0.45mGy/MBq 



























































































































































Table 5.2: Absorbed doses (mGy/MBq) to normal organs in female patients 
instead of 0.60mGy/MBq in male patients, and 0.51 mGy/MBq instead of 
0.61 mGy/MBq in female patients. 
In this study, only dosimetric analysis for safety assessment was per-
formed, whereas no lymphoma dosimetry was done. Other studies showed 
a wide variety of tumor doses, ranging from 0.6-243 Gy in case of treat-
ment with 90Y-ibritumomab [20] and 0.4-18 Gy after treatment with 131I-
tositumomab [17]. Although mean and median tumor doses vary, in both 
cases there was no correlation found between these doses and response 
to treatment, although there seems to be a tendency that higher absorbed 
doses can be achieved in smaller tumors than in larger ones, though not 
statistically significant [17]. Lymphoma dosimetry in RIT has some limi-
tations. Not all lymphomas were clearly visible on scintigraphy, although 
they responded to RIT. Secondly, even low absorbed lymphoma doses, as 
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Platelet nadir WBC nadir 
Whole body dose (Gy) 
Red marrow dose (Gy) 
Dosage (GBq) 















Table 5.3: Correlation coefficients r between doses and toxicity 
low as 4Gy, are associated with responses to treatment [21]. Absorbed 
doses alone do not account for responses, due to the intrinsic antitumor 
activity of the mAbs themselves [17,21]. Therefore, tumor dosimetry is of 
limited value in planning RIT of patients with non-Hodgkin's lymphoma. 
Conclusions 
RIT with 186Re-epratuzumab seems to be safe, and therapeutic responses 
were observed even at lower dosages. Dosimetric analysis did not reveal 
high absorbed doses to normal organs. A correlation between dosimetric 
parameters and toxicity could not be found. 
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Introduction 
Head and neck cancer 
Head and neck cancer refers to malignant tumors that arise in the mucosa 
of the upper aerodigestive tract including the oral cavity, pharynx, larynx, 
nasal cavity, and paranasal sinuses. Squamous cell carcinoma of the head 
and neck (HNSCC) account for 90% of these tumors. Malignant tumors 
arising in adjacent structures including the salivary glands, soft tissues, 
and bone develop relatively infrequently. Worldwide, the annual incidence 
is more than 500,000 cases of HNSCC, accountmg for approximately 5% 
of all newly diagnosed malignant neoplasms in North Western Europe and 
the Umted States [1,2]. About one thud of the patients present with early 
stage disease (stage I and II), whereas the remaining patients present with 
advanced disease (stage III and IV). Tumor spread from the primary site is 
dictated by the local anatomy, each site having its own pattern of dissemi-
nation. Lymphatic dissemination is an important mechanism in the spread 
of HNSCC. After penetration of the basement membrane of the epithelium, 
cancer cells enter the lymphatic system, pass through the lymphatic ves-
sels, and settle in the subcapsular sinus of the first draining lymph node. A 
tumor-inftltrated lymph node can act as a source for further dissemination 
into the surrounding lymphatics or the blood stream, the latter resulting 
in distant metastases 
Staging of the neck in head and neck cancer 
The status of the lymph nodes is the single most important tumor-related 
prognostic factor of HNSCC [3]. For optimal treatment planning, it is es-
sential to know the exact involvement of the nodes. If metastases m the 
neck are detected, the neck should be treated. In many institutions, di-
agnosis of the neck is still based on palpation. However, palpation is far 
from reliable for the detection of lymph node metastases Histopathologi-
cal evaluations have demonstrated that both the false-positive rate of 20% 
and the false-negative rate of 20-30% are unsatisfactorily high [4]. Modern 
imaging techniques, such as computed tomography (CT), magnetic reso-
nance imaging (MRI), ultrasound (US), and especially US-guided fine-needle 
aspiration cytology (FNAC), are more reliable than palpation, but also leave 
much room for improvement. Using the most optimal radiological crite-
ria, the overall error of CT and MRI m the preoperative detection of lymph 
node metastases in neck sides is about 20% [5,6]. From the perspective 
of local tumor control, especially a neck without palpable lymph nodes 
(NO) remains a diagnostic dilemma as it still is at risk for harboring occult 
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metastases. For diagnosis of the NO neck, US-guided fine-needle aspiration 
cytology (USgFNAC) has a higher sensitivity and specificity than CT and 
MRI. In experienced hands, the sensitivity for the NO neck can reach 73% 
with a specificity of 100% [7]. Despite this, USgFNAC also has some un-
favorable aspects: (i) it is an invasive method, (ii) it only gives diagnostic 
information of a selected part of the neck and not on the primary tumor 
or distant metastases, and (iii) its accuracy is strongly dependent on the 
skill of the ultrasonographer and the cytopathologist. With respect to the 
latter, selection of lymph nodes to be aspirated is not easy and is based on 
known patterns of lymphatic spread and on lymph node size and morphol-
ogy as assessed with US. Inaccuracies of USgFNAC result from absence of 
enlarged nodes, aspiration of the wrong lymph node, failure of cytological 
analysis due to the presence of few tumor cells, or the presence of mi-
crometastases in parts of the lymph nodes not aspirated (sampling error). 
The presence or absence of lymph node and distant metastases has 
a major impact on the choice of treatment. There is still a great need 
for a sensitive, specific and minimally invasive method to detect occult 
(micro)metastases in the lymph nodes in the neck as well as at distant 
sites. 
Treatment of head and neck cancer 
Therapy usually consists of surgery, radiotherapy, or a combination of 
these modalities. Generally, patients with stage I and II disease, undergo 
either surgery or radiotherapy with curative intent. Cure will be achieved 
in 70-85% of these patients. For patients with local or regional advanced 
disease (stage III and IV), the prognosis is much worse. Frequently, a com-
bination of surgery and radiotherapy is used. It is disappointing that the 
survival rates of patients with advanced stage head and neck cancer have 
not improved much over the last decades. Although many studies have 
observed a decrease of local and particularly of regional failures, because 
of the widespread use of combined surgery and radiotherapy, this is not 
reflected in a proportional increase of the five-year survival rates. As fewer 
patients die from uncontrolled disease in the head and neck, more are ex-
posed to the risk of disseminated disease below the clavicles [8]. It is 
obvious that there is a great demand for a systemic treatment effective in 
destroying (inicro)metastases at distant sites and minimal residual disease 
at the local and regional level. Initially, hope was high for chemotherapy 
to play this role, but unfortunately these expectations have not been ma-
terialized. Clearly, a more tumor-selective systemic therapy is needed. 
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Radioimmunotherapy of cancer 
One of the novel approaches for selective treatment of cancer is the use 
of monoclonal antibodies (mAbs) conjugated with radionuclides. In the 
last decade, successes have been obtained with radioimmunotherapy (RIT) 
of non-Hodgkin's lymphoma, leading to FDA approval of the anti-CD20 
mAbs yttrium-90 (90Y)-ibritumomab (Zevalm) [9] and iodine-131 (131I)-
tositumomab (Bexxar). For solid tumors, however, such promising results 
have not yet been observed, although some studies have reported encour­
aging results with RIT for small metastatic lesions or as adjuvant treat­
ment [10,11,12]. Several radioimmunoconjugates are currently evaluated 
m phase III clinical RIT trials [13]. While in the last two decades radiola­
beled mAbs have been admimstered to thousands of patients with various 
types of tumors, the application of mAbs for detection and treatment of 
HNSCC has started relatively late One of the mam reasons for the slow 
progress has been the lack of mAbs with a high specificity for HNSCC and 
a restricted reactivity with normal tissues. Only recently, the use of ra­
diolabeled mAbs has been considered as a realistic alternative approach 
for detection and treatment of HNSCC. This paper deals with the factors 
influencing tumor treatment by R1T. The progress in RTF of head and neck 
cancer will be summarized and its feasibility will be discussed. 
Target antigens 
The hybndoma technology allowed the development of mAbs specifically 
directed agamst each particular cellular antigen. In general, mice are im­
munized with tumor cells or a purified tumor antigen. Spleen cells from 
the immunized mice are fused with myeloma cells, which can be propa­
gated indefinitely and have the ability to produce mAbs. As such, the re­
sulting hybndoma cells receive the genetic information for the production 
of specific mAbs from the splemc Β lymphocytes and the growth poten­
tial and mAb-production and secretion machinery from the myeloma cells. 
After the cell fusion procedure, a hybndoma cell clone can be selected 
that produces a murine mAb with the desired antigen-specificity. In the 
last decade, new technology became available for the direct selection of 
human mAbs by using phage display libraries [14] or transgenic mice [15]. 
An ideal antigenic target for RIT is abundantly expressed by all tumors 
in the patient population, at the outer cell surface of all tumor cells, and 
not by normal tissues. Unfortunately, tumor-specific antigens have only 
been found in experimentally induced tumors and not in so-called spon­
taneous tumors. The majority of identified antigens in human tumors, 
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however, represent tumor-associated antigens, present on tumor tissue 
but also detectable on normal tissues. Expression of the target antigen in 
normal tissues can be acceptable for radioimmunoscintigraphy (RIS) when 
this normal tissue is poorly accessible for mAbs, or when it is localized 
at a site outside the anatomic region of interest. However, for RIT also 
the latter is unacceptable. Other factors influencing the suitability of anti-
gens for tumor targeting, are internalization and shedding. If the antigen-
antibody complex is internalized after binding of the radiolabeled mAb, 
optimal cellular retention of the targeted radionuclides is of importance 
for RIT, since the longer time the radionuclides stay in or near the tar-
geted cell, the higher the radiation dose that will be delivered. Shedding of 
an antigen by the tumor into the blood stream is considered to be disad-
vantageous, since circulating antigen can trap the circulating radiolabeled 
mAb before the mAb reaches the tumor and thus makes tumor targeting 
less effective. Moreover, the formed complexes may accumulate in tissues 
with a highly developed reticuloendothelial system such as liver, spleen, 
bone marrow, and lung. 
Monoclonal antibodies 
Nowadays, mAbs can be produced in large quantities, at acceptable costs 
for marketing, and with a quality that fulfils the requirements of the FDA 
and the European Medicines Evaluation Agency. Most mAbs were origi-
nally of murine origin. Administration of a murine mAb usually results 
in the formation of human anti-mouse antibodies (HAMAs). To decrease 
immunogenicity, the mAb molecule can be restructured to human-mouse 
chimeric or even humanized versions, using recombinant DNA techniques 
[16]. Fully human mAbs can be produced via phage display libraries [14] or 
by transgenic mice that contain a human immunoglobulin gene repertoire 
[15]. High binding affinity of the mAb to the target structure is generally 
considered necessary, as it minimizes the risk of competing low affinity 
interactions in normal tissues or of interactions with circulating antigen. 
However, with respect to RIT application, it has been claimed that an inter-
mediate affinity mAb will perform better than a mAb with extremely high 
affinity, since it distributes more extensively and more homogeneously 
throughout solid tumor masses [17]. So far, at least 30 mAbs directed 
against HNSCC have been described in literature. These mAbs can be di-
vided in three main categories: 
1. mAbs reactive with squamous cell carcinoma and not with other tu-
mor types: A general shortcoming of this group of mAbs is their re-
activity with normal squamous epithelia. When such mAbs are used 
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in RIS or RIT, uptake of radioactivity in the normal oral mucosa can 
occur. This can hamper tumor detection m the head and neck area 
when applied in RIS, while in RIT mucositis might occur. 
2. Pan-carcmoma mAbs: These mAbs are not only directed against HN-
SCC, but also against other tumor types. A general shortcoming of 
these mAbs is there heterogenous reaction pattern with HNSCC, and 
their reactivity with several normal tissues. 
3. mAbs recognizing stromal and/or endothelial cells of the tumor: Most 
recently a third group of mAbs has become available. These mAbs 
do not recogmze antigens expressed on tumor cells themselves, but 
they recogmze antigens on stromal and/or endothelial cells of the 
tumor. These mAbs may be especially attractive because stromal and 
endothelial markers are expressed by a diversity of tumor types, and 
are well accessible for mAbs [18-21]. Also for this category of mAbs, 
cross reactivity with normal tissues might form a limitation. 
Many of the mAbs described in literature are poorly characterized with 
respect to their reactivity profile on normal and malignant tissues. It is 
difficult to speculate about their suitability for RIS and RIT. Only a few 
mAbs have been administered to HNSCC patients for RIS, and even less 
for RIT. So far, none of them is routinely used for several reasons. High 
costs for production of a batch of mAbs for clinical use restrict preliminary 
clinical evaluation for RIS. Despite promising preclinical results, there is 
the inherent risk that the mAb is not suitable for RIS or RIT already at 
an early stage of clinical studies. However, it is also possible that a mAb, 
though not selective enough for application in RIT, is well qualified for 
other therapeutic approaches with mAbs. The latter seems to be the case 
with mAbs directed against the Epidermal Growth Factor Receptor (EGFR) 
[22]. 
Radiolabeled monoclonal antibodies 
The choice of the radionuclide to be coupled to the mAb depends on the 
antibody used, the properties of the antigen, and the purpose of the radio-
label: imaging, treatment, or treatment planning. In the latter application, 
RIS is performed as a scouting procedure prior to RIT, to enable the con-
firmation of tumor targeting and the estimation of radiation dose delivery 
to both tumors and normal tissues {i.e. dosimetry). For RIT, a therapeutic 
radionuclide is preferably a beta-emitter with a half-life of several days, as 
discussed in the previous chapters of this thesis. 
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The stability of the radioconjugate m vivo and the internalization of 
the antibody-antigen complex are also of mam importance. The radioim-
munoconjugate should be as stable as possible. Unbound radionuclides 
could result in uptake in normal organs, possibly leading to unwanted 
side-effects. For instance, unbound radiometals like 90Y accumulate in 
mineral bone, and therefore cause an increase of the bone marrow dose. 
The effect of internalization of a mAb on RIT depends on the conjugated 
radionuclide. For example, degradation of 1 3 1I-, 186Re- and 1 8 8 Re-labeled 
mAbs will result in a rapid clearance of these radionuclides from the tu­
mor. In contrast, upon internalization 177Lu-, G7Cu-, or t)0Y-labeled mAbs 
are processed, and the radionuclides will be trapped intracellularly in lyso-
somes [23]. Therefore, the phenomenon of internalization should be taken 
into account when choosing a radionuclide for RIT. 
Radioimmunotherapy of head and neck cancer 
Radiolabeled mAbs are exploited in order to irradiate tumors from the 
closest distance as possible, with low radiation burden to surrounding, 
healthy tissue. Therefore, ^-emitting radionuclides have to be used, since 
the range of ^-particles m tissue does not exceed several millimeters (ΙΟ­
Ι 00 cell diameters). Advantages of RIT over other mAb-based therapies 
are the previously mentioned cross-fire effect, the possibilit> to perform 
imaging and dosimetry, and the independence of phenomenons like mAb 
internalization, patient's immunocompetence, and multi-drug resistance 
Taking into account the availability of suitable mAbs and the fact that 
HNSCC is a radiosensitive tumor type, initiation of clinical RIT trials in 
patients with HNSCC was a logical next step. 
Chimeric mAb U36 was selected for the first clinical RIT trial in HN­
SCC patients, as this mAb is broadly applicable for targeting squamous tu­
mors as well as adenocarcinomas. Colnot et al. described the clinical use 
of the chimeric mAb U36, labeled with 1 8 6Re, in patients with recurrent 
HNSCC, either locally or at distant sites [24]. Thirteen patients received 
0.74 GBq 99mTc-labeled U36 (2 mg), followed 1 week later by a single dose 
of 186Re-labeled U36 (12 or 52 mg) m radiation dose-escalating steps of 
0.4, 1.0, and 1.5GBq/m2. The radiopharmaceutical was well-tolerated and 
excellent targeting of tumor lesions was seen m all patients. Dose-limiting 
myelotoxicity (thrombocytopema being most prominent) was the only tox­
icity observed, and the maximum tolerated dose (MTD) was reached at 
l.OGBq/m2. Pharmacokinetics varied between patients treated at the same 
dose level and were accurately predicted by the diagnostic procedure. In 
two patients with dose-limiting myelotoxicity, the tumor size was reduced 
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by RIT, while in one patient treated at MTD stable disease for six months 
was observed. 
In RIT, myelotoxicity generally is dose-limiting. A nadir of platelets and 
granulocytes typically occurs at 4-6 weeks after RIT. In this trial, the ab-
sorbed dose for bone marrow at MTD ranged from 0.73 to 1.10 Gy. The 
MTD of 1.0GBq/m2 is lower than MTDs found in comparable trials using 
186Re-labeled mAbs. With the murine mAb NR-LU-10 and the chimeric mAb 
NR-LU-13, MTDs of 3.3GBq/m2 and 2.2GBq/m2 were found, respectively 
[25,26]. In a phase I study using the 186Re-labeled anti-CD22 humanized 
mAb LL2, an MTD of 2.0GBq/m2 was established [27]. Three factors might 
have contributed to the low MTD: (i) a longer half-life of 186Re-labeled 
chimeric mAb U36 in the blood, (ii) the definition of dose-limiting toxic-
ity, defining grade 4 thrombocytopenia as platelet counts below 25 xl0 9 / l 
instead of below 10xl09 / l , and (iii) the pretreatment of the patients, al-
though the lymphoma patients in the previously mentioned RIT trial were 
more heavily pretreated. 
A noteworthy observation of the 186Re-U36 trial was the development 
of human anti-chimeric antibodies (HACAs) in 35% of the patients. Im-
munogenicity was also observed with a second anti-CD44v6 mAb, the high 
affinity murine mAb BIWA 1 [28]. To reduce immunogemcity, humanized 
versions of BIWA 1 were developed, as described by Verel et al. [29]. One of 
these mAbs called BIWA 4 (bivatuzumab), was selected for further clinical 
evaluation. BIWA 4 was labeled with 186Re and studied in a dose-escalation 
study [30]. The results of this study are described in the next two chapters 
of this thesis. 
Future approaches 
The dose-limiting organ in non-myeloablative R1T is the red marrow. 
Therefore, ways are being explored to overcome this limitation. When 
treating non-Hodgkin's lymphoma patients, high, myeloablative doses of 
radiolabeled mAbs can be given in combination with stem cell transplan-
tation [31,32]. An alternative way to increase hematologic tolerability is 
the harvest of stem cell-containing whole blood, without separation of the 
stem cells from the blood. This procedure, which can be performed in a 
routine clinical setting at relatively low cost, was introduced in a RIT trial 
in HNSCC by Colnot et al. [33]. The procedure and rationale in brief: be-
fore RIT, granolocyte colony-stimulating factor (G-CSF: 10^g/kg/day) was 
administered s.c. on an outpatient basis during 5 days. This treatment 
resulted in a rise of CD34+ stem cells in the peripheral blood. On day 
6, immediately prior to the administration of 18(>Re-labeled U36, 1 liter of 
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whole blood was harvested and kept unprocessed at 40C until reinfusion 
72h later. At that time, only 25% of the total 186Re-labeled U36 dose had 
remained in the blood. It was anticipated that the radiation level would 
be low enough to allow homing and proliferation of the CD34+ cells in 
the bone marrow before myelotoxicity would become manifest (4-6 weeks 
p.i ), thereby reducing the seventy of myelotoxicity. Indeed, when applying 
this technique the MTD more than doubled. Although the bone marrow 
dose ranged from 2.1 to 2.8 Gy, more than two tunes higher than in the 
previous phase I trial with U36 [24], myelotoxicity exceeding grade 3 was 
not observed. Stable disease for 3-7 months was observed in five of nine 
patients, and in all patients treated at the highest dose level of 2.0 GBq/m2 
Another possibility to increase the administered activity dose is the re-
duction of the circulation time of radioactivity by introducing multi-step 
treatment schedules Paganelli et al. treated a HNSCC patient by infusing 
non-radioactive biotinylated anti-CEA mAbs, followed by administration 
of streptavidin 36 h later [34]. As the last step m this pre-targeting ap-
proach, 18 h after the streptavidin infusion, 2.6 GBq of the fast clearing 
90Y-DOTA-biotin was infused. This patient, having a T4N3M0 HNSCC of 
the right tonsil that relapsed after chemo-radiation therapy, responded 
with a complete remission to RTT. No hematologic toxicity was observed. 
Still, the dose absorbed by the tumor was less than 10 Gy [34] Therefore, 
the authors state that this treatment modality should preferably be used 
in combination with external beam radiation 
Maraveyas et al. came to the same conclusion [35]. They studied the use 
of radioiodinated HMFG1 mAbs in patients undergoing surgery. With spec-
imens obtained during surgery, absorbed tumor doses could be estimated. 
When giving 1S1I-HMFG1 RIT, an absorbed tumor dose of approximately 
3-4Gy was achieved [35]. Since also other RIT studies suggest that tumor 
doses of at most 20 Gy can be achieved, it is realistic to expect future ap-
plication of RIT of HNSCC in an adjuvant setting. Especially the treatment 
of minimal residual disease seems to be attractive as it was demonstrated 
that mAb uptake and dose delivery are approximately 4 times higher in 
small-volume tumors (1cm3) than in the large-volume tumors (50 cm3) 
[36]. 
Also some novel approaches might be particular attractive for applica-
tion in head and neck cancer. For example, it was shown that the anti-EGFR 
mAb 425 strongly enhanced the efficacy of RIT with 186Re-labeled U36 
in HNSCC-beanng nude mice [37]. Also other studies showed synergism 
when combining EGFR inhibitors with irradiation [38,39]. Taking into ac-
count the high expression of EGFR m most HNSCC and its absence on bone 
marrow cells, such approach holds promise for future clinical application 
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Conclusions 
RIT of HNSCC has been applied in only a small number of patients. Myelo­
toxicity appeared to be dose-limiting. Nevertheless, data suggest that RIT 
could play a role as an adjuvant treatment of HNSCC. 
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Abstract 
Purpose: In previous studies, we have shown the potential of ra-
dioimmunotherapy (RIT) with 186Re-labeled chimeric monoclonal antibody 
(mAb) U36 for treatment of head and neck cancer. A limitation of this 
anti-CD44v6 mAb, however, appeared to be its immunogenicity, result-
ing in human anti-chimeric antibodies in 40% of the patients. Aiming 
for a less immunogenic anti-CD44v6 mAb, the humanized mAb BIWA 4 
(bivatuzumab) was introduced. In the present phase I RIT study, we de-
termined the safety, maximum tolerated dose (MTD), pharmacokinetics, 
immunogenicity, and therapeutic potential of 186Re-labeled BIWA 4 in pa-
tients with squamous cell carcinoma of the head and neck. 
Experimental Design: Twenty patients with inoperable recurrent and/or 
metastatic head and neck squamous cell carcinoma received a single dose 
of I86Re-labeled BIWA 4 in radiation dose-escalation steps of 0.74, 1.11, 
1.48, 1.85, and 2.22GBq/m2 (20, 30, 40, 50, and 60mCi/m2). Three pa-
tients received a second dose at least 3 months after the initial dose. After 
each administration, whole-body images as well as planar and tomographic 
images of the head and neck region were obtained, and the pharmacokinet-
ics and the development of human anti-human antibody responses were 
determined. Radiation absorbed doses were calculated for whole body, red 
marrow, organs, and tumor. 
Results: First and second administrations were all well tolerated, and 
targeting of tumor lesions proved to be excellent. The only signifi-
cant manifestations of toxicity were dose-limiting myelotoxicity consist-
ing of thrombo- and leukocytopenia and, to a lesser extent, oral mucosi-
tis (grade 2). Grade 4 myelotoxicity was seen in two patients treated 
with 2.22GBq/m2. The MTD was established at 1.85GBq/m2, at which 
level dose-limiting myelotoxicity was seen in one of six patients. Sta-
ble disease, varying between 6 and 21 weeks, was observed in three of 
six patients treated at the MTD level. The median tumor dose, recalcu-
lated to MTD level, was 12.4 Gy. The absorbed dose in red marrow was 
0.49 ± 0.03mGy/MBq for males and 0.64 ± 0.03mGy/MBq for females. 
Two patients experienced a human anti-human antibody response. Phar-
macokinetics showed consistency across patients and within the three pa-
tients receiving I8f'Re-BIWA 4 on two occasions. 
Conclusions: This study shows that 186Re-labeled BIWA 4 can safely 
be administered, also in a repeated way. The MTD was established at 
1.85GBq/m2. In comparison with the previously described anti-CD44v6 
mAb U36, the humanized mAb BIWA 4 seems to be less immunogenic. 
The fact that antitumor effects were seen in incurable patients with bulky 
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disease justifies the evaluation of RIT with 186Re-labeled BIWA 4 in an ad-
juvant setting. 
Introduction 
Squamous cell carcinoma, the predominant histological type among tu-
mors of the head and neck, accounts for approximately 5% of all malignant 
tumors in Europe and the United States. In 2000, an estimated 551,100 
new cases of squamous cell carcinoma of the head and neck (HNSCC) of 
the oral cavity, pharynx, or larynx were diagnosed worldwide [1]. Early 
stages (stage I/II) of HNSCC generally have a good prognosis after surgery 
or radiotherapy. Unfortunately, this does not hold true for advanced-stage 
disease (stage III/IV) as present in about two-thirds of all HNSCC patients. 
Despite improvements in locoregional treatment modalities, the rate of 
locoregional recurrence still is near 40%, whereas approximately 25% of 
these patients develop distant metastases. With respect to the latter, au-
topsy studies have shown incidences up to 57% [2-5]. In particular, pa-
tients with multiple lymph node metastases are at risk for the develop-
ment of locoregional recurrences and distant metastases [6,7]. Consider-
ing these figures, it is plausible that many of the advanced-stage HNSCC 
patients harbor residual tumor cells after surgery and radiotherapy. The 
role of adjuvant chemotherapy for this group of patients has not proven 
to be beneficial, and therefore the development of an effective adjuvant 
systemic treatment is a major challenge. 
Selective targeting of radionuclides to HNSCC by use of monoclonal 
antibodies (mAbs) as in radioimmunotherapy (RIT) might contribute to a 
more effective treatment of advanced-stage disease. Because HNSCC is 
relatively radiosensitive compared with other solid tumors, RIT can be-
come a realistic option. To date, most successes in the field of RIT have 
been achieved in patients with hematological malignancies, such as non-
Hodgkin's lymphomas, where high rates of partial and complete responses 
have been observed [8]. In the treatment of B-cell non-Hodgkin's lym-
phoma, most experience has been gained with iodine-131- and yttrium-
90-labeled anti-CD20 mAbs such as tositumomab and ibritumomab, re-
spectively [9-13]. 
These successes have motivated us to explore the additional value of 
RIT against HNSCC. In the selection of a suitable target antigen in HN-
SCC, CD44 splice variants containing the v6 domain appeared to be the 
most promising thus far. The CD44 protein family consists of isoforms, 
encoded by standard exons and up to nine alternatively spliced variant 
exons (v2-vl0), which are expressed in a tissue-specific way and involved 
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in physiological functions such as signal transduction, growth factor bind-
ing, cell adhesion, and cell migration. Expression of v6-containing CD44 
variants has been related to aggressive behavior of various tumor types 
and was shown to be particularly high and homogeneous on the outer cell 
surface of HNSCC [14,15]. 
In the past decade, the development of CD44v6-directed RIT in HN-
SCC has shown encouraging progress. For this purpose, two murine mAbs 
(mmAbs) became available, designated mmAb U36 and mmAb BIWA 1. Al-
though BIWA 1 resembles U36, it binds to a different epitope with a 35-fold 
higher affinity [16]. According to the numbering of Kugelman et al. [17], 
the epitope recognized by BIWA 1 consists of amino acids 360-370, and 
the epitope recognized by mAb U36 consists of amino acids 365-376. 
Biodistribution studies with radiolabeled mAbs U36 and BIWA 1 in HN-
SCC patients undergoing surgery showed promising biodistribution pat-
terns with selective tumor targeting and high tumor uptake for both mAbs 
[18,19]. Unfortunately, administration of BIWA 1 resulted in human anti-
murine antibody (HAMA) responses in 11 of 12 patients [19], a problem 
also observed after injection of mmAb U36, although to a lesser extent 
[18]. 
Subsequent phase IRTT studies with chimeric (human/mouse) mAb U36 
(cmAb U36) showed favorable targeting and (although not a primary objec-
tive) promising antitumor effects [20,21]. However, chimerization of mAb 
U36 had not resulted in a decrease of the immunogenicity because 5 of 
12 patients showed development of human anti-chimeric antibodies (HA-
CAs) [20]. Formation of HAMAs or HACAs should be eliminated to prevent 
allergic reactions and rapid clearance of the radioimmunoconjugate, es-
pecially when multiple administrations of the radioimmunoconjugate are 
anticipated. The engineering of humanized mAbs (hmAbs), being almost 
completely human apart from a small part of the antigen-binding sites, 
became the next approach to deal with this problem. In several studies, 
hmAbs showed excellent tumor targeting in combination with low or no 
immunogenicity [22,23]. 
To reduce immunogenicity, two humanized BIWA versions were devel-
oped, called BIWA 4 and BIWA 8. The intermediate-affinity mAb BIWA 4 
was selected for further clinical evaluation rather than the high-affinity 
mAb BIWA 8 because of its superior tumor targeting in HNSCC-bearing 
nude mice [16]. 
In the present study, RIT with 186Re-labeled hmAb BIWA 4 was eval-
uated in 20 head and neck cancer patients with regard to safety, maxi-
mum tolerated dose (MTD), pharmacokinetics, immunogenicity, and pre-
liminary therapeutic potential. Three of these patients received a second 
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dose, which was the same or slightly different from the first dose. 
Materials and methods 
Patient eligibility 
Patients with clinical evidence of recurrent locoregional and/or metastatic 
HNSCC, for whom no curative option was available, were candidates. A 
histologically confirmed HNSCC in the past was required for inclusion. 
Other eligibility criteria were an age between 18 and 80 years, a Karnofsky 
performance status above 60, and a life expectancy of at least 3 months. 
An interval of at least 4 weeks from the last chemotherapy or radiother­
apy was required, as well as good recovery from prior treatment. Patients 
were excluded if their WBC count was less than 3.0 xl09/l, if their gran­
ulocyte count was less than 1.5 xl09/l, if their platelet count was less 
than lOOxlO9/!, if the bilirubin level was greater than 30μιηο1/1 (upper 
limit of laboratory normals, 20μπιο1/1), or if the serum creatinine concen­
tration was greater than 150μπιο1/1 (upper limit of laboratory normals, 
110μιηο1/1). Other exclusion criteria were pregnancy, life-threatening in­
fection, severe allergic condition, organ failure, hematological disorders, 
recent myocardial infarction on electrocardiogram or unstable angina pec­
toris, congestive heart failure, and bronchial asthma. Also, premenopausal 
women were excluded when not surgically sterile or not practicing accept­
able means of birth control. The study was reviewed and approved by the 
institutional ethics committees of the VU University Medical Center (Ams­
terdam, The Netherlands) and UMC Nijmegen (Nijmegen, The Netherlands). 
All patients gave written informed consent after receiving a thorough ex­
planation of the study. 
hmAb BIWA 4 (bivatuzumab) and the v6 domain of CD44 
mmAb BIWA 1 (Boehringer Ingelheim, Vienna, Austria), the parental mAb 
of BIWA 4, was generated by immunizing BALB/c mice with glutathione 
S-transferase fusion protein containing the human CD44 domains v3-vl0 
[14]. The epitope recognized by BIWA 1 has been mapped to the v6 domain 
of CD44. Homogenous expression of v6-containing CD44 isoforms has 
been observed in squamous cell carcinoma of the head and neck, lung, 
skin, esophagus, and cervix, whereas heterogeneous expression was found 
in adenocarcinomas of the breast, lung, colon, pancreas, and stomach. In 
normal tissues, expression has been found in epithelial tissues such as 
skin, breast, and prostate myoepithelium and bronchial epithelium [24]. 
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Generation, production, and characterization of BIWA 4 have been de­
scribed previously [16]. In short, mRNA was isolated from the BIWA 1 
hybridoma cell line (Boehringer Ingelheim) using the QuickPrep mRNA Pu­
rification Kit (Pharmacia, Uppsala, Sweden). cDNA from heavy and light 
chain variable regions was generated by reverse transcription-PCR. Frag­
ments were cloned into the TA cloning vector pCR II (Invitrogen, Gronin­
gen, The Netherlands) and sequenced. Two expression vectors derived 
from the plasmid pAD CMV1 [25] were constructed, carrying the constant 
regions of human y-1 and of the human κ light chain, respectively. Sub­
sequently humanized versions of the BIWA 1 heavy and light chain vari­
able regions (generated by CDR grafting) were cloned in front of the im­
munoglobulin constant regions of the abovementioned expression vectors, 
resulting in the hmAb BIWA 4. 
BIWA 4 was stably expressed in Chinese hamster ovary cells, whereas 
high producers were selected as described previously [16]. Cultivation 
was performed in proprietary serum-free medium TH-7 (Boehringer In­
gelheim, Biberach an der Riss, Germany). Bulk substance from fermenta­
tion runs (titer after harvest, 90mg/l) was purified according to a generic 
downstream process for mAbs consisting of ultra/diafiltration, affinity 
chromatography on protein A-Sepharose, microwave treatment at 800C, 
nanofiltration, ultra/diafiltration, anion exchange chromatography on Q-
Sepharose, and ultra/diafiltration. The bulk substance was formulated in 
PBS (pH 7.4) containing 0.02% Tween 20, filter sterilized, and dispensed 
aseptically into vials. Each vial contained 5 ml of BIWA 4 at a concentra­
tion of 5 mg/ml. 
Radiolabeling and quality controls 
For coupling of 1 8 6Re to BIWA 4, the chelate 5-benzoylmercaptoacetyltri-
glycine (MAG3) was used as described previously [26]. 186Re and MAG3 
were obtained from Mallinckrodt, Inc. (Petten, The Netherlands). The 
mean specific activity of 1 8 6Re at the time of labeling was 11 ± 3 MBq/nmol 
(0.31 ± 0.07mCi/nmol). After synthesis of 186Re-MAG3, an esterification 
with tetrafluorophenol was performed. Subsequently, the ester was pu­
rified and conjugated to BIWA 4. Radiolabeled BIWA 4 was purified on 
a PD10 column (Pharmacia-Biotech, Woerden, The Netherlands) with 0.9% 
NaCl containing 5 mg/ml ascorbic acid (pH 5) as the eluent. Finally, the 
conjugates were filter sterUized. These procedures result in a sterile final 
product with endotoxin levels of < 5 endotoxin units per ml, as demon­
strated in five preceding validation runs. The molar ratio of 186Re-MAG3 
to BIWA 4 was always < 4. The radiochemical purity of the conjugates as 
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assessed by high-performance liquid chromatography and thin-layer chro-
matography was always > 95% (mean, 98 ±1.3%). After each preparation of 
186Re-BIWA 4, the immunoreactivity was determined by measuring binding 
to 0.1% paraformaldehyde-fixed cells of the HNSCC cell line UM-SCC-11B 
as described previously [16]. The immunoreactive fraction of the 186Re-
BIWA 4 preparations, as determined by a modified Lineweaver-Burk plot, 
ranged from 81% to 100% (mean, 90 ± 6.9%). 
Prestudy screening and radiological assessment 
The medical history and physical condition of all patients were examined, 
and routine laboratory analyses were performed, including complete blood 
cell counts, serum electrolytes, urine sediment, liver enzymes, and renal 
and thyroid functions. An electrocardiogram and a radiograph of the tho-
rax were obtained. For all patients with locoregional tumor recurrence, a 
CT and/or magnetic resonance imaging (MRI) scan of the head and neck 
region was performed before treatment as has been described previously 
[18], and in cases with distant metastases, a CT scan of the region of inter-
est was obtained. CT and/or MRI scans were also obtained at 6 weeks after 
administration for evaluation of RIT efficacy. To this end, perpendicular 
diameters of tumors were assessed by an experienced radiologist in both 
centers. In case of stable disease, follow-up assessments were, if possible, 
performed every 4 weeks. 
For dosimetry, tumor volume was assessed by drawing regions of in-
terest on consecutive CT or MRI slices with a VoxelQ system (Picker Inter-
national, Highland Heights, OH), as described previously [20]. This system 
enables three-dimensional reconstruction and automated volume calcula-
tion. 
Study design 
RTT was performed with a starting activity dose of 0.74 GBq/m2, followed 
by escalation with 0.37-MBq/m2 increments of 186Re-labeled BIWA 4. All 
patients received 50 mg of BIWA 4, a dose that was found to result in 
optimal tumor uptake and tumor : nontumor ratios in a preceding mAb 
dosefinding study in which doses of 25, 50, and 100mg BIWA 4 were eval-
uated [27]. A complete pretreatment assessment was performed before 
the study, and blood samples were taken for pharmacokinetic analyses. 
Monitoring of vital functions (blood pressure, pulse rate, temperature, and 
breathing rate) was performed at the screening visit; before infusion; at 10, 
60, 120, and 240 min after infusion; and 6 weeks after infusion. Patients 
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who developed an objective response or stable disease after the first dose 
of 186Re-BIWA 4 were eligible for a second administration. They under-
went the same visit schedule as for the first administration. As a safety 
precaution, all repeated administrations were conducted at least 3 months 
after the first administration, and the same inclusion/exclusion criteria 
were used as for the first dose. 
Safety 
After treatment, patients were admitted for approximately 21 h in a spe-
cial treatment room at the Department of Nuclear Medicine, and thereafter 
they stayed an additional 3 days in a single room at the Department of Oto-
laryngology/ Head and Neck Surgery. Dose rates (in )uSv/h) were measured 
1 h after administration at a distance of 100 cm with a y-radiation dose rate 
counter [at VU University Medical Center, Berthold LB 1230 (EG&G, Wild-
bad, Germany); at UMC Nijmegen, Automess 6150 AD 2 (Automess GmbH, 
Ladenburg, Germany)]. The patients were discharged 4 days after admin-
istration of 186Re-BIWA 4, and the set of pretreatment laboratory analyses 
was repeated weekly for at least 6 weeks. The severity of toxicities was 
graded according to the National Cancer Institute Common Toxicity Cri-
teria (CTC), version 2.0. The MTD was defined as the dose level at which 
grade 4 hematological or grade 3 non-hematological toxicity developed in 
not more than one of six patients. 
Tumor response 
Tumor response was assessed according to the WHO guidelines using 
physical examination or radiographic criteria. Stable disease was defined 
as a decrease of < 50% or an increase of < 25% of the sum of the perpen-
dicular diameter products and no appearance of new lesions, which had to 
persist for at least 4 weeks. Progression was defined as a > 25% increase 
in the size of one or more lesions or the appearance of a new lesion. 
Imaging studies 
Simultaneously acquired planar anterior and posterior whole-body scans 
were obtained within 1 h after administration of the radioimmunoconju-
gate; 21, 48, 72, and 144 h after administration of the radioimmunoconju-
gate; and, if feasible, for up to 2 weeks after administration of the radioim-
munoconjugate. For all scintigraphic studies, a large field-of-view gamma 
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camera [at VU University Medical Center, Dual Head Genesys Imaging Sys-
tem (ADAC Laboratories, Milpitas, CA); at UMC Nijmegen, Siemens Mul-
tispect 2 (Siemens, Erlangen, Germany)] equipped with low-energy high-
resolution parallel-hole collimators and coimected to a computer system 
[at VU University Medical Center, Pegasys (ADAC Laboratories); at UMC 
Nijmegen, ICON version 7.1 (Siemens)] was used. Camera quality control 
was performed at each imagmg session. With the aliquot retamed from 
the radiounmunoconjugate preparation for injection, a weighed dilution 
of the injected patient dose was prepared as standard, put in an Adams' 
phantom, and measured simultaneously during whole-body imaging. Lat-
eral, anterior, and posterior planar images of the head and neck region 
were acquired at 21, 48, 72, and 144 h. Single photon emission computed 
tomography (SPECT) images were acquired at 72 h. Acquisition parame-
ters for planar and SPECT images were as described previously [18], with 
a Harming filter used for postfiltermg (cutoff at 1 cycle/cm). In each of the 
study centers, all images were interpreted by one experienced examiner, 
who was unaware of the site of recurrence and/or the presence of distant 
metastases. 
Dosimetry 
Dosimetry to assess dose delivery to whole body, bone marrow, organs, 
and tumor was performed as described previously [20]. Patients 5 and 
17 were excluded from dosimetric analysis due to insufficient data. In 
short, whole-body scintigraphy was used to draw regions around organs 
and sites of interest. Residence times m these organs and sites were cal-
culated and entered in the MIRDOSE3 computer program, version 3.1 (Oak 
Ridge Associated Universities, Oak Ridge, TN). If CT/MRI scanning before 
treatment with 186Re-BIWA 4 showed a measurable tumor lesion, and if 
this lesion was visible on scintigraphy after RIT, dosimetry of the tumor 
was performed. The red marrow dose was calculated usmg a blood-derived 
method as described previously [20,28]. 
Pharmacokinetics 
Serial blood samples were taken from a peripheral vein of the arm oppo-
site to the infusion site at the following time points: premfusion; at the 
end of the infusion; and at 5 and 30nim and 1, 2, 4, 16, 21, 48, 72, and 
144 h after administration of 186Re-BIWA 4. Preliminary results obtained 
from the first four patients showed that blood sampling at additional time 
pomts in the second week after administration would improve the charac-
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terization of the 186Re-BIWA 4 pharmacokinetics. Therefore, for patients 
5-20, blood samples were also taken at 240 and 336h after administra-
tion. Plasma samples were prepared for determination of the concentra-
tion of immunoreactive BIWA 4 by validated ELISA methods, essentially as 
described previously [19]. In this sandwich-type ELISA, microtiter plates 
were absorptively coated with the fusion protein GST-CD44v6. In a first 
step, BIWA 4 in the plasma sample bound to the immobilized antigen 
CD44v6. After incubation, unbound BIWA 4 and plasma components were 
removed by washing. In a second step, rabbit anti-human IgG labeled with 
horseradish peroxidase (DAKO, Copenhagen, Denmark) was used for de-
tection of bound BIWA 4, and tetramethyl-benzidine (Kirkegaard & Perry, 
Gaithersburg, MD) was used for detection of enzyme activity. 
In addition, whole-blood and serum samples were prepared and 
counted in a gamma counter [at VU University Medical Center, 1470 Wiz-
ard (Wallac, Turku, Finland); at UMC Nijmegen, 1480 Wizard (Wallac)], and 
radioactivity levels were expressed as percentage of injected dose per kilo-
gram (% ID/kg). Background activity and decay were corrected for, and the 
% ID/kg was determined by comparison with an aliquot retained from the 
conjugate preparation for injection. 
Human anti-BIWA 4 response 
Evaluation of the immunogenicity of the BIWA 4 radioimmunoconjugate 
was conducted by determination of human anti-hmAbs in serum sam-
ples taken before administration of 186Re-BIWA 4 and 1 and 6 weeks after 
administration, using a validated bridging ELISA. In short, BIWA 4 anti-
bodies labeled with the chelator MAG3 were immobilized onto microtiter 
plates. Antibodies to BIWA 4-MAG3 present in the serum sample bound 
simultaneously to the solid phase and to biotinylated BIWA 4-MAG3 that 
was added at the same time in a fixed amount. Streptavidin coupled to 
horseradish peroxidase (Boehringer Mannheim, Mannheim, Germany) was 
used for signal generation by the peroxidase/tetramethyl-benzidine sys-
tem. Due to the lack of a positive human anti-BIWA 4 serum, which would 
be desirable as a standard, the validation of the present assay was done 
with a rabbit antiserum from an animal that was previously immunized 
with nomadioactive 185Re-MAG3-BIWA 4. The assay only enabled the rel-
ative measurement of the human anti-human antibody (HAHA) titer in 
equivalents of the anti-BIWA 4 titer of the reference rabbit serum. For an 
easier handling of data, the dilution factors of the rabbit reference serum 
were converted into Boehringer Ingelheim titer units. The titer unit was de-
fined as dilution of the rabbit reference serum (l:x) multiplied by 18,000. 
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Assay performance during the study was assessed by back-calculation of 
calibration standards, tabulation of the standard curve fit function param-
eters, measurement of quality control samples, and construction of a pre-
cision profile. Triplicate determinations in three randomly assigned wells 
of a microtiter plate were used for unknown samples, calibration stan-
dards, and quality controls. The lower and upper limits of determination 
of the assay were 0.180 and 60 Boehringer Ingelheim titer units (1:100,000 
to 1:300 dilution of the rabbit reference serum). A serum sample was con-
sidered HAHA positive only if all of the following criteria were met: (a) the 
measured titer was above the lower limit of determination/quantification; 
(b) the titer in the postinjection sample was at least two times higher than 
that in the preinjection sample; (c) the sample could be serially diluted with 
a strong correlation between titer and dilution factor; (d) the titer could be 
blocked by addition of BIWA 4; and (e) the titer could not be blocked by a 
non-specific IgG mAb. 
Results 
Twenty patients (14 males and 6 females; age range, 42-73 years; mean 
age, 58 years) entered this study. Their characteristics are shown in Ta-
ble 7.1. Thirteen patients had received surgical treatment of their disease 
at an earlier stage. All patients had been treated previously with radiother-
apy, and some of them had also been treated with chemotherapy. Two pa-
tients were treated at the lowest dose level of 0.74GBq/m2, four patients 
were treated at l.UGBq/m2 (one patient more than planned because of 
death of one of the patients during follow-up), three patients were treated 
at 1.48 GBq/m2, six patients were treated at 1.85 GBq/m2, and five patients 
were treated at 2.22 GBq/m2. Three patients received a second administra-




(yrs) Site of disease 
Prior treatment besides 
radiotherapy 
Surgery + MTX3 + Cis 
Surgery 
Surgery 
Surgery + MTX 
Doce + Cis + 5-FU 










Surgery + Cis 
Surgery 
Surgery + MTX13 
Surgery + Doce + Cis + 5-FU 





























































Oral cavity, and metastasis parotid gland, bilateral 
Neck recurrence, right side 
Neck recurrence, left side 
Oral cavity, and neck recurrence, left side 
Hypopharynx, and metastases thoracic wall and lung 
Parotic gland, and neck recurrence, left side 
Neck recurrence, bilateral 
Neopharynx, and neck recurrence, right side 
Neck recurrence, right side, and metastasis left lung 
Tonsillar cavity and base of tongue, right side 
Hypopharynx, neck recurrence left side, and lung metastasis 
Neck recurrence, bilateral, and lung metastasis, bilateral 
Floor of mouth, and lung metastasis 
Neck recurrence, right side 
Neck recurrence at tracheostoma 
Nasal vestibule and neck recurrence, right side 
Multiple s.c. metastases 
Recurrent disease mandibula, left side 
Skin metastasis neck, left side, and lung metastasis, right side 
Oropharynx and sinus maxillaris, right side, and lung metastasis 
a MTX, methotrexate; Cis, cisplatin; Doce, docetaxel; 5-FU, fluorouracil; Vin, vincristin; Bleo, bleomycin, Cyclo, cyclophosphamide; 
Etopo, etoposide; Doxorub, doxorubicin 
b MTX prescribed for rheumatoid arthritis. 
Table 7.1 Patient and tumor characteristics 




























































































































































































































Facial edema (1) 
None 
None 






Gout (2), Loss of taste (2) 
Loss of taste(2) 
Oral mucositis (2) 
Oral mucositis (2) 
Fever (3), febrile neutropenia (3), 
oral mucositis (2), 
Candida stomatitis (2) 
Oral mucositis (2) 
Oral mucositis (1) 
None 
Fever (3), febrile neutropenia (3), 
oral mucositis (2), Candida 
stomatitis (2), petechiae (1) 
Fever (4), febrile neutropenia (4), 
increased anemia (4), fatigue (3) 
Minor signs of petechiae (1) 
None 
None 
a Possibly related to study drug 
b NA, not applicable due to insufficient follow-up. 
1 Patient received 18(,Re-BIWA 4 on two occasions. 
Table 7 2 Administered dose and toxicity 
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Safety and non-hematological toxicity 
Administration of 186Re-BIWA 4 was tolerated well, and no side effects 
were observed directly after and during the first few days after treatment. 
No changes occurred in the physical parameters during the first few days 
after administration, and no changes in blood parameters indicated tox-
icity of organs such as the liver or kidneys. Non-hematological toxicity 
defined as drug-related CTC grade 3 or 4 occurred in four patients (Ta-
ble 7.2). One patient (patient 5) treated at the 1.11-GBq/m2 dose level 
was admitted to the hospital because of unexplained seizures 5 days after 
treatment. During hospitalization, Quincke's edema or angioedema caused 
respiratory distress 8 days after the start of RIT, which was treated with 
infusion of prednisolone and inhalation of bronchodilatators. After treat-
ment for low serum sodium levels and treatment with antiepileptic drugs, 
the patient left the hospital again 11 days after the start of RTT. She was 
found dead at home 22 days after start of treatment. No signs indicating 
a relationship between antibody administration and death were noticed, 
but the possibility of a relationship could not be excluded. Permission for 
autopsy was not given by the relatives. Analysis of pre- and posttreat-
ment serum samples showed absence of HAHA. Because this patient was 
not évaluable for hematological toxicity and antitumor response, an extra 
patient was treated at the 1.11-GBq/m2 dose level. 
Febrile neutropenia occurred in patients 13 and 16 (both CTC grade 
3) and in patient 17 (CTC grade 4), all of whom were treated at the 2.22-
GBq/m2 dose level. All three patients received empirical antibiotic and 
antimycotic treatment until WBC counts had recovered and the patients 
were afebrile. CTC grade 3 fatigue occurred in patient 17 at approximately 
4 weeks after administration of 2.22GBq/m2 186Re-BIWA 4. The fatigue 
was most likely related to the aggravation of the pre-existing anemia. Main 
non-hematological toxicity consisted of mild (maximum CTC grade 2) mu-
cositis (Figure 7.1) in two of the six patients treated at the 1.85-GBq/m2 
dose level and in three of the five patients treated at the 2.22-GBq/m2 
dose level. This form of toxicity is most likely drug-related because the 
CD44v6 target antigen is known to be expressed in normal mucosa. The 
mucositis usually started 1-2 weeks after administration of the conjugate 
and disappeared 2 weeks after onset. Most other toxicity was not related 
to the conjugate, except for reversible loss of taste in one patient, observed 
after both injections of 186Re-BIWA 4. 
For patients treated at the MTD level, mean radiation dose rate mea-
sured 1 h after injection at a distance of 100 cm was 4.9μ5ν/1ι. These dose 
rates would result in cumulative doses far less than the annual limit of 
2 mSv, which, according to Dutch guidelines for radionuclide therapy, is 
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Figure 7.1: Example of oral mucositis (patient 12). Mucositis (encircled) occurred 
in this patient from day 11-32 after injection of 1.8S GBq/m- 18riRe- BIWA 4. 
considered to be acceptable for medical personnel and family members. 
Hematological toxicity 
The bone marrow appeared to be the dose-limiting organ. A significant 
decrease of platelet and WBC counts was observed for patients treated 
at the highest dose levels, with a nadir of 4-5 weeks after injection of 
the conjugate (Figure 7.2). Hematological dose-limiting toxicity defined as 
drug-related CTC grade 4 was reported in three patients (Table 7.2). Re-
versible CTC grade 4 leukocytopenia and granulocytopenia were observed 
in two patients (patients 13 and 17) treated at 2.22 GBq/m2, at 4 and 5 
weeks after injection, respectively. In addition, the anemia present before 
entering the study worsened slowly in patient 17 and finally resulted in 
a CTC grade 4 anemia, which was treated with blood transfusions. Re-
versible CTC grade 4 thrombocytopenia and grade 4 leukocytopenia were 
observed in one patient (patient 18) treated at 1.85 GBq/m2, who received 
concomitant treatment with methotrexate for rheumatoid arthritis. Clin-
ical symptoms of thrombocytopenia in this patient consisted of mild pe-
techiae. Patient received a total of two pooled donor units of platelets 
on day care basis. All three patients with grade 4 hematological toxicity 
received antibiotic and antimycotic treatment until WBC counts had recov-
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ered and the patient was afebrile. MTD was established at 1.85GBq/m2. 
Nadirs of each individual patient are listed in Table 2. Drug-related throm­
bocytopenia and leukocytopenia occurred about 21 days after start of RIT, 
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Figure 7.2- Relationship between myelotoxicity and administered l!t(>Re- BIWA 4 radioac­
tivity dose Myelotoxicity, measured as mean percentage decrease from baseline for WBCs 
(A) and platelets (B) after administration of 0.74 (*), 1.11 (a), 1.48 (Δ), 1 85 (o), or 
2.22GBq/m2(0). 













Figure 7.3: Whole-body scans of patient 10 acquired within 1 h (A) after adminis­
tration of 186Re-BIWA 4 and after 21 (B), 48 (C), 72 (D), and 144 h (E). Immediately 
after injection, activity is mainly present in blood pool. Relative uptake of the ra-
dioimmunoconjugate in the tumor in the right tonsillar cavity and base of tongue 
increases over time. 
Imaging 
Whole-body scans obtained directly after administration of 186Re-BIWA 4 
showed mainly blood-pool activity, which decreased over time. Represen­
tative whole-body scans are shown in Figure 7.3. At later intervals, a ho­
mogenous distribution was observed in the lungs, liver, spleen, and kid­
neys, whereas relative uptake at tumor sites gradually increased. In gen­
eral, no selective accumulation at nontumor sites was visible except for up­
take in squamous epithelia (oral mucosa, nasal mucosa, and skin), testes, 
feces, and urine (bladder). Planar and SPECT images obtained showed im­
proved delineation of small tumors in the head and neck region (see Fig­
ure 7.4). However, visualization of distant metastases, concerning mainly 
lung metastases, was in most cases hampered by the presence of blood-
pool activity and the small size of the lesions. 
Pharmacokinetics 
Concentrations of 186Re-BIWA 4 were assessed by measuring immunore­
active BIWA 4 in plasma with an ELISA assay as well as by measuring 
radioactivity in serum. Because each patient received BIWA 4 as a 50-
mg infusion, the immunoreactive BIWA 4 concentrations are presented 
as a group to demonstrate the consistency of data across patients (Fig-




Figure 7.4: Frontal (A) and lateral (B) planar image of the head and neck region of 
patient 16, 72 h after administration of 18(>Re-BIWA 4. Accumulation of radiola­
beled hmAb BIWA 4 is visible in tumor recurrence in right nasal cavity, and at two 
cutaneous metastases in the neck (arrows). 
ure 7.5A). In a similar way, the normalized (% ID/kg) radioactivity data are 
presented (Figure 7.5B). Overlaying the immunoreactivity and radioactiv­
ity data demonstrates that plasma BIWA 4 concentrations and radioactiv­
ity serum concentrations track each other well, indicating that the 186Re-
BIWA 4 conjugate remained stable after i.v. injection. This graphical con­
sistency between plasma BIWA 4 concentrations and serum radioactivity 
concentrations was observed for each patient and within the three patients 
receiving 186Re-BrWA 4 twice (Figure 7.6). However, modeling of the data 
revealed that the geometric mean serum half-life for the radioactive por­
tion of 186Re-BIWA 4 was significantly longer than the plasma half-life of 
BIWA 4 portion: 126.5 ± 36.3 versus 95.1 ± 15.9h (P < 0.001). Differences 
noted in the modeling occurred at late time points, when most of the ra­
dioactivity was already eliminated or physically decayed. These data might 
indicate that a small proportion of injected radiolabeled BIWA 4 loses bind­
ing capacity at late time points after injection, by which detection in ELISA 
becomes impossible. 
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150 200 250 300 
Time after administration (hr) 
Figure 7.5: Average blood clearance curves of 18('Re-BIWA 4 as assessed by ELISA for mea-
suring immunoreactive BIWA 4 in plasma (A) or by l8CRe radioactivity measurement in 
serum (B). Individual data points are depicted after administration of r)0mg of BIWA 4 
labeled with 1.18-4.00 GBq of l8,'Re to 20 HNSCC patients. 
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Figure 7 6: Blood clearance curves of l8(,Re-BIWA 4 for patients who received the conjugate twice. Blood clearance 
was assessed by ELISA for measurmg immunoreactive BIWA 4 in plasma (A-C) or by ""'Re activit} measurement 
in serum (D-F), after the first (Δ) and second (Q) administration of IK('Re-BIWA 4 to patients 11 (A and D), 12 
(B and E), and 14 (C and F). 
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Dosimetry 
Twenty-one patient studies [5 female, 13 male (of which 3 patients re-
ceived two administrations)] could be used for dosimetry. The mean 
whole-body absorbed self-dose was 0.28 ± 0.02mGy/MBq for males and 
0.37 ± 0.03mGy/MBq for females. The mean red marrow dose was 
0.49 ± 0.03 mGy/MBq for males and 0.64 ± 0.03 mGy/MBq for females. 
The normal organ with the highest absorbed dose appeared to be the kid-
neys (mean dose in males, 1.61 ± 0.75 mGy/MBq; mean dose in females, 
2.15 ± 0.95 mGy/MBq, which is not expected to lead to renal toxicity). The 
doses delivered to the tumors (n = 15), recalculated to the MTD level of 
1.85GBq/m2, ranged from 3.8 to 76.4 Gy for tumors ranging in size from 
285.9 to 5.1 cm3. The median absorbed dose was 12.4Gy. The largest tu-
mor (285.9cm3) showed the lowest absorbed dose (3.8 Gy), whereas the 
two tumor localizations with the highest absorbed dose (65.1 and 76.4 Gy) 
appeared to be small lesions (11.5 and 5.1 cm3, respectively). However, no 
clear correlation was found between tumor absorbed dose and tumor size. 
Human anti-BIWA 4 response 
HAHA analyses were évaluable for all patients. Two of the 20 patients 
(patients 10 and 17) showed a HAHA response (Table 7.3). For both pa-
tients, the titer of the week 6 sample was elevated and regarded as HAHA 
positive. 
Tumor response 
All patients treated with doses of up to 1.48 GBq/m2 186Re-BIWA 4 showed 
progressive disease upon RTT. One patient (patient 5) was not évaluable 
for tumor size measurements, due to intercurrent death (see "Safety and 
non-hematological toxicity"). 
Three of the six patients (patients 10, 11, and 12) treated with 
1.85 GBq/m2 186Re-BIWA 4 developed stable disease after the first admin-
istration (Table 7.4). As a result, patients 11 and 12 received a second 
administration, and progressive disease was observed after a total of 18 
weeks (patient 11) and 21 weeks (patient 12) after first administration of 
the trial drug. 
One patient (patient 14) treated with 2.22 GBq/m2 186Re-BIWA 4 expe-
rienced stable disease after the first treatment. Progressive disease was 
observed after a second treatment with 1.85 GBq/m2 186Re-BIWA 4, ap-
proximately 24 weeks after the first administration of the trial drug. 































































































































a Week-6 sample taken 2 weeks after RIT. 
Positive responses. 
Table 7.3: Human anti-hmAb BIWA 4 antibody response 
The overall time to progression for patients who did not respond to 
therapy ranged from 0 to 55 days, with a mean of about 5-6 weeks, ir-
respective of the treatment group. The survival time of the patients who 
did not obtain stable disease upon 186Re-BIWA 4 treatment ranged from 
21 to 219 days. For the four patients with stable disease, the survival time 
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Table 7 4: Tumor response 
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Discussion 
RTF with 186Re-BIWA 4 seems to be safe, and no severe side effects were 
observed in this phase I study besides dose-limitmg myelosuppression at 
a 186Re dose level of 2.22 GBq/m2 Furthermore, mild mucositis was ob-
served at the highest 186Re dose levels of 1.85 and 2.22 GBq/m2. Mucositis 
is most probably caused by bmding of 186Re-BIWA 4 to the CD44v6 tar-
get antigen as present m oral mucosa. The MTD of 186Re-BIWA 4 was es-
tablished at 1.85 GBq/m2, which seems to be higher than the 1.0GBq/m2 
found m a previous phase I trial with the other anti-CD44v6 conjugate 
186Re-cmAb U36 [20] In the trial with 186Re-cmAb U36, no mucositis be-
came apparent. Because BIWA 4 and cmAb U36 have a comparable bio-
logical half-life in blood, differences in MTD cannot be explained by dif-
ferences in pharmacokinetics. We believe that the large increments of 
the radiation dose-escalation steps used m the 186Re-cmAb U36 phase I 
trial can partly explain the difference in MTD and that the use of smaller 
dose-escalation steps would most likely have resulted m a higher MTD for 
186Re-cmAb U36. Also, the heterogeneity of the HNSCC patient population 
might have contributed to this difference. 
Of great importance is the low immunogemcity of this humamzed mAb 
directed against the CD44v6 antigen. Ten percent of the patients treated 
m the present study developed HAHAs. In the meantime, 28 more patients 
have been treated with 25-100 mg of radiolabeled BIWA 4 in three parallel 
radioimmunoscintigraphy/biodistribution studies with HNSCC, non-small 
cell lung cancer, and breast cancer patients. HAHA responses were ob-
served in none of these patients, resulting m an overall HAHA response 
rate of 4% for all four studies. This is considerably lower than the 40% HA-
CAs as found with the cmAb U36 [20] and the 90% HAMAs as found with 
the parental mmAb BIWA 1 [19] None of the three patients who received a 
second administration developed HAHAs, which illustrates the possibility 
for repeated treatment with BIWA 4 
Humamzation of other mAbs has been performed with variable suc-
cess. For mstance, hmAb Ml95 elicited no immune response in a study 
group of 14 patients [23], compared with 37% HAMAs found with mmAb 
M195 [29] Furthermore, hmAb BrE-3 showed 14% HAHAs [22], compared 
with mmAb BrE-3, which showed immunogemcity m 46 7% [30] and 83% 
[31], respectively On the other hand, hmAb A33 elicited HAHAs in 26 of 41 
patients [32] Although significantly lower as compared with its parental 
mmAb A33, for which HAMAs were found in all treated patients [33], this 
example illustrates that humamzation does not always solve the problem 
of immunogemcity 
7. RIT in head and neck cancer patients 133 
A secondary objective in this phase I study was to determine the thera-
peutic effects of RIT with 186Re-BIWA 4. Stabilization of tumor growth was 
observed in three of six patients treated at the MTD level, with durations 
ranging from 6 to 21 weeks. This is consistent with efficacy results ob-
tained in previous phase I RIT trials with 186Re-cmAb U36. In a first phase I 
trial with 186Re-cmAb U36, stable disease was observed in one of six pa-
tients treated at MTD. In a second phase I trial with 186Re-cmAb U36, re-
infusion of granulocyte colony-stimulating factor-stimulated unprocessed 
whole blood was used to reduce myelotoxicity and to increase the MTD 
[21]. In this procedure, granulocyte colony-stimulating factor is adminis-
tered s.c. at home during 5 days before the start of RTT. On day 0, just 
before administration of 186Re-labeled mAb, 1 liter of whole blood is har-
vested and kept unprocessed at 40C until reinfusion after 72 h. Indeed, by 
using this facile procedure, the administered dose could be increased from 
1.0 to 2.0GBq/m2, without exceeding grade 3 myelotoxicity and grade 2 
mucositis. In this particular study, stable disease was observed in five of 
nine patients, for a period ranging from 3 to 7 months. All three patients 
treated at the highest dose level showed stable disease. Whether such a 
procedure for further dose escalation is also applicable for 186Re-BIWA 4 
remains to be established. It might well be that a second dose-limiting 
toxicity, most probably mucositis, will become manifest. Furthermore, it 
has to be considered that all HNSCC patients included in the phase I RIT 
trials described above had a history of external beam irradiation, which 
had caused severe mucositis in some of the patients. 
The observation of antitumor effects in patients with bulky disease of-
fers opportunities for further development of RIT with single or multiple 
doses of 186Re-labeled BIWA 4 in an adjuvant setting. The tumor absorbed 
doses, recalculated to MTD level, ranged from 3.8 to 76.4 Gy, whereas 
the median absorbed dose was 12.4 Gy. The tumor with the highest ab-
sorbed dose of 76.4 Gy appeared to be a small lesion of 5.1 cm3, which 
remained stable in size upon RIT (patient 10). It is unlikely that antitumor 
effects are caused by immune modulating effects because BIWA 4 lacks 
antibody-dependent cell-mediated cytotoxicity or complement-dependent 
cytotoxicity-mediating activity in vitro. Recently, we reported on the re-
lationship between HNSCC size and mAb accumulation [34]. Data for this 
report were obtained from several radioimmunoscintigraphy and biodistri-
bution studies with the anti-HNSCC mAbs E48 and U36 in HNSCC patients. 
mAb uptake in small-volume tumors (1 cm3) was approximately 4 times 
higher than uptake in tumors with a large volume (> 50cm3). Therefore, 
in our view, these data justify evaluation of RIT with 186Re-BIWA 4 as a 
systemic adjuvant treatment. 
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In conclusion, this study shows that RIT with 186Re-BIWA 4 is safe. By 
using BIWA 4, a humanized anti-CD44v6 mAb, the rate of HAHA responses 
was reduced to a minimum, and repeated administrations appeared pos­
sible. The MTD was established at 1.85 GBq/m2, at which dose level stabi­
lization of disease was observed in three of six inoperable HNSCC patients 
with bulky disease. The application of RIT with 186Re-BIWA 4 therefore 
holds promise, especially in an adjuvant setting. 
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Abstract 
From December 1999 until July 2001, a phase I dose escalation study was 
performed with 186Re-labeled bivatuzumab, a humanized monoclonal anti-
body against CD44v6, on patients with inoperable recurrent or metastatic 
head and neck cancer. The aim of the trial was to assess the safety and 
tolerability of intravenously administered 186Re-bivatuzumab and to deter-
mine the maximum tolerated dose (MTD) of 186Re-bivatuzumab. The data 
were also used for dosimetric analysis of the treated patients. Dosimetry 
is used to estimate the absorbed doses by nontarget organs, as well as by 
tumors. It can also help to explain toxicity that is observed and to predict 
organs at risk because of the therapy given. 
Methods: Whole-body scintigraphy was used to draw regions around 
sites or organs of interest. Residence times in these organs and sites were 
calculated and entered into the MIRDOSE3 program, to obtain absorbed 
doses in all target organs except for red marrow. The red marrow dose 
was calculated using a blood-derived method. Twenty-one studies on 18 
patients, 5 female and 16 male, were used for dosimetry. 
Results: The mean red marrow doses were 0.49±0.03 mGy/MBq for men 
and 0.64 ± 0.03 mGy/MBq for women. The normal organ with the highest 
absorbed dose appeared to be the kidney (mean dose, 1.61 ±0.75 mGy/MBq 
in men and 2.15 ± 0.95 mGy/MBq in women; maximum kidney dose in all 
patients, 11 Gy), but the doses absorbed are not expected to lead to renal 
toxicity. Other organs with doses exceeding 0.5 mGy/MBq were the lungs, 
the spleen, the heart, the liver, the bones, and the testes. The doses deliv-
ered to the tumor, recalculated to the MTD level of 1.85GBq/m2, ranged 
from 3.8 to 76.4 Gy, with a median of 12.4Gy. A good correlation was 
found between platelet and white blood cell counts and the administered 
amount of activity per kilogram of body weight (r = -0.79). 
Conclusion: Dosimetric analysis of the data revealed that the range of 
doses to normal organs seems to be well within acceptable and safe limits. 
Tumor doses ranged from 4 to 76 Gy. Given the acceptable tumor doses, 
186Re-labeled bivatuzumab could be a good candidate for future adjuvant 
radioimmunotherapy in patients with minimal residual disease. 
Introduction 
Squamous cell carcinoma (SCC) is the predominant histologic type among 
tumors of the head and neck. They account for approximately 5% of all 
malignant neoplasms in Europe and the United States. Worldwide, more 
than 500,000 new cases were diagnosed in 2000 [1]. Patients with early 
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stages of disease (stage I or II) are usually treated with surgery or radio­
therapy and have a good prognosis. Patients with stage III or IV disease 
usually undergo combined surgery and radiotherapy, but the failure rate 
is high: Locoregional disease recurs after conventional therapy in about 
40% of these patients, and distant metastases develop in nearly 25%. The 
management of these advanced stages of disease especially leaves room 
for improvement. Development of an effective systemic adjuvant therapy 
for eradication of minimal residual disease is a major challenge. The use 
of radiolabeled monoclonal antibodies (mAbs) for this purpose may be 
a promising approach, since SCC of the head and neck (HNSCC) is a ra­
diosensitive tumor type. The use of radiolabeled mAbs for the treatment 
of malignancies is called radioimmunotherapy (RIT). RIT appeared to be a 
successful treatment modality in patients with non-Hodgkin's lymphoma, 
a radiosensitive tumor type [2]. RIT is also used in studies for the treat­
ment of solid tumors. For treatment of HNSCC, the CD44 antigen seems a 
suitable target. A particular CD44 isoform, containing the variant exon v6 
(CD44v6), is expressed homogeneously in almost all tumors derived from 
squamous epithelium, whereas its expression on normal human tissues 
is highly restricted [3]. This expression is maintained in tumor metas­
tases, as immunohistochemical evaluation showed homogeneous expres­
sion of CD44v6 in 94 of 95 lymph node metastases [3]. Antibodies directed 
against CD44v6 were already used in previous clinical RIT trials. In 1998, a 
phase I study using the 186Re-labeled chimeric mAb U36 was performed for 
evaluation of the safety and efficacy of RIT [4]. In 5 of 12 patients treated 
with U36, human anti-chimeric antibodies developed. Therefore, a human­
ized mAb called bivatuzumab, which is also directed against CD44v6, was 
developed for further clinical trials. 
In most RIT trials, the radionuclide 1 3 1 I or 90Y is used. 1 3 1 I emits 
low-energy ^-radiation and high-energy, high-abundance y-radiation. Al­
though, in most cases, treatment with 131I-labeled mAbs can be given on an 
outpatient basis in the United States [5,6], the high-energy, high-abundance 
y-radiation emitted by 1 3 1 I may, in some countries, require hospitaliza­
tion of patients to protect relatives and the general public from radiation. 
90Y decays by high-energy ^-emissions but lacks y-radiation. Therefore, 
scintigraphy and dosimetry cannot be performed when only 90Y-labeled 
mAbs are used — a limitation, especially when a new mAb is clinically eval­
uated in RIT for the first time. For this study, 1 8 6Re was used because of its 
excellent physical properties. 186Re decays by both β- and y-emission. The 
mean energies of the ^-emissions are 362 keV (71% of disintegrations) and 
309keV (22%). The low-energy (137keV), low-abundance (10%) y-radiation 
is ideal for scintigraphy, as shown in Figure 8.1, and permits treatment on 
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an outpatient basis even at high doses. 
I 
day 0 day 1 day 2 day 3 
Figure 8.1: Biodistribution directly after and 1, 2, and 3 d after '^'Re-bivatuzumab RIT in 
patient #6, who had carcinoma in the left parotic region. 
Given the encouraging RIT results with 186Re-U36, the ideal physical 
properties of 186Re, and the availability of a humanized mAb, this study 
was conducted to assess the safety and tolerability of intravenously ad-
ministered 186Re-bivatuzumab and to determine the maximum tolerated 
dose (MTD) of 186Re-bivatuzumab. The data of this trial were also used 
for dosimetric analysis. Dosimetry can be used to give insight into the ra-
diation doses absorbed by nontarget organs, as well as by tumors. It can 
also help to explain toxicity that is observed and to predict organs at risk 
because of the therapy given. 
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Materials and methods 
Patient eligibility 
Patients with a history of histologically confirmed HNSCC were candidates. 
At the time they entered the study, they had to have either distant metas-
tases or local or regional recurrent disease for which curative treatment 
options were not available. The tumor had to be measurable clinically or 
radiologically. The patients had to be between 18 and 80 y old, give written 
informed consent, and have a life expectancy of at least 3 months and a 
Karnofsky performance status of over 60. 
Patients with serious concomitant pathology, such as life-threatening 
infections, organ failure, or a recent myocardial infarction, were excluded. 
Other exclusion criteria were allergic diathesis, hematologic disorders, 
congestive heart failure, unstable angina pectoris, bronchial asthma, preg-
nancy, or the absence of acceptable means of birth control in fertile 
women. 
The white blood cell (WBC) count had to be at least 3.0xl09/l, the 
granulocyte count at least 1.5xl09/l, and the platelet count at least 
100 xl09/l . The last course of chemotherapy or radiotherapy had to have 
been at least 4 weeks before inclusion in the study. 
Bivatuzumab 
Bivatuzumab (also known as BIWA 4) is a humanized mAb of the IgGl 
isotype. It was produced and supplied by Boehringer Ingelheim Pharma 
GmbH & Co KG. Bivatuzumab recognizes a transmembrane glycoprotein 
on the outer cell surface. After binding of the mAb to the antigen, an epi-
tope encoded by CD44v6, it is slightly internalized (< 20%). This antigen 
is expressed by all primary head and neck tumors and by the majority 
of cells within these tumors. In addition, homogeneous expression has 
been observed in SCC of the lung, skin, esophagus, and cervix [3]. Het-
erogeneous expression was found in adenocarcinomas of the breast, lung, 
colon, pancreas, and stomach [3]. In normal tissues, expression has been 
found in epithelial tissues, such as skin, breast, prostate myoepithelium, 
and bronchial epithelium [3]. The reactivity of bivatuzumab is essentially 
restricted to squamous epithelia. 
Bivatuzumab was labeled with 186Re using 5-benzoyl-mercaptoacetyl-
triglycine (MAG3) as a chelator by the method of Visser et al. [7]. The 
radiochemical purity of each 186Re-bivatuzumab batch, as assessed by 
thin-layer chromatography or high-pressure liquid chromatography, al-
ways exceeded 95%. The immunoreactive fraction of each batch ranged 
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from 81% to 100%, with a mean of 90%. 186Re and MAG3 were obtained 
from Mallmckrodt. 
Study design 
The present clinical trial was an uncontrolled dose escalation study. All 
patients underwent prestudy screening, consisting of a review of their his-
tory and physical examination, including examination by an experienced 
oncologic ear, nose, and throat surgeon; laboratory analysis; electrocar-
diography; CT of the thorax; and radiologic assessment of the tumor site 
by CT, MRI, or ultrasound. 
Study treatment consisted of a single injection with 50 mg of bi-
vatuzumab labeled with 186Re in increasing doses, starting at 0.74 GBq/m2 
(20mCi/m2), with increments of 0.37GBq/m2 (10mCi/m2). Two patients 
were entered at the lowest dose level, at which toxicity did not exceed 
grade 1 according to the Common Toxicity Criteria, version 2.0, of the Na-
tional Cancer Institute. At the higher dose levels, 3 patients were entered 
per level. If dose-lumtmg toxicity occurred (grade 3 non-hematologic or 
grade 4 hematologic toxicity), the group treated at that dose level had to 
be extended to a total of 6 patients. The MTD was defined as the dose level 
at which not more than 1 of 6 patients experienced dose-linutmg toxicity. 
Patients who responded to the first treatment with 186Re-bivatuzumab 
were eligible for a second administration. They underwent the same visit 
schedule as for the first administration. 
Pharmacokinetics 
Blood samples for pharmacokinetic analysis were taken directly after in-
jection, at 5 and 30 mm after injection, and at 1, 2, 4, 16, 21, 48, 144, 240, 
and 336h after injection. Both serum and blood samples were counted 
m a well-type y-counter (Wizard 1470 [at the Amsterdam study center] or 
Wizard 1480 [at the Nijmegen study center]; Wallac) along with standards 
of the injection solution. The amount of activity in the samples was ex-
pressed as percentage mjected dose per kilogram of blood or serum. 
Scintigraphy 
Whole-body scintigrams for visual assessment of biodistribution and for 
dosimetric analysis were made within 1 h after injection and at 21, 48, 72, 
and 144 h after injection. A known aliquot of the mjected dose (gamma 
camera standard) was inserted in an acrylic block of 15-cm height and was 
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scanned at the same time for reference purposes. At the Nijmegen study 
center, images were acquired using a Siemens double-head gamma camera. 
The images were processed at ICON workstations using a locally developed 
dosimetry tool. This tool allows copying and transferring regions of inter-
est (ROIs) between various whole-body studies. At the Amsterdam study 
center, the data were acquired with an ADAC double-head gamma camera. 
Data were transferred electronically in Interfile format and were converted 
without loss of information to ICON files. These data were analyzed using 
the same dosimetry tool. 
ROIs were drawn around the gamma camera standard; the whole body; 
the heart and its background; the right lung and its background; the liver; 
the spleen and its background; the left kidney and its background; the 
testes, if applicable, and their background; and the tumor, if visible, and 
its background. All images were reviewed by one physician. The counts in 




The activity in the body (CWB) was determined as the geometric mean of the 
counts in the anterior image (CAWB) minus the counts in the standard ROI 
on the anterior image (CAST), and the counts in the posterior image (CPWB) 
minus the counts in the standard ROI on the posterior image (CPST)· This 
is depicted in equation 8.1: 
CWB = V(CAWB - CAST) • (CPWB - CPST). (8.1) 
The activity in the standard (CST) is determined as the geometric mean 
of the counts in the ROI on the anterior image (CAST) and the counts in the 
ROI on the posterior image (CPST): 
CST = VCAST • CPST- (8.2) 
The activity in the heart (CH) was determined as the geometric mean 
of the counts in the anterior ROI (CAH) and in the posterior ROI (CPH) 
minus background (equation 8.3). The background in the anterior image 
(CAH.BG) was calculated by multiplying the counts per pixel in the ROI for 
the background of the heart by the number of pixels in the ROI of the heart. 
Similarly, the background in the posterior image (CPH,BG) was calculated. 
Partial background subtraction was used: Only a fraction of the counts in 
the background ROIs was subtracted [8]. This fraction (F) was calculated 
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by dividing abdomen thickness minus organ thickness by the abdomen 
thickness. For the heart, F equals 0.5 [8]. 
CH = V(CAH - 0.5 • CAH,BG) · (CPH - 0.5 · CPH.BG)· (8.3) 
The activity in the lungs, spleen, and kidneys (CQRG) was determined 
as the geometric mean of the counts in the anterior ROI (CAQRG) and in 
the posterior ROI (CPQRG), minus F = 0.66 times the background in the 
anterior image (CAQRG.BG) and the posterior image (CPORG.BG). respectively 
(equation 8.4) [9]. The background for each organ was calculated similarly 
to the background for the heart. The activity in the lungs was assumed to 
be 2 times the activity in the right lung. The activity in the kidneys was 
assumed to be 2 times the activity in the left kidney. 
CQRG = ^(CAORG - 0.66 • CAORG,BG) • (CPQRG - 0.66 · CPORG,BG). (8.4) 
The activity in the liver (Cu) was determined as the geometric mean of 
the counts in the anterior ROI (CAu) and in the posterior ROI (CPu) (equa-
tion 8.5). No background correction was made, since the liver occupies 
almost the entire thickness of the patient's abdomen [8]. 
Cu = VCAu · CPu- (8.5) 
The activity in the testes (CTE) was determined using the anterior image 
only (the geometric mean of the counts in the anterior ROI [CATE] and the 
background in the anterior image [CATE.BGD (equation 8.6). 
CTE = CATE _ CATE,BG- (8.6) 
The activity in the tumor (CT) was determined using either the anterior 
image (the geometric mean of the counts in the anterior ROI [CAT] and the 
background in the anterior image [CAT.BG]) or the posterior image (the geo-
metric mean of the counts in the posterior ROI [CPT] and the background in 
the posterior image [CPT.BGD. depending on the site of the tumor (equation 
8.7). 
CT = CAT - CAT.BG or CT = CPT - CPT.BG- (8.7) 
Attenuation correction 
The attenuation of the activity in the whole body and in the abdominal or-
gans was considered to be caused by 11.25 cm of tissue between the center 
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of the patient and the skin. The attenuation of activity in the intrathoracic 
organs is less, because the lungs contain air, leading to less attenuation. 
Therefore, the residence times of these organs are multiplied by 0.85 to 
correct for the differences in attenuation in the abdomen and thorax. 
The residence times of the testes and the tumor are multiplied by 0.25 
and 0.58, respectively. The attenuation of the testes by an overlying layer 
of 1.5 cm of soft tissue can be defined using equation 8.8, in which μ equals 
0.144 cm"1 for 137-keV photons in tissue, and χ = 1.5 cm of tissue. The 
attenuation of the abdomen can be defined using the same equation and 




The distance between the center of the tumor and the skin is thought to 
be 7.5 cm, leading to a correction factor of 0.58, which is calculated using 
the same method as described for attenuation correction of the testes. 
Residence times 
Equations 8.1-8.7 were applied to each imaging time-point to yield time-
activity curves for each organ. The activity in the whole body at each 
time-point was decay corrected. Time-activity curves for the whole body 
were obtained by assuming no biologic clearance of injected activity at the 
first imaging time-point. The decay-corrected counts were fit to a single-
component exponential clearance expression, yielding the biologic half-
life. Assuming that 100% of the injected dose was present at the first 
imaging time-point, the percentage of the injected dose for each succeed­
ing scan was calculated by dividing counts of each succeeding scan by the 
counts of the first scan. These data were fit in a single-component ex­
ponential clearance expression, yielding the residence time value of the 
whole body. 
Residence times in all organs were calculated using the trapezoidal 
method. First, a Unear extrapolation was made between the assumed up­
take fraction of 0 at the time of injection and the measured fractional 
uptake at the time of the first image. This extrapolation was not corrected 
for physical decay. From each time-point to the next, a line was drawn 
between the fractions of uptake. The areas under all these lines were 
summed. The remaining area under the curve from the end of data col­
lection until infinity was determined by considering only physical decay of 
the radionuclide. 
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Absorbed doses 
The absorbed dose to the organs was calculated using the MIRD schema. 
Tumor, heart (contents), lungs, liver, spleen, kidneys, red marrow, testes, 
urinary bladder, and the rest of the body (remainder) were considered 
source organs. The tumor as a source organ was considered to be lo­
cated at the site of the thyroid gland. Because the organ anatomically 
nearest to the tumor is the thyroid gland, one cannot estimate the ab­
sorbed dose to it. The absorbed dose to the thyroid is expected to be 
(very) low, since no uptake in the thyroid (and the stomach) is seen, mean­
ing that neither circulation of perrhenate (1 8 6Re04
_) nor actual uptake of 
radiolabeled antibody occurs in the thyroid. For the bladder, the dynamic 
bladder model was used. A voiding interval of 4 h was assumed. Using 
the counts for the whole body, the biologic half-life was determined as 
described previously. Biologic half-life and voiding interval were entered 
into the dynamic bladder model, yielding the residence time in the urinary 
bladder. The calculated residence times as described in the previous sec­
tion were entered into the MIRDOSE3 computer program, version 3.1 (Oak 
Ridge Associated Universities) [10], to compute the absorbed doses, using 
the reference adult software phantom for the men. For the women, the 
adult female phantom was used. 
The absorbed doses in the tumors were calculated using the known 
fraction of activity in the tumor, divided by the weight of the tumor. To 
assess the volume of the tumor, its 3 dimensions — as assessed by CT 
scanning — were multiplied by π/6. The weight was estimated by multi­
plying the volume of the tumor by its density, being 1.0 g/cm3. This calcu­
lated weight was entered into MIRDOSE3, in which a sphere represents the 
tumor. The dose rate in each tumor was estimated using iterative approx­
imation. 
The red marrow dose (DRM) was estimated using the blood clearance 
data, as described by Shen et al. [11]. The absorbed dose in the red marrow 
(cGy/mCi) is calculated according to equation 8.9: 
D = 0.5 · 0.19 • Cbiood + 0.2128 ÀwB ( 8 9 ) 
In equation 8.9, Ht represents the patient's hematocrit before in-
fusion (1/1), Cbiood is calculated using the residence times in blood 
(kBq • h · ml"1 • MBq-1), ÂWB represents the whole-body residence time (h), 
and Wbody represents the body weight of the patient (g). 
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Statistical analysis 
Associations between myelotoxicity and doses were calculated with 
SPSS 10.0 software (SPSS Inc.) using the Pearson correlation test. Two-
sided significance levels were calculated for all parameters, with Ρ < 0.05 
considered statistically significant. 
Results 
Twenty patients with locoregional recurrence or metastases of head and 
neck cancer, and for whom no curative options were available, were in­
cluded in the trial and treated with 186Re-bivatuzumab. Three of these 
patients received a second injection with 1.85GBq/m2 (50mCi/m2) 186Re-
bivatuzumab at least 12 weeks after the first injection. The specific clinical 
data of the patients treated and the trial outcome are described elsewhere 
[12]. For 2 patients treated, not enough data were available for adequate 
dosimetric analysis. Thus, the results of the dosimetry of 21 RIT proce­
dures on 18 patients are presented. 
Red marrow doses 
The doses absorbed in the red marrow were estimated for all 21 patient 
studies, as presented in Table 8.1. The data of men and women are pre­
sented separately, since men and women have different mean blood vol­
umes according to the standard phantom models (5.21 in men, 3.91 in 
women). Therefore, the weight of the bone marrow differs between the 
sexes, leading to differences in absorbed marrow doses. Table 8.2 shows 
the mean absorbed doses at the different dose levels. 
Because pharmacokinetic data were used to estimate the red marrow 
doses, the small variance in absorbed doses suggests a consistency in the 
pharmacokinetics of these patients. 
Absorbed doses in other organs 
The calculated residence times in the source organs were entered into the 
MIRDOSE3 program. The results of the MIRDOSE3 analysis are listed in 
Tables 8.3 and 8.4. Since 2 different models were used (adult and female 
adult), the data for men and women are presented separately. As stated 
earlier, the thyroid dose could not be estimated. Although MIRDOSE3 lists 
both the effective dose and the effective dose equivalent, these values are 
not applicable to patients receiving radiation therapy. As an alternative, 


















































































































Table 8.1: Absorbed doses in red marrow 
the absorbed total-body dose was calculated, considering the body as an 
organ. 
Table 8.3 shows the mean absorbed doses, expressed as mGy/MBq and 
grouped by dose level, in all target organs of male patients. The mean dose 
actually absorbed by all organs was determined by MIRDOSE3 using the 
reference adult phantom and was calculated by multiplying the mGy/MBq 
values by the actual dose, in megabecquerels, that the patients received. 
The data for the women were processed similarly, using the female 
adult phantom. The mean absorbed doses, expressed as mGy/MBq, are 
presented in Table 8.4. The absorbed doses in women appear to be higher 
than those in men because of the different reference body weight of the 
2 models (female adult, 57 kg; adult, 70 kg). Because the data of only 5 
women could be used for dosimetric analysis, no mean absorbed doses per 
dose level could be given, except for the highest dose level of 2.22 GBq/m2 
(60mCi/m2), at which 2 women were treated. 

























Mean absorbed red 










Table 8.2: Mean absorbed doses 
The organ that received the highest doses was the kidney (1.61 ± 
0.75 mGy/MBq in men, 2.15 ± 0.95 mGy/MBq in women). Other or-
gans receiving absorbed doses exceeding 0.5 mGy/MBq were the lungs 
(1.16±0.29mGy/MBqinmen, 1.46 ±0.22 mGy/MBq in women), the spleen 
(1.11 ± 0.39 mGy/MBq in men, 1.56 ± 0.53 mGy/MBq in women), the heart 
(0.83 ± 0.21 mGy/MBq in men, 1.27 ± 0.20mGy/MBq in women), the liver 
(0.76±0.17mGy/MBqinmen, 1.12 ± 0.26mGy/MBq in women), the bones 
(0.92 ± 0.05 mGy/MBq in men, 0.92 ± 0.03 mGy/MBq in women), and the 
testes (0.73 ± 0.23 mGy/MBq). 



















Mean absorbed organ 0.74 GBq/m2 
dose ± SD (mGy/MBq) 
2.08E-01 ± 2.08E-02 
2.01E-01 ± 2.14E-02 
2.08E-01 ± 2.11E-02 
2.05E-01 ± 2.15E-02 
2.05E-01 ± 2.15E-02 
2.04E-01 ± 2.13E-02 
2.05E-01 ± 2.14E-02 
8.35E-01 ± 2.12E-01 
1.61E+00 ± 7.52E-01 
7.62E-01 ± 1.72E-01 
1.16E+00 ± 2.89E-01 
2.02E-01 ± 2.13E-02 
2.08E-01 ± 2.11E-02 
9.22E-01 ± 4.65E-02 
2.00E-01 ± 2.12E-02 
l . l l E + 0 0 ± 3.86E-01 
7.31E-01 ± 2.28E-01 
Urinary bladder wall 3.03E-01 ± 3.27E-02 
Total Body 
LLI = lower large 
2.81E-01 ± 1.66E-02 
intestine; UU = upper large 





















l . U G B q / m ' 
(n = 3) 
0.44 ± 0.03 
0.42 ± 0.04 
0.44 ± 0.04 
0.43 ± 0.04 
0.43 ± 0.04 
0.43 ± 0.04 
0.43 ± 0.04 
1.50 ±0 .10 
2.54 ±1 .70 
1.63 ±0 .28 
2.25 ±0 .77 
0.43 ± 0.04 
0.44 ± 0.04 
1.96 ± 0.08 
0.42 ± 0.04 
1.65 ±0 .81 
1.88 ±0.32 
0.60 ± 0.03 
0.58 ± 0.03 
1.48GBq/m2 
(n = 2) 
0.50 ± 0.09 
0.48 ± 0.09 
0.49 ± 0.09 
0.49 ± 0.09 
0.49 ± 0.09 
0.49 ± 0.09 
0.49 ± 0.09 
2.53 ±0 .47 
4.20 ±0 .03 
2.39 ±0 .63 
3.29 ± 0.60 
0.48 ± 0.09 
0.49 ± 0.09 
2.53 ± 0.06 
0.47 ± 0.09 
2.67 ±0 .27 
1.77 ±0.12 
0.85 ±0 .28 
0.71 ±0 .10 
1.85GBq/m2 
(n = 8) 
0.68 ± 0.07 
0.66 ± 0.07 
0.68 ± 0.07 
0.67 ±0 .07 
0.67 ± 0.07 
0.67 ± 0.07 
0.67 ± 0.07 
2.78 ±0 .82 
6.14 ± 3.06 
2.53 ± 0.48 
4.00 ± 0.84 
0.66 ± 0.07 
0.68 ± 0.07 
2.97 ±0.14 
0.65 ± 0.07 
3.78 ±1 .35 
2.28 ±0 .81 
1.01 ±0 .09 
0.92 ± 0.05 
2.22GBq/m' ; 
(n = 2) 
0.89 ± 0.09 
0.86 ± 0.09 
0.88 ± 0.09 
0.87 ± 0.09 
0.88 ± 0.09 
0.87 ± 0.09 
0.87 ±0 .09 
3.21 ±1 .09 
5.28 ±2.45 
2.75 ± 0.98 
3.89 ±2 .20 
0.86 ± 0.09 
0.89 ± 0.09 
3.51 ±0 .16 
0.85 ± 0.09 
5.17 ±0.75 
2.89 ± 1.31 
1.14±0.15 
1.14 ±0.02 




















Urinary bladder wall 
Uterus 
Total Body 
Mean absorbed organ 
dose ± SD (mGy/MBq) 
2.75E-01 ± 3.56E-02 
2.66E-01 ± 3.68E-02 
2.66E-01 ± 3.63E-02 
2.74E-01 ± 3.62E-02 
2.70E-01 ± 3.70E-02 
2.70E-01 ± 3.66E-02 
2.71E-01 ± 3.63E-02 
2.71E-01 ± 3.69E-02 
1.27E+00 ± 1.97E-01 
2.15E+00 + 9.51E-01 
1.12E+00 ± 2.59E-01 
1.46E+00 ± 2.17E-01 
2.67E-01 ± 3.66E-02 
2.70E-01 ± 3.66E-02 
2.75E-01 ± 3.63E-02 
9.18E-01 ± 2.56E-02 
2.64E-01 ± 3.61E-02 
1.56E+00 ± 5.30E-01 
3.51E-01 ± 3.91E-02 
2.69E-01 ± 3.66E-02 
3.72E-01 ± 2.61E-02 
Mean absorbed 
0.74 GBq/m2 1 






















LLI = lower large intestine; ULI = upper large intestine 
organ dose for different dose levels ± SD (Gy) 
.48 GBq/m-' 














































(n = 2) 
1.00 ±0 .20 
0.98 ±0 .21 
0.97 ±0 .20 
1.00 ±0 .21 
0.99 ±0 .21 
0.99 ±0 .21 
0.99 ±0 .21 
0.99 ±0 .21 
3.77 ±0 .28 
6.30 ±2 .58 
3.02 ±0.34 
4.34 ±0 .27 
0.98 ±0.21 
0.99 ±0 .21 
1.00 ±0.21 
3.18 ±0.32 
0.97 ±0 .20 
5.35 ±1 .70 
1.29 ±0 .01 
0.99 ±0 .21 
1.30 ±0 .17 
Table 8.4: Absorbed organ doses in women 
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Tumor Tumor self-dose Residence Administered Actual Tumor dose 
Patient volume S-value time activity tumor dose if treated at 











































































































Table 8.5: Dose absorbed by tumor 
Tumor dosimetry 
If CT scanning before treatment with 186Re-bivatuzumab showed a mea-
surable tumor lesion, and if this lesion was visible on scintigraphy after 
RTT, dosimetry for the tumor was performed. In this study, 15 lesions 
could be evaluated and were analyzed. 
The tumor sizes ranged from 5.1 to 285.9cm3. The tumor doses 
differed markedly: Doses ranged from 1.4 to 73.9 Gy. Because tumor 
doses in a dose-escalation study cannot easily be compared, tumor doses 
were calculated postulating that all patients were treated at MTD, being 
1.85 GBq/m2 (50mCi/m2). The recalculated tumor doses ranged from 3.8 
to 76.4 Gy, with a median dose of 12.4Gy. The tumor doses of all individ-
ual lesions are listed in Table 8.5. 
In the patient studies used for tumor dosimetry, stable disease was 
observed in 2 cases. The actual absorbed doses in the tumors of these 
patients were 74 and 16Gy, respectively. 
Correlation between toxicity and absorbed doses 
Because hematologic toxicity appeared to be dose-limiting, and because 
no other serious toxicity was observed, platelet and WBC nadir levels were 
compared with total injected activity, injected activity per square meter 
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of body surface area, injected activity per kilogram of body weight (all 
parameters listed in Table 8.6), whole-body absorbed dose (listed in Ta-
bles 8.3 and 8.4), and red marrow absorbed dose (as listed in Table 8.1). 
Correlation coefficients between nadir of platelets and WBCs, and the 5 pa-
rameters mentioned above, were plotted (Figure 8.2), calculated, and listed 
in Table 8.7. The injected activity per kilogram of body weight appeared 
to correlate best with hematologic toxicity, with a correlation coefficient 
of -0.79. Second-best correlations were found between whole-body dose 
and WBC nadir (r = -0.75) and between administered activity per square 




















































































































































Table 8.6: Administered doses and toxicity 
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Figure 8.2: Correlation of platelet and WBC nadirs with total injected activity (A), injected 
activity per square meter of body surface area (B), injected activity per kilogram of body 
weight (C), whole-body absorbed dose (D), and red marrow absorbed dose (E). 
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Parameter 
Dose (GBq) 
Dose level (GBq/mJ) 
Dose per kg (MBqAg) 
Whole-body dose (Gy) 













Table 8.7: Correlation coefficients of hematologic toxicity versus dose 
Discussion 
Dosimetric analysis of patients treated with 186Re-bivatuzumab did not re-
veal unexpectedly high absorbed doses in normal organs. The organ that 
received the highest dose is the kidney. Patients treated at MTD and 1 
dose level higher (1.85 and 2.22 GBq/m2, respectively) had absorbed doses 
in the kidneys of maximally HGy, thus not exceeding 20-25 Gy, a dose 
that is thought to cause renal toxicity [13]. Other organs receiving rela-
tively high absorbed doses are the lungs (maximally 5.4 Gy). Because lung 
toxicity is expected at doses of more than 27Gy [14], the doses found in 
this trial were thought not to lead to pulmonary problems. For the spleen, 
the heart, the liver, and the bones, doses were considered to be within safe 
ranges as well. The absorbed dose in the testes appeared to be maximally 
4Gy, assuming that there was uptake in the testes only and not in the 
epididymides or scrotal skin. Some uptake in the scrotal skin could be ex-
pected, using a radiolabeled antibody that could target skin. In a particular 
patient, 2 separate testicles were seen, thus suggesting that not the scro-
tum was visualized, but the testes. Relatively high uptake of radiolabeled 
immunoglobulins in the testes is not unusual. It was also described for 
patients who received 1H In-labeled polyclonal IgG for infection detection 
[8]. Few data on the effects of radionuclides on fertility and deterministic 
effects have been published. Commentary 7 of the National Council on Ra-
diation Protection and Measurements gives a threshold value of 3.5 Gy for 
external-beam radiation. Because the dose rate of radionuclide therapies 
is lower when compared with external-beam radiation, doses that can be 
tolerated by normal organs are higher than doses delivered by external-
beam radiation. The effects of RIT on fertility have not been sufficiently 
established. 
The absorbed dose to the red marrow was calculated using the pharma-
cokinetic data. Because pharmacokinetic data did not vary much between 
patients [12], the interindividual variation in red marrow doses per admin-
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istered megabecquerel was small as well. There are some factors associ-
ated with stable clearance of the mAbs. The antibody is humanized, so 
aberrant clearance caused by neutralizing antibodies (human anti-murme 
or human anti-chimenc) is not to be expected. There is no antigemc sink 
in the bone marrow or other organs influencing clearance of the antibody. 
Because there is uptake neither m the bone marrow nor in the bone, the 
main contributor to the red marrow dose is activity m the blood. There-
fore, we think it appropriate to use the blood-derived method of Shen et 
al. to estimate red marrow dose [11]. 
The absorbed red marrow dose correlated well with the blood cell 
nadirs (r = -0.69 for platelets, r = -0.72 for WBC). The whole-body 
dose even showed a slightly better correlation (r = -0.69 for platelets, 
r = -0.75 for WBC). Surprisingly, both dosimetry-independent parame-
ters, the administered activity per kilogram of body weight (r = -0.79) 
and the administered activity per square meter of body surface area 
(r = -0.73), correlated well with the blood cell nadirs. The reason to cor-
relate parameters such as dose/kg or absorbed whole-body dose with tox-
icity is that there are as many administration and dosing schemes as there 
are RIT trials. Most RTT trials concern the treatment of non-Hodgkin's lym-
phoma patients. Although trials on patients with this disease cannot be 
compared with trials on patients with head and neck cancer (differences 
in pretreatment, intrinsic activity of the mAbs used, localization of disease 
m the bone marrow, use of murme mAbs), the method of dosing the activ-
ity can be discussed. The 2 main dosmg schemes are dosimetry based or 
weight based. The first method uses a tracer dose of 13 ̂ -labeled mAb to 
determine the therapeutic dosage of radioiodmated anti-CD20 mAb tosi-
tumomab that would lead to a whole-body dose of 0.75 Gy [15]. The sec-
ond method uses a body weight-derived dosmg scheme for the 90Y-labeled 
anti-CD20 mAb ibntumomab (15 MBq/kg) and does not analyze dosimetric 
data before treatment [16]. In retrospect, we can consider the suitability 
of these alternative methods of dosing if they had been applied in the 
present study. If a dose of 55 MBq/kg (the lowest dose at which grade 4 
hematologic toxicity was observed) had been defined as MTD, only 3 pa-
tients would have appeared to tolerate a dose of more than 55 MBq/kg 
without having grade 4 hematologic toxicity (Table 8.6). Two of them had 
grade 3 toxicity. If a 0.84-Gy whole-body dose (the lowest whole-body dose 
at which grade 4 hematologic toxicity was observed) had been chosen as 
MTD, 9 patients would have been undertreated, smce they appeared to tol-
erate higher whole-body doses. Our data suggest that to dose using the 
patient's weight can be safe and has the lowest chance of undertreating 
patients. 
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The absorbed doses in the tumors tend to vary enormously. These 
doses were similar to those achieved by treatment with the other anti-
CD44v6 conjugate, 186Re-U36 [4]. The absorbed dose is higher in small 
lesions than in larger tumors. Although it is to be expected that the small-
est tumors will have the highest doses, the actual doses in these tumors 
could be lower: The statistical error could be significant, because the num-
ber of pixels in such a small ROI is low. In the estimation of tumor doses, 
the influence of necrosis within a tumor is not considered. Radiolabeled 
antibodies can reach only viable tumor cells, since there are no blood ves-
sels in necrotic parts of the tumor. Moreover, intratumoral pressure plays 
a more important role in large lesions. The absorbed dose in the tumor 
could therefore be estimated more precisely by dividing the absorbed en-
ergy through the weight of viable tissue, leading to higher absorbed doses. 
The fact that high tumor doses can be achieved encourages the thought 
that 186Re-bivatuzumab can be an effective systemic adjuvant treatment 
for patients with head and neck cancer with minimal residual disease. 
Conclusion 
Dosimetric analysis of the data on treatment of patients with 186Re-
bivatuzumab revealed that the range of doses to normal organs seems to 
be well within acceptable and safe limits. Attention should be paid to the 
absorbed dose in the testes. Hematologic toxicity was dose-limiting. The 
administered activity per kilogram of body weight correlated best with the 
extent of hematologic toxicity. Doses absorbed in tumors were quite sim-
ilar to those achieved by treatment with the other anti-CD44v6 conjugate, 
186Re-U36. Given the acceptable tumor doses, 186Re-labeled bivatuzumab 
could be a good candidate for future adjuvant RIT in patients with minimal 
residual disease. 
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Chapter 9 
General discussion and future 
perspectives 
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164 9. General discussion 
Radioimmuno therapy (RIT) is a new treatment option for various tu-
mors. Especially in the treatment of patients with non-Hodgkin's lym-
phoma (NHL) successes have been achieved. In this thesis, the results 
of preclinical RIT studies in a mouse lymphoma model and RIT studies of 
patients with NHL and of patients with squamous cell carcinoma of the 
head and neck (HNSCC) are described. In both studies, humanized mon-
oclonal antibodies (mAbs) were used. Since human(ized) mAbs are less 
immunogenic than murine or chimeric mAbs, the chance to elicit human 
anti-murine antibodies (HAMAs) or human anti-chimeric antibodies (HA-
CAs) are reduced. Therefore, retreatment with these mAbs is possible, as 
shown in Chapter 7. 
The choice of an optimal radionuclide for RTT is essential as well. Ide-
ally, a radionuclide for RIT should emit ^-particles as well as low-energy, 
low-abundance y-photons, the latter used for imaging. The half-life should 
be at least several days to ensure time for shipping and labeling of the mAb 
and to deliver enough dose to the tumor, since optimal uptake of radio-
labeled mAbs is achieved after several days. Rhenium-186 (186Re) meets 
these criteria. In the studies described in this thesis, 186Re was used for RIT 
of patients. The combination of the radionuclide and the mAb should have 
an optimal biodistribution, meaning that the radiopharmaceutical should 
accumulate in and should be retained by the tumor, whereas there should 
be neither unwanted accumulation in normal organs, nor high doses ab-
sorbed by the normal organs. In this respect, 186Re can compete with other 
radionuclides. Although in a mouse lymphoma model the uptake and re-
tention of 186Re-epratuzumab in the tumor were not as high as the tumor 
uptake and retention of 88Y- and 177Lu-epratuzumab, the accumulation of 
186Re in the bone is significantly less than that of 88Y and 177Lu (Chapter 3). 
The clinical data presented in Chapters 4 and 7 confirm that RIT with 
both 186Re-epratuzumab and 186Re-bivatuzumab is well-tolerated. The 
dosimetric data described in Chapters 5 and 8 convincingly show that 
treatment with these 186Re-labeled mAbs is safe with respect to absorbed 
doses to normal organs. In these two phase I trials objective responses 
were observed in one third of the patients with NHL, and in none of the 
patients with HNSCC. 
Although the studies presented in this thesis give insight in optimal 
conditions for RIT, it does not answer which subpopulation of patients 
can be treated best on what time. 
Two radiopharmaceuticals have been registered for clinical use in the 
USA so far, both for treatment of patients with NHL with a relapse after all 
conventional options have been tried. Chapter 4 describes the results of 
RIT in the same group of patients. In these patients, few therapies given 
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in a palliative setting show such encouraging results, with high remission 
rates. Therefore, it is likely that this non-myeloablative approach will be 
frequently used in relapsed or refractory lymphoma patients for whom 
no other options are left. Still, other approaches, like myeloablative RTF 
or first-line RIT, could possibly result in more and/or longer lasting re-
missions than conventional therapies, as described in Chapter 1. Future 
research should emphasize these approaches. 
The future role of RIT of solid tumors seems to be hampered by the 
use of mAbs that lack intrinsic anti-tumor activity. Therefore, the radia-
tion dose should be sufficiently high to induce anti-tumor effects and very 
radiosensitive tumors should be selected. As described in the Chapters 7 
and 8, no objective responses in patients with inoperable and incurable 
HNSCC were achieved. Other RIT studies in patients with solid tumors 
for whom no curative options are available, showed similar results. Given 
the low tumor doses in macroscopic, irresectable tumors, whereas higher 
doses can be achieved in small and very small tumors, the most promising 
indication for RTF in the treatment of solid tumors is within an adjuvant 
setting after radical surgery, perhaps in combination with chemo- or radio-
therapy. Hopefully, humanized mAbs like bivatuzumab will enter phase III 





In this thesis, the potential of radioimmunotherapy (RIT) for two types 
of cancer is investigated. Treatment of non-Hodgkin's lymphoma (NHL) is 
described in the Chapters 1-5, whereas treatment of squamous cell carci-
moma of the head and neck (HNSCC) is described in the Chapters 6-8. 
For RTF of both tumor types, humanized monoclonal antibodies (mAbs) 
against tumor-specific antigens are used. In the clinical studies, mAbs 
were labeled with 186Re, an ideal radionuclide for therapy and imaging. 
In Chapter 1, an overview is given of NHL, its treatment, and the role 
of mAbs in lymphoma management. Trials using unlabeled mAbs as well 
as trials using radiolabeled are discussed. Not only overall response rates 
and the additional value of radionuclides over unlabeled use of mAbs are 
described, but especially treatment strategies, dosing schedules, toxicity, 
and current status of these treatments are highlighted. 
In Chapter 2, the development of a human lymphoma mouse model 
is described. Human lymphoma xenografts in general grow only poorly 
in mice. Even when immunocompromized, most mice will not develop 
tumors after inoculation with human lymphoma cells. Therefore, two pre-
treatment regimens of nude mice to improve the implantation and growth 
rate of lymphoma xenografts were compared. In non-pretreated mice, tu-
mor induction after subcutaneous injections with Ramos cells was only 
50%, whereas 80% of the mice pretreated with cyclophosphamide and 100% 
of the mice pretreated with whole-body irradiation developed subcuta-
neous tumors. Moreover, particularly in the group pretreated with whole-
body irradiation, the tumors grew more synchronously. Pretreatment with 
cyclophosphamide or whole-body irradiation improved the tumor implan-
tation rate of Ramos cells in nude mice, providing a workable animal model 
for further lymphoma studies. 
In order to determine the optimal radionuclide for RIT of NHL, a biodis-
tribution study was performed, as described in Chapter 3. The humanized 
anti-CD22 anti-lymphoma mAb epratuzumab (hLL2) was labeled with four 
different radionuclides, 131I, 186Re, 177Lu, and 88Y. After transplantation 
of Ramos cells in nude mice, that were pretreated with cyclophosphamide 
according to the animal model provided in the previous chapter, the mice 
were injected with radiolabeled epratuzumab, or with a control mAb la-
beled with 131I or 88Y. The biodistribution of the radiolabel was deter-
mined 1, 3, and 7 days after injection of the radiopharmaceutical. Ra-
diolabeled epratuzumab had a higher tumor uptake than the control mAb 
at all time points, irrespective of the radionuclide used. Tumor accretion 
of 88Y- and 177Lu-labeled epratuzumab was higher than tumor uptake of 
131I- and 186Re-epratuzumab. Not only tumor uptake, but also bone uptake 
was higher for the former two radiolabels than for the latter on day 7 after 
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injection. It was concluded that the residualizing radionuclides 88Y and 
177Lu in combination with epratuzumab have a higher uptake and better 
retention in the tumor than the radiolabels 131I and 186Re, but the higher 
bone uptake of the former radionuclides could result in a higher radiation 
dose to the bone marrow, reducing the activity dose that can be tolerated 
without acceptable myleotoxicity. 
In Chapter 4, the results of a phase I study using 186Re-epratuzumab 
in patients with NHL were summarized. The aim of the study was to de-
termine the maximum tolerated dose (MTD) and to get a first impression 
of the therapeutic potential of this novel radiopharmaceutical. Patients 
with relapsed or refractory CD22-positive NHL of diverse histopathology 
and prior treatments received 99mTc-labeled epratuzumab, followed by RIT 
with 186Re-epratuzumab one week later. Dose escalation of RIT was started 
at 0.5GBq/m2. Three patients were entered per dose level. If no dose-
limiting toxicity occurred, the dose was increased by 0.5GBq/m2; other-
wise 3 additional patients were included on that dose level. A total of 
18 patients received a diagnostic dose of 99mTc-epratuzumab. Fifteen pa-
tients were actually treated with 186Re-epratuzumab at 4 different dose 
levels, 0.5, 1.0, 1.5, and 2.0GBq/m2. During or after infusion of 186Re-
epratuzumab, no serious adverse reactions were seen. In all patients 
a transient decrease of leukocyte and platelet levels was observed one 
month after treatment. At the 1.5-GBq/m2 dose level, one grade 4 hemato-
logical toxicity was observed. At the highest dose level of 2.0GBq/m2, no 
grade 4 hematological toxicity was seen, but white blood cell and platelet 
counts of two of the three patients did not recover completely. One pa-
tient had a complete remission lasting 4 months. Four patients had a par-
tial response, lasting 3, 3, 6, and 14 months, respectively. Four patients 
had stable disease for 3, 3, 7, and 9 months, respectively. Although no 
dose-limiting, grade 4 toxicity was observed, but given the slow recovery 
of peripheral blood counts in 2 of 3 patients treated at the dose level of 
2.0GBq/m2, this dose level was defined as MTD. A single dose of 186Re-
epratuzumab led to objective responses in 5 of 15 treated patients. 
Safety of treatment with 186Re-epratuzumab with respect to absorbed 
radiation doses to normal organs, and possible relations of hematologi-
cal toxicity with several parameters, were analyzed in Chapter 5. Thirteen 
(9 males, 4 females) of 15 patient studies could be used for dosimetric 
analysis. The absorbed dose in the spleen, an organ often involved in 
NHL, was highest with a mean of 1.89 ± 0.93mGy/MBq for males and 
2.33 ± 0.40mGy/MBq for females. The mean bone marrow doses were 
0.60 ± 0.19mGy/MBq and 0.61 ± 0.14mGy/MBq for males and females, 
respectively. All absorbed doses were within safe ranges. No correlation 
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could be found between toxicity observed and the absorbed doses. 
In Chapter 6, an overview is given of current treatment of head and 
neck cancer, and the possibilities, requirements, and restrictions of RIT 
of HNSCC are discussed. Studies using mAbs against squamous cell 
carcinoma-associated antigens, such as CD44v6, are discussed in more de-
tail. Finally, novel treatment strategies are anticipated. 
One of the limitations of previous RIT studies using mAbs against 
CD44v6 appeared to be the immunogenicity of the chimeric mAbs. Chap-
ter 7 summarizes the results a phase I study using the humanized mAb 
bivatuzumab, labeled with 186Re. In this study, the safety, MTD, immuno-
genicity, and therapeutic potential of this radiolabeled antibody prepara-
tion were determined in patients with HNSCC. Twenty patients with inop-
erable recurrent and/or metastatic HNSCC received a single dose of 186Re-
bivatuzumab in radiation dose-escalation steps of 0.74, 1.11, 1.48, 1.85, 
and 2.22GBq/m2. Three patients received a second dose of 1.85GBq/m2 
at least 3 months after the initial dose. First and second administrations 
were all well tolerated and targeting of tumor lesions proved to be ex-
cellent. The only significant manifestations of toxicity were dose-limiting 
myelotoxicity consisting of thrombo- and leukocytopenia, and, to a lesser 
extent, oral mucositis (grade 2). Grade 4 myelotoxicity was seen in 2 pa-
tients treated at a dose level of 2.22GBq/m2. The MTD was established 
at 1.85GBq/m2, at which level dose-limiting myelotoxicity was seen in 1 
out of 6 patients. Stable disease, varying between 6 and 21 weeks, was 
observed in 3 of 6 patients treated at MTD-level. Two patients experienced 
a HAHA response. It was concluded that 186Re-bivatuzumab can be safely 
administered, also when given twice. 
The data of the previous study were also used for dosimetric analysis, 
as described in Chapter 8. Whole body scintigraphy was used to draw re-
gions around sites or organs of interest. Residence times in these organs 
and sites were calculated and entered into the MIRDOSE3 program, to ob-
tain absorbed doses in all target organs except for red marrow. The red 
marrow dose was calculated using a blood-derived method. Twenty-one 
studies in 18 patients were used for dosimetry, five of them in females, 
16 in males. The mean red marrow dose was 0.49 ± 0.03mGy/MBq for 
males, and 0.64 ± 0.03 mGy/MBq for females. The normal organ with the 
highest absorbed dose appeared to be the kidney (mean dose in males 
1.61 ± 0.75 mGy/MBq, in females 2.15 ± 0.95 mGy/MBq, maximum kidney 
dose in all patients 11 Gy), which is not expected to lead to renal toxic-
ity. The doses delivered to the tumor, recalculated to the MTD level of 
1.85 GBq/m2, ranged from 3.8-76.4 Gy, with a median of 12.4Gy. A good 
correlation was found between platelet and white blood cell nadirs and the 
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administered amount of activity per kg body weight (r = -0.79). Since the 
range of the doses to normal organs was well within acceptable and safe 
limits, and given the acceptable tumor doses, 186Re-labeled bivatuzumab 
could be a good candidate for future adjuvant radioimmunotherapy in pa-
tients with minimal residual disease. 
In Chapter 9, general aspects of the studies described in this thesis are 





In dit proefschrift worden de mogelijkheden voor radioimmunothera-
pie (RIT) van twee typen maligniteiten onderzocht. De behandeling van 
non-Hodgkin lymfoom (NHL) wordt beschreven in de Hoofdstukken 1-5, 
de behandeling van plaveiselcelcarcinoom van het hoofd-hals gebied (PC-
CHH) in de Hoofdstukken 1-6. Voor RIT van beide maligniteiten wordt 
gebruik gemaakt van gehumaniseerde monoklonale antilichamen (mAbs), 
gericht tegen tumorspecifieke antigenen. In de klinische studies worden 
de mAbs gelabeld met rhemum-186 (186Re), een ideaal radionuclide voor 
therapie en scintigrafie. 
In Hoofdstuk 1 wordt een overzicht gegeven van NHL, de behandeling 
ervan en de rol van mAbs bij die behandeling. Studies waarbij gebruik 
gemaakt werd van zowel mAbs zonder radionuclide als mAbs voorzien 
van een radionuclide worden beschreven. Niet alleen responspercentages 
en de toegevoegde waarde van radionucliden in vergelijking met het onge-
labeld gebruik van mAbs, maar vooral behandelingsstrategieen, doserings-
wijzen, toxiciteit en de huidige stand van zaken worden toegelicht. 
In Hoofdstuk 2 wordt de ontwikkeling van een humaan lymfoommodel 
in muizen beschreven. Xenografts van humane lymfoomcellijnen groeien 
over het algemeen slecht in muizen. Zelfs bij de meeste immunodeficiente 
muizen ontstaan geen tumoren na inoculatie met humane lymfoom-
cellen. Derhalve werden twee verschillende voorbehandelingen van naakte 
muizen met elkaar vergeleken, teneinde de implantatie en de groeisnelheid 
van de xenografts te verbeteren. In niet-voorbehandelde muizen bleek 
de tumorinductie na subcutane injectie met Ramos-cellen slechts 50% te 
bedragen, terwijl 80% van de muizen voorbehandeld met cyclofosfamide 
en 100% van de muizen voorbehandeld met hele-lichaamsbestraling een 
subcutane tumor ontwikkelden. Vooral in de groep die bestraald werd, 
bleken de tumoren synchroner te groeien. Voorbehandeling met cyclo-
fosfamide of hele-lichaamsbestraling verbeterde de tumorimplantatie van 
Ramos-cellen in naakte muizen, waardoor een acceptabel diermodel voor 
vervolgstudies naar lymfomen beschikbaar kwam. 
Vervolgens werd een biodistributiestudie verricht teneinde het ge-
schiktste radionuclide voor RIT van NHL te bepalen, zoals beschre-
ven in Hoofdstuk 3. Het gehumaniseerde anti-CD22 antilymfoom mAb 
epratuzumab (hLL2) werd gelabeld met vier verschillende radionucliden, 
tewetenjodium-131 (131I), 186Re, lutetium-177 (177Lu) enyttrium-88 (88Y). 
Na inoculatie met Ramos-cellen werden naakte muizen, die voorbehan-
deld waren met cyclofosfamide zoals beschreven in het voorgaande hoofd-
stuk, geïnjecteerd met gelabeld epratuzumab of met een controle-mAb, 
dat gelabeld was met Π 1 Ι of 88Y. De biodistributie van het radionuclide 
werd 1, 3 en 7 dagen na injectie van het radiofarmacon bepaald. Gelabeld 
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epratuzumab had een hogere opname in de tumor dan het controle-mAb 
op alle tijdstippen, onafhankelijk van het gebruikte radionuclide. De op-
name in de tumor van met 88Y en 177Lu gelabeld epratuzumab was hoger 
dan die van epratuzumab gelabeld met 131I en 186Re. Zeven dagen na injec-
tie was niet alleen de opname in de tumor, maar ook de opname in bot van 
de eerstgenoemde radionucliden hoger dan die van jodium en rhenium. 
Geconcludeerd werd dat het gebruik van de radionucliden 88Y en 177Lu in 
combinatie met epratuzumab een hogere opname en betere tumorretentie 
gaf dan epratuzumab gelabeld met 1J1I en 186Re, maar de hogere botop-
name van yttrium en lutetium zou kunnen leiden tot een hogere beenmerg-
dosis. 
In Hoofdstuk 4 worden de resultaten van een fase I-studie met 186Re-
epratuzumab bij NHL-patienten samengevat. Het doel van de studie 
was het vaststellen van de maximaal tolereerbare dosis (MTD) en het 
krijgen van een eerste indruk van de therapeutische mogelijkheden van 
dit nieuwe radiofarmacon. Patienten met een recidief of persisterend 
CD22-positief NHL, met uiteenlopende histopathologic en voorbehandelin-
gen, kregen 99mTc-epratuzumab i.v. toegediend, een week later gevolgd 
door RIT met 186Re-epratuzumab. De dosisescalatie van deze RIT-studie 
werd gestart op een dosering van 0, 5GBq/m2. Per dosisniveau wer-
den drie patiënten geincludeerd. Indien geen dosislimiterende toxiciteit 
optrad, werd de dosering voor het volgende dosisniveau verhoogd met 
0, 5GBq/m2. Indien wel dosislimiterende toxiciteit optrad, werden nog 
eens 3 patiënten geincludeerd op dat dosisniveau. In totaal ontvingen 18 
patiënten een diagnostische dosis qqmTc-epratuziimab. Vijftien patiënten 
werden daadwerkelijk behandeld met 186Re-epratuzumab op 4 verschil-
lende dosisniveaux, te weten 0,5, 1,0, 1,5 en 2,0GBq/m2. Tijdens of 
na de infusie van 186Re-epratuzumab werden geen ernstige bijwerkingen 
waargenomen. Bij alle patiënten trad een maand na behandeling een voor 
bijgaande afname van leuco- en thrombocytengetallen op. Op het dosis-
niveau van 2,0GBq/m2 werd in één geval graad 4 haematologische toxi-
citeit waargenomen. Op het hoogste dosisniveau van 2,OGBq/m2 werd 
geen graad 4 haematologische toxiciteit gezien, maar de leuco- en throm-
bocytengetallen van twee van de drie patiënten kwamen niet op het uit-
gangsniveau terug. Eén patient was gedurende 4 maanden in complete 
remissie. Bij vier patiënten trad gedurende resp. 3, 3, 6 en 14 maanden 
een partiele respons op. Gedurende resp. 3, 3, 7 en 9 maanden hadden 
vier patiënten stabiele ziekte. Hoewel geen dosislimiterende, graad 4 toxi-
citeit werd gezien, werd het dosisniveau van 2,0 GBq/m2 beschouwd als 
MTD, gegeven het langzame herstel van thrombo- en leucocytengetal bij 2 
van de 3 patiënten behandeld met deze dosering. Een enkelvoudige toe-
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diening van 186Re-epratuzumab leidde tot objectieve responsen bij 5 van 
de 15 behandelde patiënten. 
Geabsorbeerde stralingsdoses in normale organen na behandeling met 
186Re-epratuzumab werden geanalyseerd in Hoofdstuk 5, teneinde vast te 
stellen of een behandeling veilig was en of er een relatie bestond tussen 
de waargenomen haematologische toxiciteit en enkele parameters. Der-
tien (9 mannen, 4 vrouwen) van de 15 patiëntenstudies waren geschikt 
voor dosimetrische analyse. De geabsorbeerde dosis in de milt, een or-
gaan dat vaak aangedaan is bij NHL, was het hoogst, namelijk gemid-
deld 1,89 ± 0,93mGy/MBq bij mannen en 2,33 ± 0,40mGy/MBq bij 
vrouwen. De gemiddelde beenmerg dosis was 0,60 ± 0,19mGy/MBq and 
0,61 ± 0,14 mGy/MBq voor resp. mannen en vrouwen. Alle geabsorbeerde 
doses bleven binnen veilige grenzen. Er werd geen correlatie gevonden 
tussen toxiciteit en de geabsorbeerde doses. 
In Hoofdstuk 6 wordt een overzicht gegeven van de huidige behandeling 
van hoofd-halskanker, waarbij de mogelijkheden, vereisten en beperkin-
gen van RIT bij PCCHH worden besproken. In meer detail wordt ingegaan 
op studies die mAbs tegen plaveiselcelcarcinoom-geassocieerde antigenen, 
zoals CD44v6, beschrijven. Tenslotte worden nieuwe behandelstrategieén 
toegelicht. 
Eén van de beperkingen van eerdere RIT-studies met mAbs tegen 
CD44v6 bleek de immunogeniciteit van dit chimere mAb te zijn. Hoofd-
stuk 7 vat de resultaten van een fase I studie samen, waarbij gebruik 
gemaakt werd van het gehumaniseerde mAb bivatuzumab, gelabeld met 
186Re. In deze studie werden de veiligheid, MTD, immunogeniciteit 
en de therapeutische mogelijkheden van dit radiofarmacon bepaald bij 
patiënten met PCCHH. Twintig patiënten met een inoperabel recidief 
en/of metastasen van een PCCHH ontvingen een enkele toediening 186Re-
bivatuzumab in een stralingsdosis-escalatieschema van 0,74, 1,11, 1,48, 
1,85 en 2,22GBq/m2. Drie patiënten kregen een tweede dosering van 
1,85 GBq/m2 tenminste 3 maanden na de eerste RIT. Eerste en tweede toe-
diening werden goed verdragen en er bleek uitstekende targeting van de 
tumoren te zijn. De enige wezenlijke vorm van toxiciteit bleek dosislimite-
rende thrombo- and leucopenie te zijn, en in mindere mate graad 2 orale 
mucositis. Graad 4 myelotoxiciteit trad op bij 2 patiënten, die behandeld 
waren op een dosisniveau van 2,22 GBq/m2. De MTD werd vastgesteld op 
1,85 GBq/m2, het dosisniveau waarop dosislimiterende myelotoxiciteit op-
trad bij 1 van de 6 patiënten. Stabiele ziekte, variërend van 6-21 weken, 
werd geconstateerd bij 3 van de 6 patiënten behandeld op MTD-niveau. 
Bij twee patiënten werd een HAHA-respons gemeten. De conclusie luidde 
dat 18GRe-bivatuzumab veilig toegediend kan worden, ook voor een tweede 
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keer. 
De data van de voorgaande studie werden tevens gebruikt voor 
dosimetrische analyse, zoals beschreven in Hoofdstuk 8. Hele-lichaams-
scintigrafïe werd gebruikt om de hoeveelheid activiteit in bepaalde ge-
bieden of organen vast te stellen. Verblijfstijden in die gebieden of orga-
nen werden berekend en ingevoerd in het MIRDOSE3-programma, teneinde 
geabsorbeerde doses te berekenen voor alle doelorganen met uitzonde-
ring van het beenmerg. De beenmergdosis werd berekend met een op 
de verblijfstijd in het bloed gebaseerde methode. Eenentwintig studies 
van 18 patiënten (vijf mannen, zestien mannen) werden gebruikt voor 
dosimetrie. De gemiddelde beenmergdosis bedroeg 0,49 ± 0,03 mGy/MBq 
bij mannen en 0,64 ± 0,03 mGy/MBq bij vrouwen. Het normale orgaan 
met de hoogste geabsorbeerde dosis bleek de nier te zijn. De gemid-
delde nierdosis bij mannen bedroeg 1,61 ± 0,75 mGy/MBq en bij vrouwen 
was deze 2,15 ± 0,95 mGy/MBq, met een maximale nierdosis in de to-
tale patiëntengroep van 11 Gy, hetgeen naar men aanneemt niet tot nier-
toxiciteit leidt. De tumordoses, herberekend naar het MTD-niveau van 
l,85GBq/m2, bedroeg 3,8-76,4Gy, met een mediane dosis van 12,4Gy. 
Er werd een goede correlatie gevonden tussen thrombo- en leucocyten-
nadir en de toegediende hoeveelheid activiteit per kg lichaamsgewicht 
(r = -0,79). Aangezien de geabsorbeerde doses in normale organen bin-
nen acceptabele en veilige grenzen lagen, en gegeven de acceptabele tu-
mordoses, zou 186Re-bivatuzumab een goede kandidaat zijn voor toekom-
stige adjuvante RIT van patiënten met minimale residuele ziekte. 
In Hoofdstuk 9 tenslotte worden algemene aspecten van de in dit proef-
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Lieve Michiel en Nicole, lieve Rolf en Pamela, vorig jaar tijdens jullie 
huwelijksvoltrekking vertelde ik al hoe belangrijk jullie voor mij zijn. Ik 
dank jullie voor alles. M'CHIÌÌ., de lay-out is fantastisch. 
Liefste Sjaanke, het boek is uit, we sluiten weer een periode af. Voor 
ons ligt weer een nieuwe weg. Samen met Tobias gaan we heel erg genieten 
van de komende maanden, voor en na 31 mei. Ik houd van jou. 
Correctie der drukproeven op Fuerteventura 
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Ernst Postema werd op 13 augustus 1971 geboren te Blokzijl. Hij groeide 
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het Chr. College Nassau-Veluwe te Harderwijk Vanaf 1989 studeerde hij 
geneeskunde aan de Erasmus Universiteit Rotterdam, alwaar hij in 1996 
het artsexamen aflegde Na AGNIO chirurgie geweest te zijn in zieken-
huis sint Antomushove te Leidschendam, was hij sinds 1 september 1997 
werkzaam op de afdeling nucleaire geneeskunde van het UMC St Radboud, 
waar hij bij opleider en promotor prof.dr. F.H.M. Corstens opleiding en 
onderzoek als AGIKO combineerde. Het stagejaar interne geneeskunde 
doorliep hij in het Shngeland ziekenhuis te Doetinchem bij opleider dr. F. 
de Vries. Sinds zijn registratie per 1 augustus 2003 bleef hij als nucleair 
geneeskundige werkzaam op de afdeling nucleaire geneeskunde van het 
UMC St Radboud. Per 1 april 2004 zal hij zijn loopbaan vervolgen in het 






behorend bij het proefschrift 
"Radioimmunotherapy using 186Re-labeled humanized monoclonal antibodies" 
1. De gehumaniseerde antilichamen epratuzumab en bivatuzumab zijn dus-
danig weinig immunogeen dat herhaalde toediening mogelijk is. 
dit proefschrift 
2. Gezien de relatief lage tumordosis in grote tumoren, maar de uitsteken-
de targeting van plaveiselcelcarcinoomcellen zou radioimmunotherapie 
bij voorkeur in adjuvante setting bij minimale residuale ziekte gegeven 
moeten worden. 
dit proefschrift 
3. Het gebruik van een radionuclide gekoppeld aan een werkzaam mono-
klonaal antilichaam heeft bij de behandeling van non-Hodgkin lymfoom 
toegevoegde waarde. 
dit proefschrift 
4. De keuze voor een radionuclide voor radioimmunotherapie op klinisch-
practische gronden leidt niet tot slechtere klinische resultaten dan een 
keuze gebaseerd op theoretische of dierexperimentele argumenten. 
dit proefschrift 
5. Dosimetrie is slechts de getalsmatige onderbouwing van klinisch reeds 
waargenomen feiten. 
6. Bij radioimmunotherapie is de nucleair geneeskundige niet een nucleair 
adviseur, maar primair geneeskundige. 
Postema et al.JNucl Med 2003; 44: 853 
7. In tegenstelling tot wat in de literatuur gesuggereerd wordt, is er geen 
toegevoegde waarde van FDG-PET bij de stadiëring van de hals bij hoofd-
halscarcinoom. 
Postema et al, Eur J Nucl Med Mol Imaging 2003; 30: S159 
8. Aangezien direct contact tussen oog en genitaal weinig waarschijnlijk is, is 
de hand de meest waarschijnlijke vector bij het ontstaan van een chlamy-
dia conjunctivitis op volwassen leeftijd. 
Postema et al, Genitourin Med 1996; 72: 203-205 
9. Door de invoering van de euro hoeft er niet meer zo vaak geld gewisseld 
te worden. Dit geringe persoonlijke voordeel valt in het niet bij de struc-
turele prijsverhogingen die bij de invoering van de euro hebben plaats-
gevonden. De Zweden hebben derhalve gelijk. 
10. Zelfklevende postzegels zijn zeer gebruiksvriendelijk, maar het einde voor 
de filatelist. 
E.J. Postema 
Nijmegen, 23 maart 2004 


